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A. List of abbreviations  
Less frequently used abbreviation are defined upon their first use in the text. 
AGC   Protein kinase A/G/C like 
ATP   Adenosine triphosphate 
C. elegans  Caenorhabditis elegans (roundworm) 
Cdk   Cyclin-dependent kinase 
CKI   Cyclin-dependent kinase inhibitor 
D. melanogaster Drosophila melanogaster (fruit fly) 
DP/SP   single/ double positive 
ENU   N-ethyl-N-nitrosourea 
FACS   Fluorescence-activated cell sorter 
HM   Hydrophobic motif 
IRES   Internal ribosomal entry site 
KD   Kinase-dead (mutation of ATP binding pocket) 
LATS   Large tumor suppressor 
MEF   Mouse embryonic fibroblast 
MOB   Mps-one binder 
MST   Mammalian Ste20 like kinase 
NDR   Nuclear Dbf2 related kinase 
NTR   N-terminal regulatory domain 
OA   Okadaic acid 
RASSF  Ras-association domain family 
S/Ser   Serine 
S. cerevisiae  Saccharomyces cerevisiae (budding yeast) 
S. pombe  Schizosaccharomyces pombe (fission yeast) 
  iii 
STK   Serine/threonine kinase 
T/Thr   Threonine 
TA   Mutation of hydrophobic motif phosphorylation site to alanine 
Trc   Tricornered 
WT   Wild-type 
YAP   Yes-associated protein 
  iv 
B. Summary 
Protein kinases are important players in signal transduction. They are involved in the 
regulation of almost every aspect of biological regulation. Given their central role in 
signal transduction, aberrant protein kinase activities are involved in a variety of 
human diseases, such as diabetes or cancer. The human genome encodes for 518 
protein kinases, which are further classified into groups, families and sub-families 
based on their catalytic domain. The NDR kinase family belongs to the AGC group 
(protein kinase A/G/C like) of serine/threonine kinases. Members of this family are 
highly conserved from yeast to men. Genetical and biochemical work on NDR kinases 
in yeast and invertebrates revealed, that NDR kinases are involved in the regulation of 
important biological processes such as mitotic exit, morphogenesis, neuronal and 
epithelial morphology, growth, proliferation and apoptosis amongst others. Although 
NDR kinases are implicated in a variety of biological processes amongst species, the 
topology of the signaling pathways regulating NDR kinases are remarkably 
conserved. NDR kinases from yeast to men are regulated by members of the Ste20 
like kinases, MOB adaptor proteins and scaffolding proteins. The human genome 
encodes for 4 members of the NDR kinase family: NDR1, NDR2, LATS1 and 
LATS2. Although many of the biochemical mechanisms regulating NDR kinases have 
been worked out using human NDR1 and NDR2, functions for these two kinases have 
only been reported recently: Human NDR has been shown to function in centrosome 
duplication, the alignment of mitotic chromosomes and apoptosis signaling. Defects 
in regulation of these processes have been linked to tumor development.  However, 
these functions were investigated using cell culture systems and physiological 
functions for NDR1 and NDR2 remain to be defined. Interestingly, NDR1 in these 
contexts has been shown to be regulated by components of the HIPPO tumor 
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suppressor pathway. The tumor suppressor proteins Rassf1a, MST1/2 and hMOB1 
have been shown to not only regulate NDR kinase activity, but also the activity of the 
other NDR family members LATS1 and LATS2. LATS kinases function as tumor 
suppressors by restricting the activity of the YAP oncogene. Given the interaction 
with known components of the HIPPO pathway, a tumor suppressive function for 
NDR1 and NDR2 seems possible. However, although first functions for human NDR 
kinases have been defined recently, signaling mechanisms downstream of NDR1 and 
NDR2 remain elusive. Addressing two of the major questions relating to mammalian 
NDR kinases, we define a first physiological function for NDR kinases in mice in 
tumor suppression. Deficiency and heterozygosity of NDR1 predisposes mice to T-
cell lymphoma development. Reduction of NDR kinase expression results in 
increased resistance to pro-apoptotic stimuli. Furthermore we identify a novel role for 
NDR1 and NDR2 in the regulation of cell cycle progression. NDR1/2 directly 
regulate the protein stability of the proto-oncogene c-myc and the cyclin-dependent 
kinase inhibitor p21. Mammalian NDR kinases therefore seem to play important roles 
in tumor and cell biology by regulating proliferation and apoptosis. 
  1 
1. Introduction 
1.1 Protein kinases: central players in health and disease 
Protein kinases represent central players in signal transduction. This class of enzymes 
catalyzes the transfer of the gamma-phosphate residue from ATP to the hydroxyl-
groups of the amino-acids serine, threonine or tyrosine (1). Protein kinases thereby 
create phosphorylation-marks on proteins which serve diverse functions in signal 
transduction such as activation/inactivation of enzymes, binding sites or localization 
signals. Protein kinases are therefore involved in almost every aspect of signal 
transduction and the proper regulation of their activity is crucial for the normal 
physiology of organisms (2). 
The human genome encodes for approximately 518 different protein kinases which 
represents ~2% of all human genes (2). This protein family, also referred to as 
kinome, therefore constitutes one of the biggest enzyme families in the human 
genome. Based on the catalytic domain, Manning et al. grouped the protein kinases 
into various groups, families and 
sub-families, with tyrosine kinases 
representing the biggest group, 
followed by the CAMK, the CMGC 
and the AGC group of kinases 
(Figure 1). The kinase domain 
consists of 250-300 amino-acids, 
which contains conserved residues 
that contribute to nucleotide binding, 
metal-binding, substrate binding, 
Figure 1. Dendrogram of 491 eukaryotic protein kinase domains 
from 478 genes. Major groups are labeled and colored. 
(Taken from (2)). 
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and phosphoryl- transfer. These residues are located within functional domains 
(subdomains) that are used to describe structural details of protein kinases (1). Given 
their central role in physiology, de-regulated kinase signaling has long been 
associated with the development of human diseases, such as diabetes, immune-
defects, inflammation and cancer (3). 
Diabetes mellitus is a disease which is characterized by the inability of the organism 
to either produce or properly respond to the hormone insulin, resulting in the inability 
to regulate blood glucose levels (4). In 1963 it was shown that a central enzyme 
important for insulin action, glycogen synthase is regulated by phosphorylation. These 
initial findings were followed by a long series of studies revealing that insulin exerts 
its function largely by initiating a kinase signaling cascade involving prominent 
members of the kinase family such as the insulin receptor, PI3Ks, PKB and GSK3 
amongst others. Conversely, main players in the insulin-signaling cascade are under 
investigation for the treatment of diabetes (4). 
Cancer is a heterogeneous disease evoked by the uncontrolled growth and 
homeostasis of cells. There are more than 100 distinct types of cancer, and subtypes 
of tumors can be found within specific organs. Despite this plethora of cancers, the 
principle alterations a cell has to acquire to become a tumor cell have been described 
in a ground-breaking review by Hanahan and Weinberg (5). Tumor cells are 
characterized by self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of programmed cell death (apoptosis), limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis (Figure 2). Not 
surprisingly, protein kinases encounter central nodes in the regulation of each of these 
processes. Indeed, several kinases have been shown to act as oncogenes, such as 
BCR-ABL, Her2 or Src or are activated by oncogenes such as RAS. Interestingly, 
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recent research revealed that the 
PI3K pathway, a well known 
kinase signaling cascade 
represents the most highly 
mutated pathway in human 
cancers (6). Given the central 
roles of kinases in the 
development and onset of 
tumors, several kinases have 
emerged as drug targets over the 
years and successful therapies 
have been developed targeting 
these aberrant kinase activities. One famous example of these targeted therapies is the 
use of Gleevec to inhibit BCR-ABL in human chronic myeloid leukemia (CML). 
More than 90% of all cases of CML show a reciprocal chromosome translocation 
between chromosome 9 and 22 known as Philadelphia-Chromosome, resulting in the 
expression of a fusion protein kinase known as BCR-ABL. More than 20 years ago, 
Novartis in Basel, Switzerland started to use small molecules to inhibit protein 
kinases. This initiative let to the development of an inhibitor of the BCR-ABL kinase 
termed Gleevec, which got the FDA approval 2001 and stands as a powerful example 
of the possibilities of targeted therapies not only addressing aberrant kinase-activities 
but also other enzymes (3).  
These two examples of the roles of protein kinases in health and disease should 
highlight the importance of protein kinases as possible drug-targets. Investigating the 
functions of protein kinases therefore continues to present an important field of 
Figure 2. Acquired capabilities of cancer. It was suggested that most if 
not all cancers have acquired the same set of functional capabilities 
during their development, albeit through various mechanistic strategies.  
(Taken from 5) 
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research not only to provide novel targets for drug-discovery but also to understand 
fundamental processes in biology. 
 
1.2 The NDR kinase family  
The AGC (protein kinase A/G/C-like) group of protein kinases represents the third 
largest group of protein kinases in the human genome and consists of 63 members 
organized into 14 families (Figure 3) (2). Members of the AGC group are 
serine/threonine kinases. Notable representatives of this group are the protein kinase 
A (PKA), protein kinase C (PKC) and the protein kinase B (PKB) isoforms. 
The NDR kinases represent one family within the AGC group. The human genome 
encodes four related NDR kinases: NDR1 (also known as serine/threonine kinase 
Figure 3. Dendrogram of the AGC-group of serine/threonine kinases. The AGC-group is divided into families and 
subfamilies as shown. Taken from www.cellsignal.com 
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(STK) 38/STK38), NDR2 (or STK38-like/ STK38L), LATS1 (Large-tumor 
suppressor 1) and LATS2 (Large-tumor suppressor 2) (7). NDR kinases are highly 
conserved from yeast to men and members can be found in yeast (Dbf-2/Dbf20p and 
Cbk1p in S. cerevisiae and Sid2p and Orb6 in S. pombe), C. elegans (SAX-1 and 
LATS) and D. melanogaster (Trc and LATS) as well as in other fungi, protozoan and 
plant genomes (7). Genetic and biochemical studies have shown that NDR kinases 
regulate various processes ranging from mitosis, morphogenesis, cell growth and 
proliferation, apoptosis, centrosome duplication, as well as various developmental 
processes (8). Taken together, NDR kinases in different species have been implicated 
in central important nodes in cellular signal transduction and research is ongoing to 
further define the biological roles of NDR kinases. 
 
1.2.1 Structural characteristics of NDR kinases 
The primary structure of NDR kinase family members is conserved from yeast to men 
(Figure 4) (7). As mentioned above, the kinase domain can be subdivided into 12 
different subdomains based on the existence of conserved key residues (1). Although 
NDR kinases show typical characteristics of AGC group kinases such as the 
activation segment and the hydrophobic-motif phosphorylation sites, they exhibit two 
defining features: an insertion of 30-60 amino-acids in the kinase domain between 
subdomain VII and VIII and an N-terminal regulatory domain (NTR) (Figure 4).  
The NTR contains a significant number of conserved basic and hydrophobic residues 
and has been shown to be responsible for the interaction with regulatory proteins of 
the MOB family as well as S100B (9, 10). Mutation of the conserved basic residues 
on NDR resulted in severely impaired binding of NDR kinases to MOB1 (9, 11, 12). 
Further insight was given by the analysis of the MOB1 structure in combination with 
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an NDR N-terminal peptide (13). Interestingly the interaction area on MOB1 has been 
shown to be largely negatively charged, further supporting a NDR/MOB complex 
formation based on electrostatic interactions. 
Although the 30-60 amino-acid insert between kinase subdomain VII and VIII is not 
conserved on the primary sequence between NDR family members, all show a stretch 
of basic amino-acids towards the C-terminus (9). As the insert precedes the activation 
segment, the positive charges of the cluster seem to impact on NDR kinase activity, 
since mutation of the basic amino-acids to alanines in NDR1 resulted in increased 
kinase activity (9). Therefore, the short stretch of basic amino-acids is referred to as 
an auto-inhibitory sequence (AIS) (9). 
 
Figure 4. Primary structure of selected NDR family kinases. Eight members of the NDR kinase family are depicted from 
unicellular and multicellular organisms (H.s. Homo sapiens, D.m. Drosophila melanogaster, C.e. Caenorhabditis elegans, A.t. 
Arabidopsis thaliana, T.b. Trypanosoma brucei). The NTR (grey), the kinase domain (green) with the activation segment 
(yellow) and the hydrophobic motif (brown) are indicated. In addition, the auto-inhibitory sequence (red) and conserved 
phosphorylation sites (blue dots) are highlighted. Taken from (7). 
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1.2.2 Regulation of NDR kinases 
Regulation by Phosphorylation 
Being members of the AGC group NDR kinases contain two conserved 
phosphorylation sites required for kinase activity: one in the activation loop (S281 in 
human NDR1) and one in the hydrophobic motif (T444 in human NDR1) (7). 
However, opposed to other AGC group kinases the activation loop phosphorylation of 
NDR kinases seems to be performed by auto-phosphorylation (14, 15). Still the 
hydrophobic motif (HM) is targeted by upstream kinases (7). The importance of the 
HM-motif for NDR kinase activation is further highlighted by the possibility to create 
a constitutively active NDR kinase by exchanging the HM of NDR2 with that of the 
constitutively active kinase PRK2 (14). Consistently, mutation of the hydrophobic 
motif phosphorylation site to alanine results in a complete loss of kinase activity (14).  
Both phosphorylation sites are targeted by PP2A. Treatment of cells with okadaic acid 
or calyculin A (potent inhibitors of PP2A) results in increased phosphorylation and 
activation of yeast, fly and mammalian NDR kinases (16-19). In addition, 
recombinant PP2A is able to completely inactivate human NDR1 in vitro (19). 
In higher eukaryotes a third phosphorylation site in the NTR is conserved (T74 in 
human NDR1 or S690 in human LATS1) (14, 15). The functional relevance of this 
site has not been evaluated. Mutation of this site to alanine has been shown to 
decrease both basal NDR kinase activity and NDR activation after okadaic acid 
treatment. However, this mutation also severely impairs NDR binding to MOB 
proteins and S100B (9). It remains to be shown, whether the effects of mutating T74 
are a result of impaired binding to MOB1 or whether this phosphorylation regulates 
the kinase activity itself and whether phosphorylation of this site occurs in vivo. 
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Regulation of NDR kinases by Ste20 like kinases 
First insights into the identity of upstream kinases for NDR kinase family members 
came from genetic studies in yeast. The yeast Ste20-like kinases Kic1p, Nak1p, Sid1p 
and Cdc15p have been placed upstream of the yeast NDR kinases Cbk1p, Orb6p, 
Sid2p and Dbf2p (18, 20, 21), however only Cdc15p was shown to directly 
phosphorylate and activate Dbf2p (18). Further evidence was gathered from work in 
Drosophila. Genetic and biochemical studies revealed that the Ste20-like kinase 
Hippo functioned upstream of LATS (22-27). Furthermore Hippo was able to interact 
with LATS and phosphorylate it in vitro. Interestingly, later it was shown that Hippo 
is also capable of phosphorylating and activating the NDR1/2 homologue trc in 
Drosophila, already indicating a diversion of Ste20-like kinase signaling on the level 
of NDR kinases (28).  
The first upstream kinase solely phosphorylating the HM of NDR kinases was 
identified as the mammalian Ste20 like kinase 3 (MST3) (29). MST3 phosphorylates 
human NDR1/2 on T444/442 both in vitro and in vivo. The MST family of kinases 
consists of 5 members: MST1, MST2, MST3, MST4 and MST5 (also termed SOK1 
or YSK1). Recent work has shown that also other members of the MST family 
represent in vivo upstream kinases for NDR family kinases. MST1 and MST2 have 
been shown to activate LATS1 and LATS2 in vivo (16). Interestingly MST1 is also 
able to regulate NDR1/2 in vivo (30, 31). Also MST2 was shown to phosphorylate 
NDR1/2 in vitro (31), but it has also been suggested to function as upstream kinase in 
vivo (32). Taken together, genetic and biochemical work from different organisms 
have established members of the Ste20-like kinase family as upstream kinases for 
NDR family members and indicated conserved signaling pathways across species. 
However, the existence of several members of Ste20-like kinases being able to 
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phosphorylate one given NDR kinase and the possibility of one Ste20-like kinase 
regulating 2 or even 4 different NDR kinase family members already implicates a 
significant complexity in NDR kinase signaling. 
 
Regulation of NDR kinases by MOB proteins 
The N-terminal region (NTR) represents one defining feature of NDR kinases. It has 
been shown to interact with members of the MOB family of adaptor proteins. MOB 
stands for Mps one binder. In S. cerevisiae Mob1p has been identified as regulator of 
Mps1 and Dbf2 localization and activity (33, 34). In addition yeast genomes encode 
for a second MOB isoform, Mob2p, which controls Cbk1p activity and localization in 
polarized growth (35, 36). 
The human genome encodes 6 MOB related genes: MOB1A/B, MOB2 and 
MOB3A/B/C (30). So far only MOB1A/B and MOB2 have been shown to interact 
with NDR-family kinases and impact on NDR kinase activity (30). Whereas 
MOB1A/B has been shown to bind to and regulate the kinase activity of all four 
human NDR kinases, MOB2 solely binds to NDR1/2 (9, 11, 37, 38).  
Most insight into the regulation of NDR kinases by MOB proteins has been gathered 
from work on human MOB1A/B. MOB1 isoforms interact with NDR and LATS in 
the N-terminal region and it seems likely that positively charged residues in the NTR 
interact with a negatively charged surface on MOB1 (9, 12, 13, 38). Recently it has 
been shown that interfering with MOB1-NDR1 complex formation also functionally 
impairs NDR1 in the context of centrosome duplication (30). Furthermore, mutation 
of the conserved residues important for MOB1 binding in LATS1 resulted in impaired 
kinase activity (38). Recent work showed that in addition to NDR kinase binding, 
MOB1 proteins are also capable of binding to MST1/2, possibly functioning as a 
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bridge between upstream kinase and NDR kinase (31, 39, 40). Indeed, the existence of 
a complex between Ste20-like kinase, MOB1 protein and NDR kinase has been 
reported (31). MST1/2 are also able to phosphorylate MOB1 and thereby strengthen 
complex formation with NDR kinases (39). However, although the interaction with 
MOB1 is required for NDR1/2 HM phoshorylation (30, 31), LATS1/2 HM-
phosporylation seems to be regulated differently (39). In addition, exactly how 
MOB1-NDR association, apart from proximity to the upstream kinase, impacts on 
NDR activity has not been clarified yet. One study indicates that binding of MOB1 
releases NDR1/2 from auto-inhibition by the AIS (9). More work and especially 
crystal structures of the MOB1-NDR kinase complexes are needed to further define 
the interplay between Ste-20 kinase, MOB1 protein and NDR kinase. However the 
data obtained so far indicate a model, in which MOB1 is phosphorylated by MST1/2 
resulting in efficient complex formation between NDR kinase and MOB1 (41). 
Consecutively NDR kinases are phosphorylated by the upstream kinase resulting in 
full NDR kinase activation (Figure 5). 
Much less is known about the role of MOB2 in NDR kinase signaling. However, it is 
interesting, that the NDR kinase-family is divided in terms of MOB2 binding. The 
NDR part of the family (such as human NDR1/2, trc, Cbk1 and Orb6) binds to MOB2 
(35, 37, 42, 43), whereas the LATS part (LATS1/2, dLATS, Dbf2 and Sid2) does not. 
Conflicting data exists about the function of the NDR-MOB2 interaction. Work in 
budding and fission yeast indicates, that the MOB2-Cbk1/Orb6 interaction is 
important for NDR kinase localization and activity (35, 43). In Drosophila, work from 
the Adler lab has shown that dMOB2 interacts and co-localizes with tricornered, 
however, no kinase activity was measured in this study (42). Interestingly, 
overexpression of dMOB2 in this system resulted in a weak tricornered phenotype, 
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indicating, that dMOB2 could function as an inhibitor of tricornered. In higher 
eukaryotes, it has been shown, that MOB2 could activate NDR1/2 in vitro, however, 
the in vivo role of MOB2 for NDR1/2 has not been addressed so far. Recent work 
from the Hemmings lab, showed a different role for MOB2 for NDR kinase activity 
(Kohler et al. unpublished data). Addressing MOB2 function in vivo, the authors 
could show that MOB2 does not function as an activator, but rather an inhibitor of 
NDR kinase activation, both in apoptosis and centrosome duplication. Furthermore, 
although the exact binding site of MOB2 on NDR1 could not be mapped, the NTR 
seemed to be important and MOB2 was capable of competing with MOB1 for NDR1 
binding (Kohler et al. unpublished data). Taken together, MOB proteins have been 
shown to be important regulators of NDR family kinases across species. With MOB1 
proteins being activators of all NDR kinase family members tested so far, the role of 
Figure 5. Current model of human NDR family kinase activation by MST kinases and MOB1 proteins. As an initial step, 
MST1/2 phosphorylate MOB1 which results in efficient complex formation with NDR kinases. Binding of MOB1 to NDR 
kinases facilitates activation loop auto-phosphorylation and hydrophobic motif phosphorylation by MST1/2. Fully active NDR 
kinases subsequently phosphorylate substrates such as YAP. Note that for substrate phosphorlyation NDR1/2 seem to stay in a 
complex with MOB1, whereas LATS1/2 do not seem to depend on MOB1 binding for continued activity. Taken from (41). 
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MOB2 proteins seems to be more complex; not all NDR family members bind to 
MOB2 and the function of MOB2-NDR complexes needs to be further defined. 
 
Regulation of NDR kinases by scaffolding proteins 
A third class of proteins represent conserved regulators of NDR kinase activity. In 
yeast, C. elegans, D melanogaster and humans, large scaffolding proteins have been 
identified, which impact on NDR kinase activity and function (21, 32, 44-47). In yeast 
the proteins Tao3p and Mor2p impact on Cbk1p and Orb6p respectively (21, 47), 
whereas in C. elegans SAX-2 has been shown to genetically interact with SAX-1 (45). 
In drosophila the scaffolding protein furry genetically and biochemically interacts 
with tricornered and was shown to be essential for trc kinase activity (46). Recently 
murine furry has been cloned, which  interacts with  NDR1 and seems to regulate its 
activity, although the functional context of this regulation remains unclear, as this has 
not been tested in terms of NDR1/2 signaling in the context of apoptosis and 
centrosome duplication (32). 
For LATS1/2 in humans and LATS in Drosophila different scaffolding proteins have 
been described. The relatively small WW domains containing WW45 in mammals 
and Salvador in flies, have been shown to be important for LATS function (16, 25, 26, 
48). Interestingly, these proteins are less conserved and so far no clear yeast 
orthologue has been described. 
However, both classes of scaffolding proteins seem to function by linking NDR 
kinases with their respective upstream kinases. Work is still needed to define the role 
of scaffolding proteins for NDR kinase activity and function, especially with respect 
to MOB-NDR interaction. 
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1.2.3 Functions of NDR kinases 
Functions for NDR kinases have first been worked out using genetic approaches in 
yeast. In S. cerevisae and S. pombe Dbf2p and Sid2p have been implicated in the 
regulation of the mitotic exit network (MEN) and the septation initiation network 
(SIN) (49), whereas the other members Cbk1 (in S. cerevisae) and Orb6 (in S. pombe) 
function in the regulation of morphogenesis (50, 51). Since then NDR kinases have 
been implicated in a variety of important biological functions such as the regulation of 
proliferation, cell growth and apoptosis, tumor suppression, neuronal growth, 
differentiation and tiling, centrosome duplication and embryonic development (Table 
1). Although in lower eukaryotes the functions of NDR kinases have been worked out 
in a quite detailed manner using genetical approaches, only recently biochemical 
approaches identified substrates for NDR kinases. In addition, biochemical work in 
higher eukaryotes provided insights into the mechanisms of NDR kinase regulation, 
but only recently the physiological functions of NDR kinases in these systems begin 
to unravel. In the following several functions for NDR kinases in different model 
organisms are highlighted. 
 
Regulation of mitotic exit and septation initiation in yeast 
The mitotic exit network ensures that each daughter cell receives only one copy of 
each chromosome (49). Only then exit from mitosis and cytokinesis are initiated. 
Intensive research in budding and fission yeast revealed a conserved signaling 
network in control of this process, which is termed mitotic exit network (MEN) in S. 
cerevisiae and septation initiation network (SIN) in S. pombe (49, 52, 53). The NDR 
family kinases Dbf2 and Sid2p play important roles in the regulation of MEN and 
SIN. In S. cerevisiae the activation of MEN involves the small GTPase Tem1p, which 
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stimulates the activation of the Cdc15p protein kinase, which subsequently activates 
the NDR kinase Dbf2. Dbf2 in turn phosphorylates the phosphatase Cdc14p, which 
results in re-localization of Cdc14p from the nucleolus into the cytoplasm, where it 
de-phosphorylates and inactivates the Cyclin B-Cdk complex, which allows exit from 
mitosis. The SIN is organized in a similar manner, consisting of the small GTPase 
Spg1p, the protein kinases Sid1p, Cdc7 and Sid2p, as well as the coactivator MOB1p 
regulating the phosphatase Clp1p.  
Interestingly, LATS1 has been implicated in the regulation of mitotic exit in human 
cells (11). However, the network and the mechanisms regulating mitotic exit in 
human cells remain poorly defined and future studies are needed to show, whether the 
function of NDR kinases in regulating mitotic exit are conserved in higher eukaryotes. 
 
Kinase Species Functional information 
Dbf2p S. cerevisiae Controls mitotic exit and cytokinesis# 
Cbk1p S. cerevisiae Centerpiece of RAM network; couples cell morphology with 
the cell cycle 
Sid2p S. pombe Regulates septum formation and cytokinesis# 
Orb6p S. pombe Links morphological changes with the cell cycle 
TBPK50 T. brucei Coordinates cell shape and cell cycle 
SAX-1 C. elegans Important for neurite outgrowth and dendritic tiling# 
Trc D. 
melanogaster 
Controls epidermal outgrowths, and dendritic tiling and 
branching# 
Lats/Warts D. 
melanogaster 
Central player in the Hippo pathway; required for dendritic 
maintenance# 
LATS1 H. 
sapiens/M. 
musculus 
Regulates G2/M cell cycle transition, apoptosis and mitotic 
progression; part of the G1 tetraploidy checkpoint; the LATS1 
cDNA can rescue the loss of D. melanogaster Lats/Warts# 
LATS2 H. 
sapiens/M. 
musculus 
Controls cell proliferation, genomic stability and mitotic 
progression; linked to the G1 tetraploidy checkpoint; essential 
gene, since LATS2 null mice die before embryonic day 12.5# 
NDR1/STK38 H. 
sapiens/M. 
musculus 
Required for centriole duplication and FAS mediated apoptosis. 
Implicated in the regulation of mitotic chromosome alighment. 
The NDR1 cDNA can compensate for the loss of D. 
melanogaster Trc# 
NDR2/STK38L H. 
sapiens/M. 
musculus 
Functions in the regulation of neuronal growth and 
differentiation. Overexpression of NDR2 can induce 
centrosome duplication and can rescue defects in centriole 
dublication upon RNAi mediated knock-down of NDR1 # 
 
Table 1. Selected functions of NDR kinase family members. Modified from (8). #References for the indicated functions can 
be found in the text. 
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Neuronal morphology and differentiation in C. elegans and D. melanogaster 
Work in C. elegans and D. melanogaster revealed a function for NDR kinases in the 
regulation of neuronal growth, morphology and differentiation. The group of C. 
Bargmann could show that in C. elegans the NDR family kinase SAX-1 together with 
the large scaffolding protein SAX-2 regulates neurite outgrowth and dendritic tiling 
(45, 54). Dendritic tiling is a neuronal phenomenon in which the dendrites of a group 
of neurons with the same response characteristics completely innervate a tissue in a 
non-redundant manner (55). This process ensures that receptive fields of neurons do 
not overlap and prevents misconnections in neuronal systems. The involvement of 
NDR family kinases in this process has been shown to be conserved in Drosophila 
(17). A study performed in the Jan Laboratory revealed that the NDR kinase 
tricornered (trc) together with the large scaffolding protein furry controls dendritic 
tiling in fly neurons (17). Importantly, they could also show that this process is 
dependent on the kinase activity of trc, which is directly regulated by furry (17, 46). 
Further insight into the function of NDR kinases in neuronal morphology came from 
the same lab (28). Using biochemical and genetic approaches Emoto and colleagues 
could show that both tricornered and LATS are regulated by the Ste20 like kinase 
Hippo, revealing for the first time, that one given Ste20-like kinase could regulate two 
different NDR kinase family members, which was subsequently also shown in 
mammalian systems (28). While Hippo regulated trc for proper dendritic tiling and 
neurite outgrowth, Hippo signaling to LATS was important for maintenance of neurite 
structures (28). Interestingly, this indicated that two distinct NDR kinase family 
members could regulate two different aspects of the same biological process. In 
addition, recent work implicated the Drosophila target of rapamycin complex 2 
(TORC2) in the regulation of trc activity in the process of dentritic tiling (56). Taken 
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together, work in invertebrates revealed an important function for the NDR kinases 
tricornered and LATS in neuronal morphology and differentiation. However, 
downstream signaling mechanisms of LATS and tricornered in the process of 
dendritic tiling and the maintenance of neurite structures remain to be described. It 
will be important in future studies to test, whether this function is conserved in higher 
eukaryotes. Interestingly, one report identified the murine NDR2 gene as being 
upregulated in amygdala neurons from fear-conditioned mice (57). In cultured cells 
NDR2 was involved in neuronal growth and differentiation, especially in neurite 
outgrowth, indicating a conserved role for NDR kinases in neuronal morphology (57).  
 
Tumor suppression in Drosophila and higher eukaryotes: The HIPPO pathway 
The NDR kinase LATS (large tumor suppressor) has first been identified in screens 
for putative tumor suppressors performed in Drosophila by two independent labs (58, 
59) and subsequently been found to also function as tumor suppressor in mice (60). In 
addition, the Ste20-like kinase Hippo was placed upstream of LATS in tumor 
suppression (22, 27). Since then more than 10 different proteins have been implicated 
in the regulation of the emerging tumor suppressor pathway arranged around Hippo 
and LATS (41). This tumor suppressor pathway, which also seems to be conserved in 
mammalian systems, is nowadays collectively called the Hippo-pathway.  
The major players in this pathway in flies are the kinase Hippo, the co-
activator/scaffold proteins Salvador and Mats, and the NDR family kinase 
Warts/LATS, which negatively regulates the Yorkie proto-oncogene, thereby 
controlling cell growth, proliferation and apoptosis (61) (Figure 6). Various stimuli 
from upstream molecules, such as Fat/Expanded and Merlin (62-65), activate the 
Hippo kinase, which forms a complex with salvador (27). This complex then 
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phosphorylates LATS, which in turn phosphorylates Yorkie (23). Importantly Yorkie 
represents the first in vivo substrate for an NDR kinase family member identified. 
Yorkie is phosphorylated by LATS on Serine 168, which results in 14-3-3 binding 
and nuclear exclusion (66). Yorkie functions as a transcriptional co-activator which 
interacts with the TEAD transcription factor scalloped to regulate the expression of 
dCyclinE, dE2F1, dIAP and the bantam microRNA (67-73). 
Recent results from mammalian cells indicate that this pathway is conserved in higher 
eukaryotes (74). The mammalian HIPPO pathway is composed of the Hippo 
homologues MST1/2, the mammalian salvador protein WW45, the Mats homologues 
MOB1A/B as well as the mammalian LATS kinases LATS1/2, and the Yorkie-related 
transcriptional coactivators YAP and TAZ (41). Interestingly, the mammalian HIPPO 
pathway differs in some components from its Drosophila counterpart. First on YAP 5 
LATS1/2 responsive phosphorylation sites have been identified (in addition to S127, 
the site homologous to S167 in Yorkie, S61, S109, S164 and S397) (75). Although 
S127 seems to be main site regulating YAP nuclear localization (76), one study 
Figure 6. Schematic representation of the HIPPO pathway in Drosophila and mammals. Corresponding components are 
shown in the same color.  Question marks denote unknown components and dashed lines indicate unknown biochemical 
mechanisms. Abbreviations are as follows: Ex (Expanded), Mer (Merlin, also called NF2), Hpo (Hippo), Sav (Salvador), Mats 
(Mob as tumor suppressor), Wts (Warts), Yki (Yorkie). Taken from (61). 
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reported that all serines have to be mutated to affect YAP phosphorylation at least in 
cell culture systems (75). In addition, the activity of MST1/2 in mammalian systems is 
regulated by the RASSF1A tumor suppressor protein (77). RASSF1A binds to 
MST1/2 through their SARAH domains and thereby stimulates MST1/2 kinase 
activity (77). In Drosophila however, dRASSF, although functioning as a tumor 
suppressor by inhibiting dRaf1, inhibits Hippo activation by competing with salvador 
for Hippo binding (78). Recently, another RASSF isoform, RASSF6, has been 
indicated to function in a similar manner than dRASSF in mammalian cells (79). 
Another difference so far is due to mammalian YAP being able to bind to other 
transcription factors than TEAD1-4. In apoptosis signaling YAP stimulates the 
transcriptional activity of the p53 isoform p73 (80, 81). In addition, YAP is able to 
bind to RUNX1/2 and other PPXY-motif-containing transcription factors as well as 
the ErbB4 cytoplasmatic domain (82, 83).  
The evaluation of the conserved tumor suppressive function of the HIPPO pathway in 
mammals has so far mainly been performed in cell-culture systems and evidence for a 
tumor-suppressor function for some crucial components from gene-knockout studies 
in mice is still lacking. However, for some components of the mammalian HIPPO 
pathway a tumor suppressive function in mice has been validated. One of the earliest 
components which was targeted in mice was LATS1 (60). LATS1 deficient mice are 
viable and fertile (although an increased rate of infertility was noted) and develop soft 
tissue sarcoma and ovarian tumors. Interestingly, LATS2 deficient mice are 
embryonic lethal (84, 85). Although LATS2-/- MEFs display loss of contact inhibition 
and genomic instability, due to the embryonic lethality, tumor spectrum and 
penetrance in these mice have not been analyzed so far. Similar to LATS2 mice, mice 
lacking WW45 are embryonic lethal (48). No mice lacking MOB1A/B have been 
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described so far. RASSF1A and Merlin/Nf2 have been targeted in mice as well and 
their tumor-suppressive role has been confirmed (86, 87). Recently Zhou and 
colleagues confirmed the tumor suppressive role of the Hippo homologues MST1 and 
MST2 (88). Mice deficient for MST1 have been described earlier; however they did 
not exhibit increased tumor susceptibility, but rather defects in T-cell proliferation and 
homing (89, 90). Subsequently, mice deficient for MST2 have been described, which 
did not show any phenotype (91). Mice double deficient for MST1 and MST2 have 
been shown to be embryonic lethal, confirming a redundant role for MST1 and MST2 
in embryonic development (91). Using a floxed allele for MST2 on an MST1 
deficient background and adenoviral mediated cre-recombinase delivery to the liver, 
Zhou and colleagues could show that mice lacking MST1/2 in the liver develop 
tumors in a YAP-dependent manner (88). However it is important to note, that 
although YAP phosphorylation upon deletion of MST1/2 was severely impaired, no 
changes in LATS1/2 phosphorylation were observed. In addition, fractionation 
experiments revealed a YAP-kinase activity different from LATS1/2 to be responsive 
to MST1/2 deletion, which led the authors to conclude that a different YAP kinase 
apart from LATS1/2 exists in the liver. Interestingly, hydrophobic motif 
phosphorylation of the other NDR family kinases in mice, NDR1/2, was clearly 
reduced, suggesting a possible role for NDR1/2 in suppressing liver-cancer 
development downstream of MST1/2. In cell culture systems NDR1/2, however, 
failed to phosphorylate YAP (75). More work and more sophisticated mouse models 
are needed to further define the components of the mammalian HIPPO pathway. It 
will also be important in the future to define the transcriptional targets regulated by 
the mammalian HIPPO pathway. Still, work from Drosophila and mammalian 
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systems defines the HIPPO pathway as an important regulator and integrator of cell 
growth, proliferation and apoptosis. 
  
The functions of NDR1 and NDR2 in mammalian systems 
Although the major mechanisms of biochemical regulation for NDR family members 
have been worked out using human NDR1 and NDR2, functions for NDR1/2 have 
only recently been identified. By looking at the subcellular localization of NDR1 
Hergovich and colleagues identified a subfraction of NDR1 binding to the 
centrosomes (92). Overexpression of NDR1 and NDR2 in this system resulted in 
centrosome overduplication. Later it was shown that the role of NDR1/2 in 
centrosome duplication was dependent on MOB1 and MST1 (30). Furthermore, 
another study from the Hemmings lab described the activation of NDR1/2 
downstream of RASSF1A and MST1 in apoptosis signaling (31). Interestingly, RNAi 
mediated knock-down of NDR1/2 resulted in apoptosis defects upon FAS-induced 
apoptosis. Recently a function for NDR1/2 in the alignment of mitotic chromosomes 
has been described (32). By studying the mammalian homologue of furry, Chiba and 
colleagues indicated a function for NDR1/furry in microtubule stability and dynamics. 
However, the results of this study remain to be confirmed, as the well established 
centrosome phenotype of NDR1 depleted cells could not be reproduced. In addition, 
the authors fail to reproduce the stimulating effect of MOB1 on NDR kinase activity. 
Taken together, although characterized well in terms of biochemical activation, the 
physiological functions of mammalian NDR1 and NDR2 remain poorly defined, 
which can be mainly attributed to the lack of in vivo substrates identified for NDR1 or 
NDR2. Future studies using mice carrying targeted alleles for NDR1 and NDR2 are 
warrant to further define physiological functions of NDR1 and NDR2. 
  21
2. Scope of the thesis 
The aim of this study was to further investigate the functional roles of NDR1 and 
NDR2 in cell-culture systems and mice. Although in the meantime NDR1/2 have been 
implicated in the process of centrosome duplication, apoptosis and the alignment of 
mitotic chromosomes, we describe the first physiological function for NDR kinases in 
mice. Loss of NDR1 predisposed mice to the development of T-cell lymphoma both 
upon age and after carcinogen treatment. Although loss of NDR1 was compensated by 
increased levels of NDR2 in healthy tissues, total NDR kinase levels were found to be 
reduced in murine as well as human T-cell lymphoma samples. Interestingly, 
interfering with NDR2 upregulation in healthy, untransformed cells resulted in 
increased resistance to pro-apoptotic stimuli, indicating that by ensuring proper 
apoptotic responses NDR kinases function as tumor suppressors in mice. 
In addition a novel function of NDR1/2 was identified. By analyzing NDR kinase 
activation in a cell cycle dependent manner, we found that NDR1/2 were activated in 
G1-phase of the cell cycle. RNAi mediated knock-down of both NDR1 and NDR2 
resulted in proliferation defects due to a G1-block. Importantly, NDR kinases were 
found to directly impact on the stability of c-myc and p21 by different mechanisms. 
Whereas c-myc directly bound to NDR1/2 in a kinase-activity independent manner, 
p21 was found to be directly phosphorylated by NDR1/2. These findings represent the 
first downstream signaling mechanisms of NDR1/2 in a functional context.  
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3. Results 
The results obtained during this thesis are separated into two manuscripts. Manuscript 
one entitled "Ablation of mammalian NDR1 kinase predisposes mice to T-cell 
lymphoma development" describes the work performed with NDR1 targeted mice and 
the role of NDR kinases in tumor development. The second manuscript describing the 
role of NDR kinases in G1-progression/S-phase entry and the work on signaling 
mechanisms downstream of NDR is entitled "Human NDR kinases control G1 
progression/S-phase entry by regulating p21 and c-myc stability". The numbering of 
figures and references in these manuscripts is restricted to each manuscript, meaning 
that for each manuscript the numbering of figures and references starts with 1. 
3.1 Ablation of mammalian NDR1 kinase predisposes mice to T-cell lymphoma 
development  
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3.1.1 Abstract 
Defective apoptosis has been shown to contribute to the development of a variety of 
human malignancies. The kinases NDR1 and NDR2 have been implicated in the 
regulation of apoptosis downstream of the tumor necrosis factor-receptor family 
member FAS. FAS signaling is crucial for lymphocyte homeostasis with defects being 
linked to lymphoproliferative disorders, autoimmunity and cancer. To further analyze 
the role of NDR1 downstream of FAS, NDR1-deficient mice were generated. Mice 
lacking NDR1 appeared normal and NDR1-deficient T-cells exhibited normal responses 
to different pro-apoptotic stimuli. Analysis of NDR1 and NDR2 expression revealed 
that NDR1 loss is functionally compensated by an increase in NDR2 protein levels. 
Despite this compensation NDR1-deficient and heterozygous mice showed significantly 
increased T-cell lymphoma development. Analysis of NDR1 and NDR2 expression in 
T-cell lymphoma samples revealed that tumor development in mice and human is 
accompanied by a decrease in NDR kinase levels. Thus, reduction of NDR1 triggers a 
decrease in total NDR kinase expression. Taken together, our data suggests that low 
expression of NDR kinases results in defective response to pro-apoptotic stimuli, 
thereby facilitating tumor development. 
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3.1.2 Introduction 
Apoptosis signaling in the immune system has been implicated in a variety of biological 
processes ranging from the regulation of immune cell development to lymphoid 
homeostasis and the clearing of cells after immune responses (1). Defects in apoptosis 
signaling predispose to the development of diseases such as autoimmunity or cancer (1).  
FAS signaling in immune cells has been shown to be important for the control of 
lymphocyte homeostasis with defects resulting in lymphadenopathy, autoimmunity and 
lymphoma development (2). Signaling downstream of FAS is initiated upon binding of 
its ligand FASL to the extracellular domain of the receptor resulting in receptor 
clustering and recruitment of the adaptor protein FADD and procaspase 8 with 
subsequent activation and cleavage of procaspase 8. Active caspase 8 in turn cleaves 
other proteins such as the effector caspases 3 and 7 leading to full activation of the 
apoptotic program (2). 
Among the substrates of active caspases following FAS activation is the mammalian 
Ste20- like-kinase 1 (MST1) (3). MST1 has been shown to be a pro-apoptotic kinase 
activated by cleavage upon FAS activation. Members of the NDR/LATS family of 
protein kinases are among the substrates phosphorylated by MST1 (4, 5).  
Four members of the NDR/LATS family exist in mammalian genomes (LATS1/2 and 
NDR1/2)  (6). The NDR kinase family members LATS1/2 function as tumor 
suppressors as part of the HIPPO pathway in Drosophila and mice (7, 8). Work using 
cell culture systems has implicated the other mammalian NDR kinase family members 
NDR1 and NDR2 in the regulation of centrosome duplication, mitotic chromosome 
alignment and apoptosis induction (4, 9, 10). NDR1 and NDR2 display high sequence 
identity and so far no differences in biochemical regulation or function have been 
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described, although both kinases show a distinct expression pattern in mammalian 
organisms (11). While NDR1 is highly expressed in immunological organs and 
especially in the thymus, NDR2 is mainly expressed in tissues of the digestive tract 
indicating tissue specific functions of both isoforms. Given the predominant expression 
of NDR1 in lymphocytes and its suggested role in apoptosis signaling downstream of 
FAS, we generated mice lacking NDR1 to analyze its role in apoptosis signaling in 
lymphocytes. 
Here we present evidence that NDR1 functions as a haploinsufficient tumor suppressor. 
Reduction in NDR1 gene-dose is functionally compensated by increased NDR2. 
Despite this apparent compensation, complete loss or heterozygosity of NDR1 
predisposes mice to T-cell lymphoma development, which is accompanied in mice by a 
reduction in both NDR1 and NDR2 levels. Consistent with this finding, NDR1 levels in 
human T-cell lymphoma samples are frequently reduced indicating a conserved tumor 
suppressor function for NDR1 in T-cell lymphoma. 
 
3.1.3 Results 
Generation of NDR1-deficient mice  
To obtain mice deficient for NDR1, exon 4 of the gene encoding NDR1 was targeted 
(Figure S1A). Successful recombination was demonstrated by Southern blotting and 
PCR (Figure S1B, C). The absence of NDR1 protein was confirmed in the knock-out 
mice using an antibody specific for murine NDR1 (Figure S1D). There was also a 
decrease in NDR1 protein in heterozygous mice, suggesting a gene-dose effect. Since 
complete ablation of the gene encoding the respective NDR orthologue (tricornered; trc) 
in Drosophila results in embryonic lethality (12), variation in genotype ratio among the 
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progeny of NDR1 heterozygous matings was analyzed (Figure S1E). As the progeny 
showed the expected Mendelian ratio, the deletion of NDR1 did not lead to obvious 
developmental defects. In addition organ weights and architecture in young NDR1+/+, 
NDR1+/- and NDR1-/- mice were analyzed without showing significant differences. 
Thus, ablation of NDR1 in mice results in viable, fertile animals without obvious 
defects. 
 
NDR1 is activated in thymocytes in response to different apoptotic stimuli 
An earlier report described the activation of NDR kinases in transformed cells in 
response to FAS and TNFα treatment. Furthermore, shRNA-mediated knock-down of 
both isoforms resulted in increased apoptosis resistance (4). To confirm these findings 
in untransformed cells, freshly isolated thymocytes were treated with stimuli to activate 
extrinsic and intrinsic apoptotic pathways (Figure 1A). Two hours after induction of 
apoptosis with anti-FAS antibody, there was an increase in hydrophobic motif 
phosphorylation of NDR (T444-P) which coincided with MST1 activation as monitored 
by cleavage and phosphorylation of MST1 (Figure 1A). A similar activation of NDR 
was observed after gamma irradiation and dexamethasone treatment (Figure 1A). These 
results showed, that NDR1/2 were not only activated in response to extrinsic apoptotic 
stimuli, but also to intrinsic stimuli.  
Next, we tested whether loss of NDR1 would result in increased apoptosis resistance of 
thymocytes. Freshly isolated thymocytes from NDR1+/+, NDR1+/- and NDR1-/- mice 
were treated with gamma irradiation, etoposide, dexamethasone or anti-FAS antibody 
and apoptosis was measured 10 h after induction (Figure 1B). Furthermore thymocyte 
cell death upon treatment with anti-CD3/CD28 antibodies and cytokine withdrawal was 
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accessed (Figure 1B/C). No statistically sig
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r anti-CD3/CD28 treatment were detected 
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fter anti-CD3/CD28 treatment. However, a 
Figure 1. NDR1 is activated in response to different pro-apoptotic stimuli, but largely dispensable for apoptosis induction. 
A: Thymocytes were isolated from young wild-type mice (4-6 weeks old) and apoptosis was induced by gamma irradiation, 
dexamethasone or treatment with anti-FAS antibody+ cycloheximide. Cells were lysed after the indicated incubation times and 
analyzed for the activation of NDR1/2 and MST1 (** uncleaved form of MST1; * cleaved form). B: Thymocytes were isolated and 
treated with gamma irradiation, dexamethasone, anti-FAS+CHX, etoposide or anti-CD3/CD28 and apoptosis was measured 10 h 
later (or 24h later for anti-CD3/CD28) by PI/AnnexinV staining. Specific survival of cells was calculated as the ratio of 
PI/AnnexinV double-negative cells with and without treatment (n = 3, * P<0.005). C: Isolated thymocytes were seeded into 
IMDM+10%FCS and analyzed after the indicted time using a Vicell automated cell counter. D: Activation of NDR kinases in 
NDR1+/+ and NDR1-/- thymocytes. Freshly isolated thymocytes were treated with gamma irradiation and lysed after the indicated 
times. Activation of NDR was assessed using the anti-T444-P antibody; total kinase was analyzed using the NDR1 antibody for 
wild-type thymocytes and the NDR2 antibody for NDR1-deficient samples. 
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statistically significant decrease in the number of surviving NDR1+/+ when compared to 
NDR1-/- cells was detected after gamma irradiation and etoposide treatment (Figure 1B). 
Furthermore, NDR1 deficient thymocytes showed increased survival after cytokine 
withdrawal (Figure 1C). Treatments which resulted in increased survival of NDR1 
deficient thymocytes seemed to also result in increased survival of NDR1+/- cells. In 
addition, mature T-cells were tested for a defect in response to activation-induced cell 
death (AICD) and cytokine withdrawal (Figure S2). Again, loss of NDR1 and in the 
case of cytokine withdrawal also heterozygosity resulted in slight, but statistically 
significant resistance of NDR1 targeted cells towards apoptosis induction.  
These results were confirmed by analyzing NDR activation in NDR1-/- thymocytes 
following apoptosis induction; a delay in NDR activation in knock-out thymocytes was 
ensates for NDR1 deficiency 
DR1 and NDR2 show  >80% identity at the protein level (11). Thus, the absence of 
l normal apoptotic responses in NDR1+/- and 
only observed after gamma irradiation (Figure 1D and S3). Taken together, these 
experiments showed that although NDR was activated in thymocytes upon treatment 
with several apoptotic stimuli, loss of NDR1 alone did not result in strong apoptotic 
resistance.  
 
NDR2 comp
N
developmental phenotypes and the overal
NDR1-/- mice might be due to compensation by NDR2. The effect of NDR1 
heterozygosity and deficiency on NDR2 expression was analyzed using tissues with 
high (thymus, spleen and lymph nodes) and low (colon) NDR1 expression (Figure 2A; 
Figure S4). NDR2 protein levels were up-regulated upon NDR1-knockout in a tissue 
specific manner (Figure 2A). Compared with a minor up-regulation of ~1.5-fold in 
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Figure 2. Reduction in NDR1 gene-dose is compensated by increased NDR2 protein levels. 
A: Analysis of NDR1/2 expression in representative tissues from NDR1+/+, NDR1+/- and NDR1-/- mice using specific antibodies 
against NDR2 and NDR1. B: Quantification of changes in NDR1 and NDR2 protein levels upon heterozygosity and deficiency of 
NDR1 protein (n = 3). Changes are expressed as fold changes in the NDR/Hsc70 ratio as compared with the wild-type level (* 
P<0.03; ** P<0.005). C: Primary MEFs expressing shRNA against firefly luciferase (shLUC) or NDR2 (shNDR2) were seeded for 
apoptosis induction 72 h after transfection. Apoptosis was induced 24 h later using 200µM etoposide or 1µg/ml anti-FAS-Ab in the 
presence of 1µg/ml CHX. Apoptosis in GFP+ cells was measured 22 h for etoposide and 18h for anti-FAS/CHX after induction by 
FACS. Results obtained were normalized to NDR1+/+-shLUC for better comparison of the two treatments (* P<0.03; ** P<0.005). 
D: Primary MEFs were transfected as described in C, sorted for GFP+ and further expanded for 48h. Apoptosis was induced using 
200µM etoposide for 22h. E: MEFs were pretreated as in D, but apoptosis was induced using 1µg/ml anti-FAS-Ab in the presence 
of 1µg/ml CHX for 18h.  
colon, there was a 2.5- to 3-fold increase in tissues with high NDR1 expression (Figure 
2B). NDR2 was slightly increased in NDR1+/- mice compared with NDR1+/+, whereas 
NDR1 protein levels were lower, reflecting the gene-dosage effect observed earlier 
(Figure S1D). These changes, however, did not result from increased transcription of 
the NDR2 gene or increased NDR2 protein stability (Figure S5). Taken together, NDR1 
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deficiency in mice appears to be compensated by an increase in NDR2 protein levels via 
a posttranscriptional mechanism.  
We analyzed next whether interfering with the observed compensation would result in 
apoptosis defects. Early passage NDR1+/+ and NDR1-/- MEFs expressing shRNA against 
h-grade peripheral T-cell lymphoma 
lthough our initial analysis revealed that loss of NDR1 is functionally compensated by 
ing 
NDR2 (shNDR2) or luciferase control (shLUC) were treated with both etoposide and 
anti-FAS. Knock-down of NDR2 in NDR1-/- MEFs resulted in a significant decrease in 
apoptotic cells compared to wild-type MEFs expressing shLUC (NDR1+/+-shLUC) 
(Figure 2C; Figure S6). Although not consistently observed in thymocytes (Figure 
1B/C), NDR1 deficiency in MEFs resulted in increased resistance towards both stimuli. 
This might indicate that compensation efficiency was cell-type dependent or disturbed 
upon ex vivo culture. However, reduction of NDR2 in the NDR1-deficient background 
further reduced apoptosis in this setting (Figure 2C). In addition, analysis of apoptotic 
extracts revealed that reduction of NDR2 in NDR1-deficient MEFs resulted in 
significantly reduced cleavage of caspase 3 after both anti-FAS and etoposide treatment 
(Figure 2D/E). This data showed that NDR2 functionally compensated NDR1 reduction 
and deficiency in untransformed cells, with defects in this compensation resulting in 
increased resistance towards apoptotic stimuli. 
 
Aged NDR1+/- and NDR1-/- animals develop hig
A
NDR2 in a gene-dosage dependent manner, with only minor apoptotic defects result
from NDR1 deficiency and heterozygosity, it seemed possible that targeting NDR1 
could contribute to the development of age-related diseases. To this end, we analyzed 
aged (17-27months) NDR1+/+, NDR1+/- and NDR1-/- mice (Figure 3A). Approximately 
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Figure 3. Aged NDR1+/- and NDR1-/- animals develop high-grade peripheral T-cell lymphoma  
A: Tumor spectrum in aged NDR1+/+, NDR1+/- and NDR1-/- mice (age 18-27 months). Mice were dissected and H&E-stained tissue 
sections were analyzed for the development of tumors. B: Bar chart representing the rates of lymphoma detected in aged NDR1+/+, 
NDR1+/- and NDR1-/- mice. In addition, the gender-specific rates of lymphoma development are shown. Note that female mice seem 
to be more prone to develop lymphoma than male. The numbers of total mice used for analysis are given in the lower panel. C: 
Example of immunohistochemical characterization of identified lymphatic lesions. Tumor cells (arrow) infiltrating kidney tissue 
were stained with antibodies against Pax-5 and CD3 to discriminate between B- and T-cells. D: Further characterization of T-cell 
lymphoma. Single-cell suspensions from lymph nodes of aged animals were stained with anti-CD4 and anti-CD8 and analyzed by 
FACS. Examples are given of a normal FACS profile from an aged NDR1-/- mouse (left panel), of the infiltration of CD4/8 double-
positive cells into lymph nodes (middle panel) and of the expansion of the CD4 single-positive population (right panel).  
 
70% of all NDR1+/- and NDR1-/- mice exami
analyzed (Figure 3B; Table S1). Female mic
male mice (Figure 3B). Immune phenotyping defined the lesions as high-grade 
peripheral T-cell lymphomas, with all tumo
analysis of T-cell lymphomas from aged ND
lesions were characterized either by infiltrati
ned exhibited lymphomas in various tissues 
e were more lymphoma-prone (80%) than 
rs being CD3 positive (Figure 3C). FACS 
R1+/- and NDR1-/- mice revealed that the 
on of CD4/CD8 double-positive (DP) cells 
into peripheral immunological organs or by expansion of CD4 single-positive (SP) 
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cells; ~60% of analyzed T-cell lymphomas were CD4/8 DP and 40% CD4 SP (Figure 
3D). Thus, deficiency of NDR1 or heterozygosity appeared to predispose mice to T-cell 
lymphoma development later in life, indicating that NDR1 seemed to act as a 
haploinsufficient tumor suppressor in T-cell lymphoma. 
 
NDR1+/- and NDR1-/- mice are highly susceptible to carcinogen-induced 
lymphomagenesis 
To examine whether younger mice show increased susceptibility to carcinogen-induced 
lymphoma development, N-ethyl-N-nitrosourea (ENU) was chosen as a carcinogen 
nce it has been reported to induce mainly T-cell lymphomas in the C57BL/6 
kg and monitored for a period of 9 months for cancer development. 
si
background (13). Mice 4-5 weeks old were injected intraperitonally with a single dose 
of ENU at 100mg/
Nine months after injection, 88% of NDR1-/- and 79% of NDR1+/- mice had developed 
tumors, compared with only 50% of wild-type mice (Figure 4A, Table S2). Analogous 
to aged mice heterozygosity in NDR1 resulted in a similar rate of tumor development 
than deficiency. Hematopoietic tumors were mainly observed, with T-cell lymphoma 
being most frequent. In addition, myeloproliferative diseases (MPD) were also found at 
later time-points (Table S2). Focusing on T-cell lymphomas, 53% of the treated NDR1-/- 
and 47% of the NDR1+/- mice developed tumors. In contrast, as already reported (13, 
14) , only 30% of the wild-type mice developed T-cell lymphomas after ENU treatment 
(Figure 4B). NDR1+/- and NDR1-/- animals not only showed increased penetrance but 
also earlier onset of T-cell lymphoma development after carcinogen treatment; tumor 
development in NDR1-/- began ~2 months earlier than in wild-type mice (Figure 4B). 
The T-cell lymphomas were characterized by a massive increase in thymus size and 
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Figure 4. NDR1+/- and NDR1-/- show a high susceptibility to ENU-induced lymphomagenesis  
A: Kaplan-Meier tumor-free survival curve of ENU-treated mice starting after injection with 100µg/g ENU at age 4 weeks and 
followed for up to 10 months. B: Kaplan-Meier lymphoma-free survival curve of ENU-treated mice. Fatal thymic T-cell 
lymphoma occurred at the highest frequency and at the earliest time points. Other hematopoietic malignancies occurred at later 
time-points (see Figure S1; Table S2). C: Examples of T-cell lymphoma from an ENU-treated NDR1-/- (middle panel; 25x 
enlarged) and an NDR1+/- mouse (lower panel; 20x enlarged). For comparison, a normal untreated thymus from a wild-type 
mouse is given (upper panel). D: Example of macroscopic (upper left panel) and microscopic infiltration of kidney tissue. 
Sections from affected organs were stained with H&E and analyzed for infiltrating tumor cells (20x upper right panel; 40x lower 
left panel). For comparison, an H&E-stained section from an unaffected wild-type kidney is given (lower right panel). E: 
CD4/CD8 profiles from thymus (upper panel), spleen (middle panel) and lymph nodes (lower panel) of ENU-treated NDR1-/- 
animals, without T-cell lymphoma (left) or with fatal T-cell lymphoma (right). Note that CD4/8 double-positive cells infiltrate 
spleen and lymph nodes.  
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weight (Figure 4C). Infiltration of other organs, such as lymph nodes, spleen and 
kidneys, leading to disruption of normal tissue architecture was frequently observed 
(Figure 4D). FACS analysis of the tumors showed them to be characterized by 
CD4/CD8 double-positive cells thereby confirming the T-cell lineage origin of the 
tumors (Figure 4E). Thus, although development of precursor and not peripheral T-cell 
lymphoma occurred after ENU treatment, NDR1+/- and NDR1-/- mice had a higher 
susceptibility to carcinogen-induced lymphomagenesis.  
Myeloproliferative diseases (MPD) were observed in addition to T-cell lymphomas 
(14). Again NDR1+/- and NDR1-/- mice were more prone to these diseases (32% and 
35%, respectively, vs. 20% in the wild type) (Figure S7A). Some mice affected by 
MPDs showed massive splenomegaly (Figure S7B). Analysis of these lesions by FACS 
showed an increase in cells belonging neither to the T-cell nor to the B-cell lineage. 
This population was found be composed of erythroid (Ter119+/CD71+) and myeloid 
(Gr-1+/Mac1+) cells (Figure S7C). In summary, loss or heterozygosity of NDR1 
predisposed younger mice to the development of T-cell lymphoma and MPDs after 
carcinogen treatment which further confirmed that NDR1 functioned as a 
haploinsufficient tumor suppressor.  
 
L
T
o
m
NDR2 protein upon loss of NDR1 were not reflected at the mRNA level (Figure S5), 
the analysis focused on the protein levels using NDR1 and NDR2 specific antibodies. 
ymphoma development is associated with a decrease in NDR1 and NDR2 expression 
he apparent gene-dosage effect of NDR1 on NDR2 expression and the predisposition 
f NDR1 targeted mice to T-cell lymphoma development prompted us to analyze tumor 
aterial from ENU-treated mice for the expression of NDR1 and NDR2. As changes in 
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Thymocyte extracts from healthy and untreated NDR1+/+, NDR1+/- and NDR1-/- mice 
were used as expression controls since tumor cells were mainly CD4/8 DP (Figure 5A). 
Loss of p27 expression was used as a tumor marker (15, 16). Comparison of the 
Figure 5. Expression of NDR1 and NDR2 in murine and human tumors  
 Analysis of NDR1 and NDR2 expression in tumor material from ENU-treated NDR1+/+ (upper panel), NDR1+/- (middle panel) 
and NDR1-/- (lower panel) mice. Single-cell suspensions from normal thymi of the indicated genotype or tumors were lysed and 
blotted for  
e 
sam  
( +/- -/-
(m
pur +
A:
 NDR1/2 expression using isoform-specific antibodies with Actin as loading control. Note that the expression of both
isoforms is down-regulated in most of the tumors compared with expression in normal thymocytes of the respective genotypes. Th
ples were also blotted for p27 as a tumor marker. B: Expression of NDR1 and NDR2 in MPD samples obtained from NDR1+/+
upper panel), NDR1  (lower panel) and NDR1  mice. Single-cell suspensions from spleens were lysed and blotted for NDR1/2 
expression with Actin as loading control. C: Expression of NDR1 and NDR2 in human T-cell lymphoma samples. Tumor tissue 
alignant T-cells >70% as judged by histopathology) was extracted and blotted for NDR1 and NDR2 using specific antibodies; 
ified CD3  human T-cells purified from whole blood were used as control.  
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expression of NDR1 and NDR2 in tumors and in normal thymocytes of the respective 
genotypes showed in most cases that both kinases were down-regulated (Figure 5A). 
For example, in NDR1-deficient tumors there was a dramatic decrease in NDR2 protein 
levels, with only one of seven tumors retaining NDR2 protein levels similar to that of 
untransformed thymocytes (Figure 5A, lower panel). The same was true for the majority 
of NDR1+/+ and NDR1+/- tumors (Figure 5A, upper/middle panel). Tumor material from 
MPDs obtained during the ENU experiment was also analyzed for NDR1 and NDR2 
expression (Figure 5B). Again, there was a reduction in total NDR kinase levels in the 
tumor samples. However, in tumors from NDR1+/+ and NDR1+/- mice, NDR1 levels 
were mainly affected. In samples lacking NDR1, there was a striking reduction in 
NDR2 protein (Figure 5B, lower panel). In summary, most murine tumors showed a 
reduction in at least one NDR kinase isoform suggesting that tumor development was 
accompanied by a reduction in total NDR kinase. 
To determine NDR1/2 expression in human T-cell lymphoma samples with different 
characteristics (Table S3), tumor biopsies with >70% malignant T-cells or purified 
CD3+ human T-cells were isolated and their lysates blotted for NDR1 and NDR2 
expression using specific antibodies (Figure 5C). Interestingly, most human tumors 
 
showed a significant decrease in NDR1 expression, similar to the situation observed in 
murine MPD samples. Thus, total NDR protein levels were reduced in murine and 
human T-cell lymphoma samples suggesting a conserved role for NDR kinases in tumor 
biology.
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Reduced expression of NDR1/2 in tumors correlates with changes in the expression of 
genes implicated in cell death regulation 
Analysis of NDR1/2 expression in tumors revealed that tumor development was 
associated with down-regulation of NDR kinases in most tumor samples (Figure 5A). 
Therefore we grouped the tumors according to their NDR expression into those with 
approximately normal NDR expression (NDR-high), those with slightly reduced NDR 
(NDR-middle), and those with strong reduction (NDR-low) and performed microarray 
analysis (Table S4). 46 genes showed at least a 1.5-fold change (P<0.05) in NDR-low 
tumors compared with normal thymocytes, NDR-high and NDR-middle tumors (Figure 
6A; Table S5). The correlations between NDR expression in tumors and changes in 
gene expression at the protein level were validated using Pou2af1 expression, as 
Pou2af1 mRNA exhibited a strong and consistent up-regulation in NDR-low tumors 
(Figure S8).  
Application of the Ingenuity Pathway Analysis Program to functionally annotate the 
genes correlating to low NDR expression, revealed enrichment of genes implicated in 
the regulation of cell death and the cell cycle (Figure 6B). Indeed, up-regulation of 
genes which have been shown to exert anti-apoptotic functions such as CD5L, MEF2c 
or Pou2af1 was observed (17-19). Furthermore, decreased expression of genes such as 
CDKN2C, TOP2A and CCND3 with pro-apoptotic function was noted (20-23). As we 
identified genes also correlating with low NDR level in tumors implicated in the 
regulation of the cell cycle, we tested, whether loss of NDR1 would impact on the 
roliferation of T-cells (Figure S9). Surprisingly, loss of NDR1 resulted in reduced 
roliferation of T-cells after stimulation with 1.0ug CD3 alone or 1.0ug CD3+1.0ug 
CD28, however stimulation with a higher dose of anti-CD3 antibody abolished this 
p
p
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Figure 6. Low NDR1/2 expression in tumors correlates with changes in the expression of genes associated with cell death 
genes discussed in the text). B: Functional analysis of genes associated with NDR-low in tumors. The list of genes obtained in B 
was imported into the Ingenuity Pathway Analysis Program and functional analysis performed. Functions with a -log(P-value) of 
TUNEL (green) was analyzed using IMARIS imaging software. D: Quantification of TUNEL positive cells in NDR-high (n=2) 
and NDR-low tumors (n=3). For each sample 27 field of view were analyzed. (** P<0.001). E: HeLa cells expressing inducible 
control siRNA (siCon). 24h later cells were treated with 100μM etoposide for 48h and afterwards analyzed using AnnexinV/PI 
staining (* P<0.002; n=3). 
A: Expression profiles of genes that were changed 1.5 fold (P<0.05) in NDR-low tumors (Table S4. Red arrows indicate selected 
>3 are shown. C: Analysis of Ki67 and TUNEL in NDR-high and NDR-low tumors. Colocalization (red) of DAPI (blue) and 
shRNA against NDR1 and NDR2 were treated with tetracycline for 72h and transfected with siRNA against MEF2c (siMEF2c) or 
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effect. Next we attempted to confirm our findings in NDR-high and NDR-low tumor 
samples (Figure 6C/S10). Addressing both proliferation and apoptosis we observed no 
major differences in Ki67 staining between NDR-high and NDR-low tumors. However, 
the numbers of apoptotic cells were significantly decreased in NDR-low tumors (Figure 
6D), confirming the apoptosis resistance in cells with decreased NDR level as observed 
earlier.  
Increased MEF2c expression has been reported to correlate with increased apoptosis 
resistance (19). We therefore tested whether siRNA mediated knock-down of MEF2c 
would rescue the apoptosis defects described for knock-down NDR1/2 HeLa cells 
(Figure 6E). Decreasing MEF2c-level in NDR1/2 depleted cells resulted in a slight but 
statistically significant rescue effect after etoposide treatment but not after FAS induced 
apoptosis (Figure S11), indicating that additional factors mediated the effects 
downstream of NDR. Taken together, low levels on NDR kinases in tumors correlated 
with changes in the expression of genes implicated in cell death and proliferation. 
However analysis showed that mainly the apoptotic response seemed to be affected by 
low NDR levels in tumors, thereby fully confirming the results obtained earlier.  
 
Decrease in E47 expression mediates apoptosis resistance upon decrease in NDR level 
To further understand the impact of NDR kinases on the expression of genes correlating 
w mon 
u
ta
has been shown to result in T-cell lymphoma and leukemia development in mice and 
men (24-26). We therefore tested whether E2A protein expression would be reduced in 
ith low levels on NDR in tumors, we performed an analysis to identify com
pstream factors regulating gene expression in our settings (Figure 7A). E2A (E12/E47) 
rgets were significantly enriched in our dataset. Loss or functional inactivation of E2A 
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tumors exhibiting reduction of NDR kinases. Only tumors with normal NDR kinase 
Figure 7. Reduction of NDR kinases result in decreased levels of E47 in tumors and cells leading to apoptosis resistance 
calculated using hypergeometric distribution. Regulators with a -log(P-value) of >3 are shown. B: Analysis of E47 expression in 
ells stably 
n NDR1/2 
depleted HeLa cells by overexpression of E47. Knock-down of HeLa cells was induced for 72h and cells were transfected with E47 
NA coupled to an IRES-gfp to monitor transfection. Apoptosis was induced 24h later using 100μM etoposide for 48h. Apoptosis 
s accessed using AnnexinV/PI staining gated on GFP-positive cells (* P<0.005; n=3). E: HeLa cells were pretreated and 
transfected as in D. Apoptosis was induced as described (4) and accessed as described in D (** P<0.025; n=3). 
A: Analysis of common upstream regulators of correlating genes. Using the Ingenuity Pathway Analysis Program Knowledge Base, 
upstream regulators of the expression of each correlating gene and the total known regulated genes were extracted. P-values were 
ENU induced tumors. C: Reduced expression of E47 upon knock-down of NDR1/2 in HeLa cells. Knock-down in HeLa c
expressing shRNA against NDR1 and NDR2 was induced for 4 days using tetracycline. D: Rescue of apoptotic defects i
cD
wa
 
levels retained high expression of the E2A isoform E47, whereas E47 expression was 
significantly reduced upon decreased NDR expression and even absent in approximately 
40% of the NDR-low tumors (Figure 7B). To validate the impact of diminished NDR 
kinase expression on E47 levels, we analyzed the expression of E47 in HeLa cells stably 
expressing validated shRNA against NDR1 and NDR2 (Figure 7C). Indeed, E47 
expression was reduced upon knock-down of NDR1/2 in HeLa cells (Figure 7C). 
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Finally, we attempted to rescue the apoptosis defects in NDR depleted cells by 
overexpression of E47 (Figure 7D/E). Indeed, overexpression of E47 rescued the 
apoptotic defects in NDR1/2 knock-down cells to ~50% after both etoposide and anti-
FAS treatment (Figure 7D/E). Taken together, reduced levels of NDR kinases in tumors 
and cells impacted on the expression of the E2A gene-product E47. Even more 
importantly, restoring E47 level reduced the apoptosis defects after Etoposide and anti-
FAS treatment, thereby giving mechanistic insight into the tumor suppressive function 
of NDR kinases. 
 
3.1.4 Discussion  
The NDR family kinases NDR1 and NDR2 have been implicated in the regulation of 
apoptosis downstream of FAS (4). We generated mice deficient for NDR1 to further 
analyze the role of NDR1 in apoptosis signaling, mainly in lymphocytes, where NDR1 
is highly expressed. We show that NDR1 in thymocytes is not only activated upon FAS 
stimulation, but also after apoptosis induction using intrinsic stimuli, such as DNA 
damage and dexamethasone. This finding attributes to NDR1 a broader role in apoptosis 
signaling and shows that NDR1 activation is not limited to death receptor stimulation. 
However, although apoptosis induction results in NDR kinase activation, loss of NDR1 
does not result in major defects in apoptosis in thymocytes and T-cells. Interestingly, in 
conditions in which loss of NDR1 results in apoptosis defects heterozygosity in NDR1 
also increased the resistance to apoptosis induction (Figure 1/S2). Analyzing the 
expression of the second NDR kinase isoform in mammals, NDR2, we find that NDR2 
is up-regulated in NDR1-deficient and heterozygous tissues. Interfering with the up-
regulation results in increased apoptotic defects. Thus, NDR2 can functionally 
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compensate NDR1 reduction indicating a tight, gene-dosage dependent regulation of 
total NDR kinase levels in vivo.  
Although NDR1 loss is compensated in young healthy mice, we still observe that loss of 
NDR1 predisposes mice to the development of T-cell lymphoma, both in older mice and 
upon carcinogen treatment of younger mice (Figure 3/4). Given that NDR1 levels are 
gene-dose sensitive, it is not surprising that even NDR1 heterozygous mice display a 
similar predisposition to tumor development, indicating that NDR1 functions as a 
haploinsufficient tumor suppressor in T-cell lymphoma (27). Indeed, under several 
onditions already loosing one allele of NDR1 results in apoptosis defects comparable 
in NDR1 deficient cells (Figure 1/S2). Although decreased levels in 
c
to those observed 
NDR1 are compensated by increased NDR2 levels, our experiments show that at least in 
terms of apoptosis the compensation is not always complete. Under certain conditions 
loss or heterozygosity of NDR1 results in increased resistance towards apoptosis 
induction. Could the increased tumor development in heterozygous and knock-out mice 
be explained by a predisposition to decrease the expression of NDR2 and thereby 
increasing the resistance towards pro-apoptotic stimuli? 
Addressing this hypothesis, we analyzed tumor material from NDR1+/+, NDR1+/- and 
NDR1-/- mice for the expression of NDR1 and NDR2. In T-cell lymphoma and MPD 
samples deficient for NDR1, the expression of the remaining isoform NDR2 is strongly 
decreased, as compared to the normal expression of NDR2 in NDR1-deficient cells 
(Figure 5). This indicates that tumor development is accompanied with defects to 
compensate for NDR1 loss. Importantly, T-cell lymphoma samples from heterozygous 
mice also display a decrease in NDR2 expression in most of the cases analyzed. 
Interestingly, T-cell lymphoma development in these mice is also accompanied by a 
 43
decrease in NDR1 expression (Figure 5). Even in tumors obtained from wild-type mice, 
a decrease in NDR1 and NDR2 amounts is observed in most cases. Thus, we can 
R1 predisposes mice to tumor 
conclude that T-cell lymphoma development in mice is accompanied by a decrease in 
both NDR kinase isoforms. Given, that in healthy tissue the reduction of NDR1 by loss 
of one allele is already compensated by increased NDR2, one might argue that T-cell 
lymphoma development is accompanied by a decrease in total NDR kinase levels. From 
this point of view, a reduction in one isoform without up-regulation of the other would 
yield a reduction of total NDR kinase levels and thereby facilitating defects in the 
response to pro-apoptotic stimuli. In line with this interpretation, NDR1 expression is 
significantly reduced without an accompanying NDR2 up-regulation in 75% of 
analyzed human T-cell lymphoma samples. Thus, human T-cell lymphoma 
development is also associated with a decrease in NDR kinase expression. Interestingly, 
NDR kinase expression is reduced in MPD samples, arguing for a tumor suppressive 
function of NDR kinases in different cell types and organs.  Taken together, T-cell 
lymphoma development in mice and humans is accompanied by a reduction in total 
NDR kinase levels. Apparently, loss of one allele of ND
development by further down-regulation of NDR1 and NDR2 expression. Recent 
publications have shown that predisposition to tumorigenesis can be strongly affected 
by even small changes in the expression and protein abundance of tumor suppressors 
(28-30), which in the case of DAPK1 in Chronic Lymphocytic Leukemia has been 
shown to impact the response of tumor cells to pro-apoptotic stimuli (28). Decrease of 
NDR kinase level could therefore similarly predispose to tumor development by 
impacting on the response of cells to apoptotic stimuli.  
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Evading apoptosis is considered to be one of the major hallmarks of cancer (31). We 
show here that NDR kinases are activated not only after extrinsic death signals, but also 
after intrinsic signals such as DNA damage. Importantly, down-regulation of total NDR 
kinase in untransformed cells results in increased resistance of these cells towards both 
extrinsic and intrinsic apoptotic stimuli. In line with this observation, tumors in which 
both NDR kinases are down-regulated exhibit a specific gene expression profile 
associated with cell death. Furthermore this genes expression profile is enriched for 
genes implicated in the regulation of the cell cycle. However, NDR1 deficient T-cells 
do not exhibit increased proliferation after stimulation. Interestingly, proliferation 
defects upon knock-out of several well known tumor suppressor proteins such as 
BRCA1, SMAD4 or VHL have been described (32-34). In addition, whereas tumors 
with low levels of NDR show a significant decrease in apoptotic cells, proliferation in 
these tumors does not seem to be significantly affected. During tumor development the 
cells probably acquire changes in other signaling pathways to overcome the defects in 
proliferation upon loss of NDR1. Still, it will be interesting for future studies to address 
the effect of NDR1 deficiency on proliferation in more detail. 
The genes correlating with low expression of NDR1/2 in T-cell lymphoma are enriched 
for targets of the E2A gene products E12/E47. Deficiency in E2A has been shown to 
result in T-cell lymphoma development in mice (24, 26). In addition, functional 
inactivation of E47 has been described in human T-cell acute lymphoblastic 
leukemia/lymphoma (25). Importantly, it has been shown that re-expression of E12/E47 
results in cell death in E2A deficient lymphoma cells (35). Strikingly, knock-down of 
NDR1/2 in HeLa cells results in decreased E47, a situation also observed in the tumors 
analyzed. Importantly, overexpression of E47 in HeLa cells depleted of NDR1/2 
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significantly rescued the apoptosis defects after both etoposide and anti-FAS treatment, 
confirming the functional link between NDR kinases and E47 expression in apoptosis. 
Reduction of NDR1/2 thus results in apoptosis resistance of tumors at least partially by 
impacting E47 protein levels. Now, future studies are needed to further define the 
impact of NDR kinases on E47 protein expression. 
The data presented here suggest that NDR kinases have a tumor-suppressive function. 
Indeed, recent publications have reported loss of heterozygosity of the genomic region 
containing the NDR1 gene in diffuse large B-cell non-Hodgkin's lymphoma, cervical 
cancer, colorectal carcinoma, lung cancer, ovarian cancer and renal cell carcinoma (36-
41). However, no deletions of the NDR2 locus have been reported so far. In addition, 
loss/reduction of NDR1 or NDR2 mRNA expression has not been associated so far with 
the development of T-cell lymphoma in humans (42). This might be explained by our 
results, as we observe changes in NDR1 and NDR2 expression mainly at the protein 
levels. Firstly, loss of NDR1 does not result in increased expression of NDR2 mRNA. 
Secondly, although we observe a strong reduction in NDR1 and NDR2 protein in 
tumors, their genes do not show up in the gene expression analysis. Therefore, it will be 
relevant in future studies to develop immuno-histological methods to analyze the 
expression of NDR1/2 in tumors at the protein level. 
In conclusion, we have identified NDR1 as a novel tumor suppressor protein in T-cell 
lymphoma. Interestingly, NDR1 shows features of haploinsufficiency, as loss of one 
allele of NDR1 predisposes mice to T-cell lymphoma development. Loss and 
heterozygosity of NDR1 results in increased apoptosis resistance of thymocytes and T-
cells under several conditions. Furthermore, our analysis shows that reduction in NDR1 
triggers the reduction of the expression of the compensating NDR2 isoform by a yet to 
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be identified post-transcriptional mechanism resulting in a total decrease in NDR 
kinases in tumors. Given that NDR1 is expressed predominantly in lymphocytes and 
that its expression is frequently reduced in T-cell lymphoma samples of murine and 
human origin, the assessment of NDR kinase protein expression in other lymphoid 
neoplasias could likely show a reduction of NDR1 (and NDR2) in these tumors as well. 
le chimeras were mated with wild-
Thus, addressing the protein levels of NDR1 (and NDR2) in tumors of different origins 
will broaden the role of NDR kinases in counteracting tumor development. 
 
3.1.5 Material and Methods 
Generation of NDR1-deficient mice and treatment  
A ~9-kb BamHI-NotI fragment containing exons 4, 5 and 6 was amplified from BAC 
clone 25140 (244/G01) (Incyte Genomics) using Expand Long Template Taq 
polymerase (Roche) and subcloned in pMCS5. A 5-kb IRES/lacZ/Neo cassette was 
inserted into the XhoI site of exon 4. The targeting vector was linearized using the SalI 
site and electroporated into 129/Ola ES cells. An external probe was used for ES cell 
Southern screening following KpnI digestion. An internal probe and a lacZ-Neo probe 
were used to characterize ES clones positive for homologous recombination. Correctly 
targeted ES cells were used to generate chimeras. Ma
type C57BL/6 females to obtain NDR1+/- mice. NDR1+/- mice were backcrossed for at 
least four generations with pure C57BL/6 mice. The progeny of NDR1+/- intercrosses 
was genotyped by multiplex PCR with three primers: (1) Ex4checkb, 5’-
GTCTTCTCATCGCTGTCACAGCT-3’; (2) Neo-2, 5’- 
GCTGCCTCGTCCTGCAGTTCATTC-3’; and (3) 6540bk, 5’- GCTCCCGCTCAGT-
TACCTGCTCC-3’. To induce lymphoma development, young female NDR1+/+, NDR1 
 47
NDR1+/- and NDR1-/- mice were injected intraperitonally at the age of 4 weeks with a 
single dose of N-ethyl-N-nitrosourea (ENU) at 100 mg/kg dissolved in PBS (pH 6.0) 
and were monitored up to 9 months after injection. All mouse experiments were 
performed according to the Swiss Federal Animal Welfare Law.  
 
Reagents and antibodies 
The following reagents were used for experiments: dexamethasone, N-ethyl-N-
itrosourea (Sigma), anti-CD3e, anti-CD28 (both from eBioscience), anti-CD4, anti-
otools), anti-p27 and anti-Actin (Santa Cruz), anti-E47 
e), anti-FAS (Jo-2; BD Bioscience), 
n
CD8, anti-B220 (from Immun
(BD Bioscience), anti-cleaved PARP (BD Bioscienc
anti-cleaved Caspase 3, anti-MST1 and anti-P-MST (Cell Signaling), anti-Hsc70 
(Stressgen). Anti-P-Thr-444/442-NDR1/2 (referred to as anti-T444-P), anti-NDR1 
(human) and anti-NDR2 have been described elsewhere (4, 43). To obtain antibodies 
specific to murine NDR1, a peptide corresponding to the C terminal part of murine 
NDR1 (ILKPTVTTSSHPETDYKNKD) was used to immunize rabbits. Antibodies 
were purified by immunoaffinity purification and tested for specificity (Figure S12). 
Antibodies against Pou2af1 were a kind gift from P. Matthias and have been described 
elsewhere (44). 
 
Cell culture and transfections 
The generation of HeLa cells expressing shRNA against NDR1 and NDR2 has been 
described previously (4). To induce knock-down of NDR1 and NDR2 cells were treated 
with tetracycline for 72h. Cells were transfected using Lipofectamine2000 (Invitrogen) 
as described by the manufacturer. Validated siRNA against MEF2c was obtained from 
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Ambion, control siRNA was from Qiagen (Figure S13A). E47 cDNA was a kind gift 
from C. Gallegos (University of Lleida, Spain) and constructs expressing E47 together 
with an IRES-gfp was obtained by subcloning E47 into a pcDNA3 vector containing an 
IRES-gfp cassette using BamHI/EcoRI (Figure S13B). 
  
Protein extraction and immunoblotting 
olated and 1 x 106 cells were seeded into 48-well plates. Apoptosis was 
duced using gamma irradiation (TORREX 120D, Astrophysics Research Corp.; 5 
toposide, dexamethasone, anti-CD3/CD28 treatment or 
Proteins were extracted from freshly isolated or cultured cells as previously described 
(45). For the extraction of frozen tissues, freshly isolated organs were flash frozen and 
minced with a tissue homogenizer using 6 µl of lysis buffer per mg tissue. Extracts were 
incubated for 1 h at 4°C and cellular debris were removed by centrifugation at 14’000 
rpm for 15 min at 4°C. Western blot was performed as described previously, except that 
blots analyzed using the Licor Odyssey System were incubated with secondary 
antibodies coupled to fluorescent dyes. Quantifications were carried out using the Licor 
Odyssey software. 
 
Apoptosis Assays 
For the analysis of thymocyte apoptosis, freshly isolated thymocytes from 4- to 6-week-
old mice were is
in
mA/120 kV and 0.13 Gy/s), e
treatment of cells with anti-Fas (Jo2; BD Bioscience) antibody in the presence of 
cycloheximide. The response to cytokine withdrawal was accessed by seeding the cells 
in IMDM+10% FCS for the indicated time and analyzed using a Vicell automated cell 
counter. For the induction of apoptosis in MEF cells, cells were seeded at consistent 
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densities 24 h before treatment. Apoptosis was induced by treating cells with etoposide 
or anti-Fas antibody in the presence of cycloheximide. Apoptosis was assessed using 
either Annexin V staining (BD Bioscience) or a cationic lipophilic dye DilC1(5) assay 
kit (Invitrogen). Cells were analyzed by FACS. Assays to assess activation-induced cell 
ath (AICD) were performed as described previously (46). In short, T-cells were 
hment columns (eBioscience) and activated for 
 NDR2 protein in mouse embryonic fibroblasts (MEFs), 
ligonucleotides targeting murine NDR2 were inserted into pTER(48) and tested in 
ions of IMCD-3 cells (Figure S14). shNDR2#13 and shLUC 
de
purified from spleens using T-cell enric
72 h on plates coated with 5µg/ml anti-CD3 antibody in the presence of 1µg/ml anti-
CD28 (both eBioscience). Activated viable cells were obtained using Lympholyte-M 
(Cedarlane Labs) and replated for 20 h on plates coated with increasing concentrations 
of anti-CD3 antibody in the presence of 50 U/ml IL-2 (Immunotools). Analysis of 
AICD was done as described previously (46, 47). 
 
Retrovirus-mediated knockdown of NDR2  
To knock down
o
transient transfect
(sequence provided upon request) were cloned into the pSUPER-retro.gfp.neo vector 
(Oligoengine) and used for further experiments. For virus production, Phoenix-Eco cells 
were transfected with jetPEI transfection reagent (polyplustransfection) and virus was 
harvested 48 h and 72 h later. Virus-containing supernatant was used to spin infect 
MEFs in the presence of 5 µg/ml polybrene (1000 g, 30°C, 1 h). Medium was changed 
after 6 h and the cells left to recover for 48 h.  
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FACS analysis 
Single-cell suspensions from lymphatic organs or tumor tissue were obtained by 
pressing the organ through a 70-µm nylon mesh. Resulting suspensions were depleted 
of erythrocytes by incubation in Gey's solution and subsequently stained with antibodies 
covalently coupled to FITC, PE or APC. The antibodies used for FACS staining were 
anti-CD3e, Gr-1, Ter119, CD71 (BD Bioscience), anti-CD4, anti-CD8 and anti-B220 
(Immunotools), and Mac-1 (Southern Biotech). Flow cytometric analysis was 
performed using a FACScalibur cell analyzer (BD Bioscience). Cell sorting was 
performed using a MoFlo device (DakoCytomation).  
 
Histopathological analysis 
Tissue specimens were fixed in 4% neutral buffered formalin and embedded in paraffin. 
ith hematoxylin and eosin (H&E) or with 
MuLV reverse transcriptase (NEB) and 
ligo-dT primers. Quantitative RT-PCR to detect mNDR2 (primer sequences upon 
Paraffin sections (4 µm) were stained w
antibodies against Pax-5 (BD Bioscience), CD3 (Dako) or Ki67 (Neomarkers). TUNEL 
staining was performed using the ApoAlert DNA Fragmentation Assay Kit (Clontech) 
as described by the manufacturer. Acquired images were analyzed using the IMARIS 
imaging software. 
 
RNA isolation and quantitative RT-PCR 
Total RNA from flash frozen organs or tumor cells was isolated with TRIzol reagent 
(Invitrogen) and further purified using RNeasy kit (Qiagen). cDNA from samples was 
generated from 2μg of total RNA using M-
O
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request) was carried out using SYBR green technology in an ABI Prism 7000 detection 
tatistical Analysis 
rformed with Student's t-test for the comparison between 
koc Biol 74, 311-330 (2003). 
. A. Strasser, P. J. Jost, S. Nagata; The many roles of FAS receptor signaling in 
system (Applied Biosystems).  
 
Microarray analysis  
RNA extracted as described above was processed and hybridized on to Affymetrix 
430v2 chips as described by the manufacturer. Data was analyzed using Expressionist 
(GenData AG). Normalized data was analyzed using N-way ANOVA (p<0.05). Only 
changes greater than 1.5-fold were analyzed.  
 
S
Statistical analyses were pe
two samples. N-way ANOVA was used for the analysis of micro-array data. 
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3.1.7 Supplemental Material 
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Figure S1. Generation of NDR1-deficient mice
A: Schematic representation of the targeting strategy. The murine Ndr1 locus was disrupted by insertion of an IRES/lacZ/neo 
cassette into exon 4 of the kinase. Binding sites of the 5’ external probe used for Southern blot analysis as well as the primers 
used for genotyping are indicated. B: Southern blot analysis of KpnI-digested tail DNA samples from a heterozygous mating. 
C: Analysis of tail DNA samples using PCR genotyping. D: Validation of successful disruption of the Ndr1 locus at the 
protein level. Thymus extracts from NDR1+/+, NDR1+/- and NDR1-/- mice were analyzed using an NDR1-specific antibody. 
Note that NDR1 protein expression was already reduced in NDR1+/- samples. E: Ratio of genotypes obtained from NDR1 
heterozygous matings, compared with the expected Mendelian ratios. 
 Figure S2. Mature T-cells from NDR1+/- and NDR1-/- mice show slightly increased apoptosis resistance 
A: Mature T-cells were isolated and seeded in IMDM+10% FCS. After the indicated time cells were harvested and cell 
viability was accessed using a Vicell automated cell counter (* P<0.04). B: Analysis of the apoptotic response of NDR1+/+ and 
NDR1-/- mature T-cells to activation-induced cell death (AICD, n = 3). Calculations were carried out as in B (** P<0.025). 
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Figure S3. No change in NDR activation in NDR1-deficient thymocytes upon dexamethasone and anti-FAS/CHX-induced 
apoptosis 
A/B: Freshly isolated thymocytes from NDR1+/+ and NDR1-/- mice were treated with 1 µM dexamethasone (A) or anti-FAS 
antibody (0.5 µg/ml) + CHX (30 µg/ml) (B) and lysed after the indicated incubation times. Activation of NDR kinases was 
assessed using the anti-T444-P antibody; total kinase was analyzed using NDR1 or NDR2 isoform-specific antibodies. 
Induction of apoptosis was analyzed by PARP cleavage.  
  
 
 
 
Figure S4. NDR1 and NDR2 show distinct protein expression pattern in mice 
A: Representative expression of NDR1 and NDR2 proteins in different tissues from wild-type mice. Tissues extracts were 
blotted with specific antibodies against NDR2 and reblotted for NDR1 after stripping using the Licor Odyssey technology. 
Hsc70 expression was used as loading control. B: Quantification of NDR1 and NDR2 tissue distribution. Blots were scanned 
using Licor Odyssey technology and the respective NDR kinase/Hsc70 ratio was normalized to the expression in liver (n = 3). 
Note that kidney samples were omitted from the quantification due to obvious degradation. 
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Figure S5. No difference in NDR2 gene expression and protein stability upon loss of NDR1
A: Analysis of NDR2 gene expression in NDR1+/+, NDR1+/- and NDR1-/- thymus, spleen and colon extracts using qRT-PCR. 
B: Analysis of NDR2 protein stability in NDR1+/+ and NDR1-/- MEFs. MEFs were treated for the indicated time with CHX 
(50ug/ml) and lysed. Blots for NDR2 and Actin were scanned using the Licor Odyssey technology.  
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Figure S6. Reduction of NDR2 level in NDR1 deficient MEFs result in increased apoptosis resistance after etoposide and anti-
FAS/CHX treatment 
A: Primary MEFs were transfected with a retrovirus coding for shRNA against firefly luciferase (shLUC) or NDR2 (shNDR2). 
The cells were seeded for apoptosis induction 72 h after transfection. Apoptosis was induced 24 h later using 200 µM 
Etoposide and apoptosis in GFP+ cells was measured 22 h after induction by FACS. Results are given for a representative 
experiment, which was repeated twice with a similar outcome. D: MEFs were treated as in A, but apoptosis was induced using 
or 1 µg/ml anti-FAS-Ab in the presence of 1 µg/ml CHX. Apoptosis was determined 18 h later. Results are given for a 
representative experiment, which was repeated twice with a similar outcome.  
 
 Figure S7. Increased development of myeloproliferative diseases (MPD) in NDR1+/- and NDR1-/- mice after ENU treatment 
A: Kaplan-Meier survival plot showing the incidence of MPDs after ENU treatment. B: Spleen weights of mice not suffering 
from T-cell lymphoma upon dissection. The average weight of unaffected spleens was 0.11 ± 0.02 g. C: Characterization of 
ith antibodies against B220, CD3 (B- vs. T-cells), CD4, CD8 (T-cell marker), CD71, Ter119 (erythroid 
MPDs found in ENU-treated mice. Splenocytes from an unaffected (upper panel) and two mice with MPD (middle and lower 
panel) were stained w
marker), Mac-1 and Gr-1 (granulocyte/ monocyte marker). Note that in mice with MPD, the B220-/CD3- population was 
markedly increased, which may be accounted for by an increase in either c- KIT+/Ter119+ cells or Mac-1+/Gr-1+ cells.  
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Figure S8. Increase in Pou2af1 correlates with low NDR levels in tumors
A: Confirmation of change in NDR-low-associated gene expression for the example of Pou2af1. Tumor extracts from all 
ENU-induced tumors were blotted for Pou2af1 expression using a murine Pou2af1-specific antibody 
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Figure S9. Loss of NDR1 results in proliferation defects in mature T-cells after TCR-stimulation 
A: Mature T-cells from NDR1+/+ and NDR1-/- mice were isolated, labeled with CFSE and seeded into wells coated with the 
indicated concentrations of anti-CD3 antibody in the presence of anti-CD28 (1μg/ml) where indicated. 72h later cells were 
harvested and analyzed using FACS. Results were analyzed using the proliferation platform of the FlowJo analysis software 
(Number of cycles and model sum are shown). B: Quantification of the number of divided cells as accessed using the 
proliferation platform of the FlowJo analysis software. 
Figure S10. No consistent differences in Ki67 staining between NDR-high and NDR-low tumors
A: Analysis of Ki67 staining in NDR-high and NDR-low tumors (see also Figure 6C). 
Figure S11. siRNA against MEF2c does not rescue apoptosis defects in NDR1/2 depleted cells after anti-FAS/CHX treatment
A: HeLa cells expressing inducible shRNA against NDR1 and NDR2 were treated with tetracycline for 72h and transfected 
with siRNA against MEF2c (siMEF2c) or control siRNA (siCon). 24h later cells were treated with anti-FAS antibody 
(0.5μg/ml) in the presence of 10μg/ml CHX for 6h and afterwards analyzed using AnnexinV/PI staining (n=3). 
 
 
 
 
Figure S12. Characterization of a murine NDR1-specific antibody
A: Whole cell extracts from HEK293 cells transfected with the indicated HA-tagged murine and human NDR isoforms were 
probed with anti-mNDR1 and anti-HA antibody. B: Whole cell/ tissue extracts from NDR1+/+ and NDR1-/- thymus, 
untransfected and HA-mNDR1-transfected HeLa cells were probed with anti-mNDR1
 
.  
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Figure S13 Confirmation of siRNA against MEF2c and overexpression of E47
A: HeLa cells expressing inducible shRNA against NDR1 and NDR2 were treated with tetracycline for 72h and subsequently 
transfected with siRNA against MEF2c (siMEF2c) or control siRNA (siCon). 24h later cells were lysed and MEF2c RNA level 
were analyzed using semi-quantitative RT-PCR with GAPDH level serving as control. Note the increase in MEF2c RNA level 
upon knock-down of NDR1/2. B: HeLa cells expressing inducible shRNA against NDR1 and NDR2 were treated with 
tetracycline for 72h and subsequently transfected with cDNA for E47. The cells were lysed 24h later and E47 level were 
analyzed using western-blotting. 
Figure S14. Testing of different shNDR2 constructs
A: IMCD-3 cells were transfected with pTER vectors containing different shRNA constructs against murine NDR2 using 
Lipofectamine 2000. Knock-down efficiency was analyzed after 72 h using an NDR2-specific antibody. Sequences #2 and #13 
were chosen for subsequent cloning into pSUPER. B: NIH3T3 cells were infected with retrovirus-containing supernatant 
expressing the indicated shRNAs. GFP+ cells were sorted 48 h after infection and expanded for another 36 h. Knock-down 
efficiency and specificity were tested using antibodies against NDR1 and NDR2.  
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Table S1. Aged mice analyzed for tumor development 
No. Genotype Gender Age at 
dissection 
Lymphomaa 
258 NDR1+/+ female 24.2 - 
440 NDR1+/+ female 23.7 + 
449 NDR1+/+ female 23.9 - 
451 NDR1+/+ female 25.6 - 
486 NDR1+/+ female 20.0 - 
353 NDR1+/+ male 25.2 - 
424 NDR1+/+ male 23.4 - 
437 NDR1+/+ male 23.7 - 
441 NDR1+/+ male 23.9 - 
482 -  NDR1+/+ male 20.5 
544 NDR1+/+ male 21.2 - 
568 NDR1+/+ male 19.9 - 
237 NDR1+/- female 24.7 + 
2 male 27.1 + 90 NDR1+/- fe
454 NDR1+/- female 25.7 + 
515 NDR1+/- female 24.1 - 
517 NDR1+/- female 24.1 + 
610 NDR1+/- female 18.9 + 
455 NDR1+/- male 24.6 - 
472 NDR1+/- male 24.5 + 
481 NDR1+/- male 20.5 - 
533 NDR1+/- male 21.1 - 
93 -/- 24.2 -  NDR1  female 
198 NDR1  female 24.8 + -/-
237 NDR1-/- female 25.1 + 
260 NDR1-/- female 25.2 + 
276 NDR1-/- female 23.4 + 
291 NDR1-/- female 27.1 + 
325 NDR1-/- female 26.5 + 
369 NDR1-/- female 24.8 + 
425 NDR1-/- female 23.4 + 
448 NDR1-/- female 23.9 + 
457 NDR1-/- female 22.1 - 
553 NDR1-/- female 21.2 + 
586 NDR1-/- female 24.9 + 
635 NDR1-/- female 17.5 + 
694 NDR1-/- female 23.1 + 
57 NDR1-/- male 26.8 + 
243 NDR1-/- male 24.4 - 
281 NDR1-/- male 21.5 + 
282 NDR1-/- male 21.5 - 
303 NDR1-/- male 25.5 - 
360 NDR1-/- male 24.1 - 
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369 NDR1-/- male 24.8 + 
479 NDR1-/- male 20.7 - 
483 NDR1-/- male 20.5 - 
496 NDR1-/- male + 22.1 
507 NDR1-/- male 23.7 - 
521 NDR1-/- male 24.0 + 
644 NDR1-/- male 25.6 + 
 
a Detection of a wa  by eva g H&E s ned paraffin sections of 
us organs ve fo a/ + e for lymphoma). T-cell origin of 
r cells was verified by subsequent stain f section ith anti-Pax-5 and anti-
 In addit is o les by FACS was done by staining single cell 
nsions of  orga
 lymphom s done luatin tai
vario  (- = negati r lymphom  = positiv
tumo ing o s w
CD3. ion analys f samp
suspe  lymphatic ns with antibodies against CD3, CD4, CD8 and B220. 
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Table S2. Overview of tumors identified in ENU-treated mic
type er 
ed mi
Number of 
mice 
hematopoietic 
tumorsa 
Numbe f mice 
with T-cell 
lympho  
Number of 
mice with 
MPD 
e 
Geno Numb of 
inject ce with 
r o
ma
NDR1+/+ 10 (50% 6 (30% 4 (20%) 20 ) ) 
NDR1+/- 19 15 (79%) 9 (47%) 6 (32%) 
NDR1-/- 17 15 (88%) 9 (53%) 6 (35%) 
 
a Hematopoietic tumors were comprised of T-cell lymphoma and myeloproliferative 
diseases as described in Fig.4 and S1. 
 
Table S3. Classification of human T-cell lymphoma samples 
Number  Classificationa NDR expression reduced: 
01 T-NHL:AITL - 
02 T-NHL:AITL + 
03 T-NHL: NOS + 
04 T-NHL: NOS + 
05 T-NHL: NOS + 
06 T-NHL: AITL + 
07 T-NHL: NOS + 
08 T-NHL: NOS + 
09 T-NHL: AITL + 
10 T-NHL: AITL + 
11 T-NHL: NOS - 
12 T-NHL: NOS - 
 
a mphoma; NOS: not otherwise specified; 
ITL: angioimmunoblastic T-cell lymphoma 
ors were classified according to the current WHO-classification. 
 Abbreviations used: NHL: non Hodkins ly
A
Tum
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Table S4. Grouping of tumors according to their NDR1/2 expression 
pressioNDR1/2 ex n Tumor sample 
  
NDR1/2 high NDR1+/+ 03 
 NDR1+/+ 04 
  
NDR1/  m2 iddle R1+ND /+ 06 
 NDR1+/- 02 
 NDR1+/- 05 
 NDR1-/- 01 
  
NDR1/2 low NDR1+/+ 01 
 NDR1+/+ 02 
 NDR1+/+ 05 
 NDR1+/- 01 
 NDR1+/- 03 
 NDR1+/- 04 
 NDR1+/- 06 
 NDR1+/- 07 
 N 1-/- 02 DR
 N 1-/- 03 DR
 N 1-/- 04 DR
 N 1-/- 05 DR
 N 1-/- 06 DR
 N 1-/- 07 DR
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Table S5. Genes statistically significant up-/down-regulated in NDR-low tumors 
Gene Symbol Description 
high/ 
normala 
NDR-middle/ 
normala 
NDR-low/ 
normala 
NDR-
Igh-6 
noglobulin heavy chain 6
chain of IgM)  3.45 115.79 
Immu  (heavy 
0.41
Mef2c myocyte enhancer factor 2C 0.67 0.58 80.07 
Saa3 yloid A 3  1.44 41.73 serum am 2.12
Napsa napsin A aspartic peptidase 7 0.61 35.00 0.4
Pou2af1 POU domain, class 2, associating 5 0.87 32.54 factor 1 0.4
Cd5l CD5 antigen-like 1 2.64 30.52 1.9
Myo1e myosin IE 0.93 1.04 22.44 
Myl4 in, light polypeptide 4  9.11 18.46 myos 5.31
Emilin2 elastin microfibril interfacer 2  0.93 12.34 0.79
Arhgef12 
Rho guanine nucleotide exchang
(GEF) 12 7 0.64 7.55 
e factor 
1.2
Ndg2 Nur77 downstream gene 2 3 1.09 6.22 2.1
A030007L17Rik RIKEN cDNA A030007L17 gene 2 1.68 5.98 1.7
Tirap 
toll-interleukin 1 receptor (TIR) 
containing adaptor protein 8 1.01 5.90 
domain-
1.1
Itgb7 integrin beta 7 5 1.02 5.40 0.4
Osbpl5 oxysterol binding protein-like 5 7 0.96 4.83 1.0
Pck2 
phosphoenolpyruvate carboxykin
(mitochondrial) 0.86 0.80 3.52 
ase 2 
Traf3ip2 Traf3 interacting protein 2 5 1.32 2.81 1.1
Nudt18 
nudix (nucleoside diphosphate 
moiety X)-type motif 18 0.76 1.11 2.41 
linked 
Cnn2 calponin 2 0.70 0.84 2.33 
St3gal1 
ST3 beta-galactoside alpha-2,3-
sialyltransferase 1 0.50 0.41 2.16 
Ripk1 
receptor (TNFRSF)-interacting serine-
threonine kinase 1 0.91 0.89 1.82 
Ipo8 importin 8 1.32 1.04 1.62 
Iqgap1 
IQ motif containing GTPase activating 
protein 1 0.97 1.05 1.62 
Wars tryptophanyl-tRNA synthetase 1.24 0.97 1.51 
     
Dlg4 discs, large homolog 4 (Drosophila) 1.86 0.95 0.65 
Wbp5 WW domain binding protein 5 0.75 1.00 0.65 
Pdgfa platelet derived growth factor, alpha 8.18 1.05 0.60 
Cep55 centrosomal protein 55 1.15 1.08 0.53 
Txndc9 thioredoxin domain containing 9 1.01 0.98 0.52 
Tmpo thymopoietin 1.06 0.88 0.51 
Top2a topoisomerase (DNA) II alpha 1.24 1.00 0.50 
Cdkn2c 
cyclin-dependent kinase inhibitor 2C 
(p18, inhibits CDK4) 1.36 1.30 0.49 
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Kif11 0.47 kinesin family member 11 1.46 1.08 
Apold1 apolipoprotein L domain containing 1 1.26 1.19 0.46 
Kif18a kinesin family member 18A 1.23 1.23 0.45 
Anln 
 binding protein (scraps 
1.13 0.45 
anillin, actin
homolog, Drosophila) 1.47 
Cenpa tein A centromere pro 0.95 1.01 0.44 
Esco2 
molog 2 (S. establishment of cohesion 1 ho
cerevisiae) 1.24 1.27 0.44 
Spc25 
spindle pole body component 25 homolog 
(S. cerevisiae) 1.07 1.11 0.42 
Pbk PDZ binding kinase 1.00 1.19 0.35 
H2afx H2A histone family, member X 1.07 0.80 0.34 
Ckap2 in 2 cytoskeleton associated prote 0.94 0.91 0.33 
Kif2c : 
3 
// similar to 
-associated kinesin) (MCAK) LOC63165
kinesin family member 2C /
Kinesin-like protein KIF2C (Mitotic 
centromere 1.56 1.25 0.30 
Ccnd3 cyclin D3 0.57 0.67 0.29 
E2f7 : 
LOC639365 0.58 0.44 0.21 E2F transcription factor 7 
Bex1 brain expressed gene 1 0.55 2.45 0.14 
 
a Express he respective value for normal 
thymocy
 
 
 
 
ion values for each tumor type was divided by t
tes. 
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3.2.1 Abstract  
The G1-phase of the cell cycle is an important integrator of internal and external cues, 
allowing a cell to decide whether to proliferate, differentiate or die. We identify here a 
role for mammalian NDR kinases in regulating G1-progression and S-phase entry. 
Although characterized well terms of biochemical regulation and upstream signaling, 
signaling downstream of mammalian NDR kinases remains largely unknown. Here 
we describe downstream signaling mechanisms by which NDR kinases regulate cell 
cycle progression. NDR kinases directly impact on the protein stability of the c-myc 
proto-oncogene and the Cyclin-Cdk inhibitor protein p21. Addressing the mechanisms 
behind the regulation of c-myc and p21 stability, we identify p21 as the first in vivo 
substrate for mammalian NDR kinases. Whereas p21 levels are regulated in a kinase 
activity dependent manner, c-myc levels are regulated independently of NDR kinase 
activity: NDR kinases bind to c-myc and interfere with c-myc ubiquitination and 
degradation. 
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3.2.2 Introduction 
In order to duplicate, cells have to proceed through a defined order of events 
collectively called the cell cycle. The eukaryotic cell cycle consists of 4 phases, which 
can roughly be defined by growth and preparation for the duplication of the genetic 
material in G1-phase, duplication of the genetic material in S-phase, preparation for 
separation in G2-phase and finally separation of the genetic material into two 
daughter cells in M-phase. Proper progression through a given cell cycle phase and 
unidirectional transition between the phases are highly controlled on multiple levels 
(1). Defects in the mechanisms controlling the cell cycle have been shown to result in 
accumulation of genetic alterations and subsequent cancer development (2). The G1-
phase of the cell cycle is a very important integrator of internal and external cues, 
allowing cells to grow, process outside information or repair damage before entering 
S-phase. In G1 a cell decides whether to self renew, differentiate or die (1). Entry into 
S-phase is mediated by the action of Cyclin-Cdk complexes. Initially Cyclin D-
Cdk4/6 and later Cyclin E-Cdk2 complexes phosphorylate the Rb tumor suppressor 
protein allowing dissociation of Rb from E2F transcription factors and subsequent 
transcription of genes required for S-phase entry (3).  
The activity of Cyclin-dependent kinases is controlled on multiple levels (4). The 
association of Cdks with Cylin subunits is a prerequisite for Cdk activation. This 
process is controlled firstly by the availability of the Cyclin sub-unit, which 
abundance is regulated both by transcriptional and post-transcriptional processes (4). 
Furthermore, Cyclin-Cdk inhibitor (CKI) proteins of the Cip/Kip and INK4 family 
control Cyclin-Cdk activity by different mechanisms. Whereas members of the 
Cip/Kip family such as p21, p27 and p57 directly inhibit the Cdk activity, the INK4 
family members p15, p16, p18 and p19 actively promote Cyclin-Cdk complex 
77 
disassembly. Interestingly, the Cip/Kip family members p21 and p27 are needed for 
efficient assembly of Cyclin D-Cdk4/6 complexes (5). Importantly, loss of several 
CKI proteins has been associated with tumor development (2). 
Members of the NDR family of Ser/Thr kinases are highly conserved from yeast to 
men and have been implicated in the regulation of a variety of biological processes 
(6). With the regulation of mitotic exit, cell growth, proliferation, centrososme 
duplication and morphogenesis, NDR kinases across species have been shown to 
function in processes tightly linked to the cell cycle (6). The human genome encodes 
four different NDR kinase family members: NDR1/2 and LATS1/2 (7). The kinases 
LATS1/2 function as part of the HIPPO pathway thereby controlling the localization 
and function of the YAP oncogene (8). The HIPPO pathway thereby controls cell 
growth, cell size, proliferation and apoptosis. Furthermore, roles for LATS1 and 
LATS2 in controlling mitotic exit and genomic stability have been described (9, 10). 
Although well characterized in terms of biochemical regulation, functions for the 
other two NDR family kinases in the human genome NDR1 and NDR2 only recently 
started to unravel. In cellular systems NDR kinases have been implicated in the 
regulation of centrosome duplication, apoptosis and the alignment of mitotic 
chromosomes (11-13). Furthermore, a recent study indicated a tumor suppressive 
function for NDR1/2 in mice by controlling proper apoptotic responses (Cornils, et al. 
submitted). Interestingly, with the involvement of MST1 and hMOB1 in the 
regulation of NDR1/2 in centrosome duplication and apoptosis and MST2 in the 
alignment of mitotic chromosomes, several components of the HIPPO pathway also 
function in the regulation of NDR1/2 (11, 13, 14). However, although first functions 
for NDR1/2 were defined recently, downstream signaling remained elusive. 
Furthermore, although NDR kinases have been implicated in cell-cycle dependent 
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processes such as centrosome duplication and the alignment of mitotic chromosomes, 
discrepancies exist whether NDR kinases are activated in M or S-phase of the cell 
cycle (11, 14). Here we addressed the activation of NDR1/2 throughout the cell cycle. 
We show that NDR1/2 are activated in G1-phase by MST3, the third MST-family 
kinase shown to function upstream of NDR1/2. Even more importantly, with the 
direct regulation of c-myc and p21 stability, we define first downstream signaling 
mechanisms by which NDR kinases control G1-progression and S-phase entry.   
 
3.2.3 Results 
NDR kinases are activated in G1-phase by MST3 
Earlier reports have implicated NDR family kinases in the regulation of cell-cycle 
dependent processes such as mitotic chromosome alignment and the regulation of 
centrosome duplication (11, 14). However it has been reported that the activation of 
NDR kinases can take place in M-phase or in S phase of the cell-cycle. In order to 
address this discrepancy we analyzed NDR activity changes during the cell-cycle. M-
phase arrested HeLa S3 cells were washed free from nocodazole, replated in fresh 
medium and followed for up to 18h after release (Figure 1A). NDR kinase activation 
was assessed using an antibody specific for the hydrophobic motif (HM) 
phosphorylation of NDR1 and NDR2 (referred to as anti-T444P). HM-
phosphorylation of NDR1/2 was nearly absent in M-phase, but increased after 3h and 
peaked around 6-8h after release. The activation of NDR1/2 coincided with 
accumulation of the G1-phase marker CyclinD1 and PI-staining confirmed that 4-6h 
after release the cells were mainly in G1. HM-phosphorylation of NDR1/2 started to 
gradually decrease after 12h up to the end of the experiment, which coincided with the 
accumulation of the S/G2-phase marker CyclinA. Thus, NDR kinases were activated 
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Figure 1. NDR kinases are activated by MST3 in G1-phase of the cell-cycle. 
A: HeLa S3 cells were synchronized using a double thymidine block followed by nocodazole arrest and mitotic shake-off. 
Floating cells were collected, washed free from nocodazole and replated in fresh medium. After the indicated time, cells 
were harvested and processed for immunoblotting and FACS analysis. Activation of NDR1/2 was accessed using anti-T444-
P, NDR1 and NDR2 antibodies. Cell cycle distribution was accessed using PI staining and FACS analysis. Cell cycle phases 
were confirmed using Cyclin B1, Cyclin D1 and Cyclin A expression. B: HeLa cells were arrested at G2/M-border using 
nocodazole treatment for 14h. Cells were released into M/G1 phase for the indicated time before harvesting. Lysates were 
subjected to immunoblotting and immuno-precipitation of endogenous NDR species using a mixture of isoform specific 
antibodies. NDR kinase activity was accessed using peptide kinase assay (n=3). C: HeLa cells were transfected with 
dominant-negative MST1, MST2 or MST3 and 24h later arrested with nocodazole for 14h. Arrested cells were harvested or 
released into G1 for 8h before harvesting. NDR activation was accessed using T-444-P antibody. Cell cycle phases were 
confirmed by analyzing Cyclin B1 and p27 expression. D: HeLa cells were transfected with control siRNA (siC) or siRNA 
against MST3 (siMST3) and treated and analyzed as described in C. MST3 activation was accessed by using a P-MST4-
T178/-MST3-T190/-STK25-T174 specific antibody (anti-P-MST3). Note that the P-MST3 signal disappears in the siMST3 
treated samples. 
 
in G1-phase of the cell cycle with the activation persisting until the end of S-phase. 
The G1-activation of NDR1/2 was confirmed by analyzing endogenous NDR1/2 
activity using a peptide kinase assay (Figure 1B). HeLa cells were arrested at G2/M-
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border and either harvested directly or released for 8h into fresh medium. Endogenous 
NDR species were immuno-precipitated and their activity measured using a specific 
peptide kinase assay. Direct assessment of NDR kinase activity confirmed that NDR 
kinases were activated in G1, whereas the activity was decreased in M-phase as 
compared to unsynchronized cells (Figure 1B).   
Three members of the mammalian STE20 like kinases have been implicated in the 
regulation of NDR1/2: MST1, MST2 and MST3 (11, 13, 14, 19). For each MST 
kinase it has been shown that the kinase-dead variant can act in a dominant negative 
manner (14). To test which of the MST kinases was important for NDR1/2 activation 
in G1, we analyzed G1 activation of NDR upon over-expression of DN-MST1-3 
(Figure 1C). Strikingly, although over-expression of DN-MST1 and DN-MST2 
resulted in a moderate decrease in NDR activation, the expression of DN-MST3 
significantly reduced NDR phosphorylation in this setting. To validate this finding we 
knocked-down endogenous MST3 using siRNA-technology and analyzed NDR 
activation (Figure 1D, Figure S1A). Depletion of endogenous MST3 resulted in 
decreased NDR activation in G1, confirming the role of MST3 for G1-activation of 
NDR1/2. To test whether MST3 phosphorylation would be increased in G1, MST3 
activity was analyzed in our setting (Figure 1D, Figure S1A). Importantly, when 
comparing P-MST3 levels in G1 phase cells versus M-phase arrested cells, an 
increase of P-MST3 was observed in G1, which was not observed in cells depleted 
from MST3. Taken together, NDR kinases were activated in G1-phase of the cell 
cycle, with the activation persisting until late S-phase. Furthermore, our experiments 
revealed MST3 as the responsible upstream kinase for NDR1/2 in this setting, 
providing the first functional link between NDR and MST3. 
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Decrease in NDR1/2 results in cell proliferation defects due to a G1 block 
To analyze whether NDR kinases functioned in cell cycle progression and 
proliferation we made use of HeLa cells expressing shRNA against NDR1 and NDR2 
(Figure 2A). Both isoforms were targeted to avoid any compensatory effects as 
described earlier (Cornils, et al.; submitted). Knock-down of NDR kinases resulted in 
consistent proliferation defects of around 50%, which were not observed in control 
clones expressing shRNA against firefly luciferase (Figure 2B/C). In addition the 
effects of single knock-down of either NDR1 or NDR2 were tested (Figure S2). 
Interestingly, no compensatory effects of knocking down one isoform were observed 
(Figure S2C). Although compensation of NDR1 deficiency by NDR2 in healthy 
tissues was described earlier (Cornils, et al.; submitted), this data suggested that in our 
setting the compensatory mechanisms regulating NDR kinase isoforms were 
disturbed. Next we tested whether the observed proliferation defects would be a result 
of a cell-cycle block. Using BrdU incorporation we observed an increase in cells in 
G1 accompanied by a decrease in S-phase in NDR1/2 depleted cells (Figure S3). As 
normal proliferating HeLa cells were mainly in G1, we employed a method described 
by Mikule et al. to verify G1 blockade (18). Before cell-cycle analysis, nocodazole 
was added for 14h to accumulate cycling cells at the G2/M-border (Figure 2D). 
Indeed, cells deprived of NDR mostly stayed in G1, confirming that knock-down of 
endogenous NDR kinase species resulted in G1-arrest. An earlier report showed that 
NDR kinases were important for centrosome duplication (12). Disturbances in 
centrosome assembly have been reported to trigger the activation of a centrosome 
integrity checkpoint resulting in the activation of p38 and p53 with subsequent 
upregulation of p21 and G1-arrest (18, 20). Furthermore, inhibiting p38 in this setting 
decreased G1-arrest. To test whether the centrosome integrity checkpoint was 
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activated by depleting NDR1/2, we treated the cells with inhibitors for p38 prior to 
G1-arrest assessment. Adding p38 inhibitors to cells deprived of NDR did not result 
in release from G1 block, indicating that the observed G1 arrest in this setting was not 
Figure 2. shRNA mediated knock-down of NDR1/2 results in defects in cellular proliferation due to a G1-block. 
A: Characterization of HeLa-Trex cells stably expressing shRNA against NDR1 and NDR2. Cells were seeded in 10cm dishes 
and shRNA expression was induced by the addition of tetracycline (TET) for the indicated time. Lysates from harvested cells 
were analyzed for NDR1 and NDR2 expression using isoform-specific antibodies. B: HeLa cells expressing shRNA against 
NDR1/2 (shNDR1/2) or firefly luciferase (shLUC) as a control were seeded in triplicates and tetracycline was added to induce 
shRNA expression. After the indicated time, cells were harvested by trypsination and counted using a Vicell-automated cell 
counter. C: Validation of proliferation defects in different clones stably expressing shNDR1/2 or shLUC (n=3). Experiments were 
performed as in B, differences in proliferation were calculated as percentage of cells without tetracycline to cells with tetracycline 
counted on day6 after induction of shRNA expression. D: Knock-down of NDR1/2 was induced for 4 days using tetracycline. 14h 
before harvesting and processing for FACS analysis, cells were treated with 2.5μg/ml nocodazole to induce G2/M-accumulation. 
Fixed cells were stained with PI and analyzed by FACS. Histograms were overlaid to facilitate better comparison of cells in a 
given cell cycle phase. E: Knock-down of NDR1/2 was induced for 4days and cell-lysates were analyzed for the expression of the 
indicated cell-cycle regulators using western-blotting. F: Knock-down of NDR1/2 was induced for the indicated timepoints and 
protein and RNA extracts were prepared to analyze p21, p27 and c-myc mRNA by quantitative RT-PCR and protein expression 
by western blotting. Values for p21, p27 and c-myc mRNA are given a fold change to untreated samples (n=3).   
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due to activation of the centrosome integrity checkpoint (Figure S4). Consistent with 
the activation of NDR1/2 in G1, reduction of NDR1/2 levels resulted in proliferation 
defects due to a G1-block. However, the observed G1-block was not mediated by a 
p38 dependent centrosome integrity checkpoint. 
 
Loss of NDR kinases results in upregulation of the cell cycle inhibitors p21 and p27 
and a decrease in c-myc protein levels. 
Next we analyzed the mechanisms underlying the G1-block by investigating the levels 
of known regulators of G1 progression/S-phase entry.  The activity of Cyclin-Cdk 
complexes important for G1-progression/S-phase entry is regulated by Cyclin-Cdk 
inhibitors such as p21 and p27 (5). Indeed, the expression of p21 and p27 was 
elevated in NDR1/2 knock-down cells without significant decrease in the expression 
of cyclins and their respective cdks (Figure 2E). Interestingly, Cyclin D1 was slightly 
increased. In addition the expression of the c-myc oncogene was reduced. These 
results were confirmed in HeLa cells expressing shRNA against NDR1 and NDR2 
alone, as well as in transiently transfected HCT116 (Figure S5A-E). Furthermore 
validated U2OS cells expressing shRNA against NDR1 together with a rescue 
construct for wild-type NDR1 were analyzed (Figure S5F/G) (12). Importantly, re-
expression of NDR1 wt not only counteracted the upregulation of p21 and p27, but 
also restored cell proliferation (Figure S5G). This suggested that the observed G1-
block upon depletion of NDR1/2 was due to the inhibition of Cyclin-Cdk complexes 
by increased levels of p21 and p27. 
It has been shown that c-myc is able to repress p21 and p27 expression (21, 22); 
therefore we tested whether for both proteins changes on the mRNA level were 
detectable (Figure 2F). Interestingly, although p27 mRNA level were clearly 
84 
increased, we did not observe any elevation of p21 mRNA. Recently it has been 
reported, that NDR1 functioned as a regulator of c-myc protein stability in B-cells, 
with decreased NDR1 level resulting in a decrease in c-myc protein, but not mRNA 
(23). In line with this observation, we did not observe decreased c-myc mRNA levels 
in our setting. Taken together, these experiments indicated that the G1-block detected 
in NDR depleted cells seemed to be a result of increased levels of p21 and p27 
accompanied by a decrease in c-myc protein. Interestingly, only the p27 mRNA was 
increased in this setting, indicating that NDR1/2 presumably impacted directly on 
both p21 and c-myc protein turnover. 
 
Hydrophobic motif phosphorylation of NDR kinases increases binding to c-myc and c-
myc protein stability 
A recent report analyzing post-transcriptional modifiers of c-myc in B-cells 
implicated NDR1 in the regulation of c-myc protein stability (23). However, although 
an interaction between NDR1 and c-myc was described, no mechanistic studies were 
performed to understand how NDR1 impacted on c-myc stability. In full agreement 
with this report, c-myc protein level were rescued by the addition of the proteasomal 
inhibitor MG132 (Figure 3A). In addition, our experiments confirmed an interaction 
between NDR1 and c-myc both with overexpressed and endogenous proteins (Figure 
S6A/C). Furthermore NDR2 was also capable of binding to c-myc with similar 
efficiency than NDR1 (Figure S6B).  
As we observed an increase in NDR1/2 kinase activation and HM-phosphorylation in 
G1-phase, we tested whether NDR kinase activity would influence NDR-myc 
complex formation. First we analyzed whether c-myc would be a substrate for NDR 
kinases. However, in in vitro kinases assays no specific phosphorylation of c-myc by 
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NDR kinases was observed (data not shown). Next, NDR1wt, NDR1kd and NDR1-
T444A (referred to as NDR1ta), a mutant where the HM phosphorylation site was 
mutated to alanine, were tested for complex formation by co-immunoprecipitation 
(Figure 3B). Interestingly, no differences in c-myc binding were observed between 
Figure 3. NDR1/2 interact with c-myc in a HM-phosphorylation dependent manner impacting on c-myc stability. 
A: Knock-down of NDR1/2 was induced for 48h. To inhibit proteasome dependent degradation of c-myc MG132 was added 
for the indicated time. B: HEK cells were transfected with c-myc together with the indicated HA-tagged NDR1 constructs. 
NDR1 species were immuno-precipitated using anti-HA antibody and binding to c-myc was analyzed by SDS-page. C: HEK 
cells were transfected with c-myc and the indicated NDR1 cDNAs together with a vector encoding FLAG-MST1. Complex 
formation was analyzed as in B. D: HEK cells transfected with c-myc, NDR1wt or NDR1ta in the presence of absence of 
FLAG-MST1 were treated with cycloheximide for the indicated time and lysates were analyzed for the expression of c-myc 
using the Licor Odyssey system. E: HEK cells were transfected with HA-tagged variants of NDR1 together with HA-MST3 
where indicated and lysates were analyzed for the expression of endogenous c-myc 24h later. 
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NDR1wt and NDR1kd, indicating that kinase activity of NDR1 did not influence 
binding to c-myc. However, binding was impaired upon expression of the T444A 
mutant. In addition, expression of a mutant in which all phospho-sites (T74A, S281A, 
T444A; referred to as NDR1-3xTA) have been mutated to alanine exhibited similar 
binding as the T444A mutant, confirming the importance of the HM-phosphorylation 
site for interaction with c-myc.  
Next we tested whether phosphorylating the HM would increase complex formation 
(Figure 3C). Indeed when MST1 as an upstream kinase was co-expressed, increased 
complex formation was observed for NDR1wt and NDR1kd, but not for NDR1ta, 
again arguing, that the effects of NDR kinases on c-myc were not dependent on NDR 
kinase activity, but on hydrophobic motif phosphorylation. MST1 was used as an 
upstream kinase in some assays, as it was assumed to be responsible for NDR 
activation in G1 before the identification of MST3 as responsible kinase. To test 
whether increased binding of NDR to c-myc would result in increased c-myc protein 
stability, c-myc turnover was analyzed in the presence of NDR1wt and NDR1ta 
together with overexpression of MST1 as an upstream kinase. Strikingly, c-myc 
stability was greatly enhanced upon overexpression MST1 together with NDR1wt. 
The non-phosphorylateable NDR1ta mutant showed no response to overexpression of 
MST1, confirming that increased binding of NDR kinase to c-myc due to HM-
phosphorylation indeed increased c-myc stability. In addition, NDR1kd showed a 
similar stabilizing activity than NDR1wt in these assays (Figure S6D), confirming, 
that NDR kinases impact on c-myc stability independently of their kinase activity. 
Finally, the effect of NDR1 overexpression and HM-phosphorylation on the stability 
of endogenous c-myc was analyzed (Figure 3E). Only overexpression of NDR1wt and 
NDR1kd increased endogenous c-myc protein level. In addition, increasing NDR1-
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HM phosphorylation by overexpressing MST3 resulted in a further increase in c-myc 
level. Taken together, these experiments confirmed the stabilizing effect of NDR1 and 
NDR2 on c-myc protein level. Furthermore our data provided mechanistic insight into 
the regulation of c-myc stability by NDR kinases: NDR kinases bind to c-myc in a 
kinase-activity independent but HM-phosphorylation dependent manner, thereby 
increasing c-myc protein stability. 
 
NDR kinases compete with the ubiquitin-ligase Skp2 for c-myc binding, thereby 
interfering with Skp2 mediated ubiquitination of c-myc. 
To further understand the mechanism behind the stabilizing effect of NDR on c-myc, 
we analyzed the NDR binding site on c-myc, using deletion mutants of c-myc (Figure 
4A). Interestingly, NDR1 bound both to the C-terminus as well as the N-terminus of 
c-myc (Figure 4B). Two Ubiquitin-ligases, Fbw7 and Skp2, have been reported to 
target c-myc for proteasomal degradation (24-27). Strikingly, Skp2 has also been 
shown to interact with c-myc both on the N- and the C-terminus (24, 25). Furthermore 
the MB2 domain of c-myc was important for interaction with Skp2 (24, 25). We 
therefore deleted the MB1 or the MB2 domain in c-myc and tested for NDR1 binding 
(Figure 4C). Strikingly, only deletion of MB2 resulted in impaired binding to NDR1, 
suggesting that NDR kinases bound to sites on c-myc overlapping with those 
described for Skp2 interaction. Therefore we postulated that if NDR kinases could 
compete with Skp2 for c-myc binding, overexpression of NDR1 would decrease 
Skp2-mediated ubiquitination of c-myc. Indeed, overexpression of NDR1wt impaired 
c-myc ubiquitination (Figure 4D). Furthermore overexpression of NDR1 interfered 
with increased c-myc ubiquitination upon overexpression of Skp2 (Figure 4E). Taken 
together our analysis suggested a role for NDR kinases in the regulation of c-myc 
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protein stability by interfering with Skp2 mediated ubiquitination. NDR kinases were 
phosphorylated in G1-phase of the cell cycle, which would result in increased binding 
of NDR kinases to c-myc competing with Skp2. NDR phosphorylation would 
gradually decrease in S-phase, allowing increased degradation of c-myc by Skp2. 
Figure 4. NDR1/2 interfere with Skp2-mediated ubiquitination and degradation of c-myc. 
A: Schematic representation of c-myc structure and deletion mutants used for interaction studies. B: EGFP-tagged NDR1wt 
together with the indicated c-myc mutants were transfected into HEK cells and binding was analyzed by co-
immunoprecipitation. Note, that although binding was reduced upon deletion of the N-terminus, still a fraction of NDR1 bound 
to c-myc-ΔN. C: Analysis of the interaction of c-myc-ΔMB mutants with NDR1wt. Experiments were performed as in B. D: 
HEK cells were transfected with c-myc and His-tagged ubiquitin (His-Ub) together with HA-NDR1wt where indicated. 
Ubiquitinated proteins where pulled-down from cell lysates using Ni-NTA sepharose and analyzed by SDS-page. Note the 
appearance of a mono-ubiquitinated form c-myc upon NDR1 co-expression. E: Impact of NDR1wt on Skp2 mediated 
ubiquitination of c-myc. Experiment was performed as in D, but where indicated HA-gfp-Skp2 was co-expressed.  
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Interestingly, so far no other factors regulating Skp2 mediated degradation of c-myc 
have been described.  
 
NDR kinases regulate p21 protein stability by phosphorylating serine 146  
Our analysis of the consequences of NDR kinase depletion on proliferation not only 
revealed a downregulation of c-myc protein, but also showed an increase in p21 
protein, without accompanying upregulation of p21 mRNA. We therefore analyzed, 
whether knock-down of NDR1/2 would impact on p21 protein stability (Figure 5A). 
As predicted, in cells depleted of NDR1/2 the stability of p21 was markedly increased 
(Figure 5A). No binding of NDR1/2 to p21 could be detected (data not shown), 
indicating a mechanism distinct from the regulation of c-myc. Earlier studies have 
shown that p21 stability is regulated at least partially by phosphorylation. Several 
phosphorlyation sites on p21 have been implicated in regulating p21 stability (28). We 
performed in vitro kinase-assays to test whether NDR was capable of phosphorylating 
p21. Indeed using recombinant and immuno-purified NDR2 phosphorylation of p21 
was detected (Figure 4B/Figure S7A). Importantly, both NDR1 and NDR2 were able 
to phosphorylate p21 in these assays, while the respective kinase-dead variants failed 
to do so (Figure S7B). Although no substrates of NDR1/2 have been described in the 
literature, one report showed that NDR1 required a stretch of basic amino acids for 
phosphorylation. Analysis of the p21 primary sequence identified a stretch of 4 basic 
amino-acids upstream of the known phosphorylation sites T145 and S146 (29). To 
map the exact phospho-acceptor site we mutated T145 or S146 or both to alanine and 
performed in vitro kinase assays (Figure 5C/Figure S7C). Strikingly, mutation of 
S146 to alanine abolished phosphorylation by NDR in these assays, showing that 
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Figure 5. NDR kinases phosphorylate p21 on S146 in vitro and in vivo. 
A: HeLa-shNDR1/2 cells were treated with tetracycline for 72h. Prior to harvesting, cells were treated for the indicated time 
with cycloheximide. p21 level were analyzed using the Licor Odyssey system (n=3). B: HA-tagged NDR2wt or HA-NDR2kd 
was immuno-precipitated from okadaic acid stimulated HEK cells and after pre-incubation with cold ATP used for in vitro 
kinase assays with GST-p21 as substrate. C: In vitro kinase assay to determine NDR phosphorlyation site on p21. GST-p21 
with mutated T145, S146 or doubly mutated T145/S146 phospho-acceptor sites were used as substrates for in vitro kinase 
assays as described in B. D: HeLa cells were transfected with the indicated HA-tagged NDR1 species together with myc-tagged 
p21. Samples were stimulated with OA for 1h before lysis where indicated. myc-tagged p21 was immunoprecipitated from 
lysates and P-p21-S146 levels were analyzed and quantified using the Licor Odyssey system (n=3). P-p21-S146 levels were 
normalized to –OA controls. E: HeLa-shNDR1/2 cells were induced for 72h with tetracycline and transfected with cDNA 
encoding myc-tagged p21. 24h after transfection cells were stimulated with OA for 1h and lysed afterwards. P-p21-S146 levels 
were analyzed as in D. F: HeLa cells were transfected with cDNAs encoding HA-NDR1wt or HA-NDR1kd in the presence of 
HA-MST3. Prior to lysis, cells were treated with CHX for 60min, where indicated. **HA-NDR1; *HA-MST3 
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NDR kinases phosphorylate p21 on S146 (Figure S7C/D). NDR kinases are 
efficiently activated by okadaic acid treatment, therefore we tested whether over-
expression of NDR1wt or NDR2wt would increase okadaic acid induced 
phosphorylation of p21 in vivo (Figure 5D/ Figure S7E). Indeed, overexpression of 
NDR1/2wt but not kinase dead or a HM mutant increased phosphorylation of p21 
upon OA treatment, confirming p21 as an in vivo substrate for NDR kinases. 
Furthermore, reduction of NDR kinases in cells by shRNA reduced OA mediated 
phosphorylation of p21 on S146 (Figure 5E). It has been shown that phosphorylation 
of S146 by atypical PKCs could destabilize p21 (30). Therefore we tested the effect of 
overexpressing NDR1 together with MST3 on the stability of p21 (Figure 5F). 
Although overexpression of NDR1wt or kinase dead did not significantly impact on 
p21 steady-state level, treatment of cells with CHX to inhibit translation, revealed that 
overexpression of NDR1wt but not NDR1kd decreased p21 stability in this setting. 
Taken together, NDR kinases directly phosphorylated p21 on S146 in vitro and in 
vivo. Furthermore, phosphorylation of S146 by NDR1/2 resulted in destabilization of 
p21, whereas in the absence of NDR1/2 p21 protein levels were stabilized.  
 
Increased p21 level upon knock-down of NDR1/2 mediate G1-block and senescence 
Our analysis revealed a role for NDR kinases in the regulation of p21 and c-myc 
stability by different mechanisms. To confirm the effects of NDR on c-myc and p21 
we performed experiments to rescue the effects of depletion of NDR2 by transient 
overexpression of NDR2 mutants refractory to shRNA (Figure 6A). Indeed, whereas 
overexpression of NDR2wt in this setting rescued both the effects on c-myc and p21 
level, overexpression of NDR2kd only restored the c-myc level. Importantly, NDR2ta 
failed to rescue either of the effects. Next we analyzed whether overexpression of c-
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Figure 6. G1-arrest upon depletion of NDR1/2 is dependent on NDR kinase activity and mediated by increase in p21-level. 
A: HeLa cells expressing shRNA against NDR2 were treated for 48h with tetracycline and subsequently transfected with the 
indicated NDR2 mutants refractory to shNDR2. Lysates were analyzed for the expression of NDR2, c-myc and p21. *HA-
tagged NDR2. B: HeLa cells expressing shRNA against NDR1/2 were induced for 72h with tetracycline and transfected with 
vectors expressing c-myc together with an IRES-gfp as a transfection marker. G1-arrest analysis was performed as described. 
Cell cycle profiles of gfp-positive cells were overlaid to allow better comparison. C: Analysis of gfp-positive cells in G1 after 
nocodazole arrest upon depletion of NDR1/2 and overexpression of c-myc (n=3). D: Analysis of c-myc, p21 and p27 in 
NDR1/2 depleted cells upon overexpression of c-myc. Cells were treated as described in B, but lysates were prepared before 
G1-arrest analysis. E: HeLa cells expressing shRNA against NDR1/2 were treated with tetracycline for 48h before being 
transfected with siRNA against p21 on two consecutive days. The cells were treated for G1-arrest analysis as decribed 24h after 
the second transfection. F: Quantification of cells in G1 after nocodazole treatment (n=3). G: Cells obtained in E were analyzed 
for the expression of p21 and NDR1/2. Note that two rounds of siRNA treatment were sufficient to reduce increased p21 level. 
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myc would be sufficient to rescue the G1-arrest observed in NDR1/2 depleted cells 
(Figure 6B/C). However overexpression of c-myc failed to relieve the cells from G1-
blockade. Interestingly, although overexpression of c-myc resulted in levels above 
endogenous, we observed that even overexpressed c-myc was destabilized in NDR1/2 
depleted cells (Figure 6D). Restoring c-myc level did not affect p21 upregulation, but 
the increase in p27 levels. The upregulation of p27 mRNA upon knock-down of 
NDR1/2 therefore seemed to be mediated by reduced repression of the p27 promoter 
by decreased c-myc level in this setting (22). As restoring c-myc level failed to rescue 
cells from shNDR1/2 induced G1-arrest, we tested the effect of siRNA mediated 
depletion of p21 (Figure 6E-G). Decreased p21 level resulted in a significant relieve 
of NDR1/2 depleted cells from G1-blockade. To further confirm the role of p21 in 
mediating the G1-block upon depletion of NDR1/2, p21 levels and G1-arrest were 
analyzed in a timecourse dependent manner (Figure 7A). This analysis showed that 
p21 levels increased gradually starting from 48h after tetracycline induction, which 
correlated with increased amounts of cells in G1 after nocodazole treatment. Although 
p27 levels, a possible read-out for decreased c-myc level (22), were increased 
generally in NDR1/2 depleted cells, no accumulation of p27 was observed. Increased 
p21 levels have been shown to not only mediate G1-arrest of cells, but also to result in 
increased senescence (31). Indeed, NDR1/2 depleted cells show morphological 
changes of senescent cells, such as flattening, increase in cell-size and filopodia 
(Figure 7B) (31). Quantification of senescence-associated beta-Galactosidase stained 
cells confirmed an increase in senescent cells upon depletion of NDR1/2 (Figure 7C). 
Taken together, although knock-down of NDR1/2 resulted in a decrease of c-myc and 
an increase of p21 levels, only downregulation of p21 affected G1-arrest in NDR1/2 
depleted cells. Furthermore increase in p21 levels correlated with increased G1-
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blockade and increased senescence, confirming, that the upregulation of p21 upon 
knock-down of NDR1/2 seemed to be the major mechanism to regulate the G1-arrest. 
 
3.2.4 Discussion 
We show here that NDR1/2 are activated in a cell-cycle dependent manner, with the 
activation starting in G1 and persisting until late S-phase. Interfering with NDR 
activation results in proliferation defects and G1-arrest indicating an important 
function for NDR kinases in regulating G1-progression and S-phase entry. 
Interestingly, we identify MST3 as responsible upstream kinase for NDR activation in 
G1. Although being the first upstream kinase described for NDR1/2, the functional 
context of NDR activation by MST3 remained elusive (19). In the context of 
apoptosis signaling and centrosome duplication NDR activity has been shown to be 
regulated by MST1 (13, 14), whereas MST2 has been implicated in NDR kinase 
regulation in the alignment of mitotic chromosomes (11). MST3 signaling has been 
implicated in the regulation of axon outgrowth, cellular migration and stress induced-
apoptosis (32-34). However, an involvement of MST3 in cell-cycle progression has 
not been described so far. Although we observe an increase of active MST3 in G1 as 
compared to M-phase, the mechanisms activating MST3 in this context remain to be 
analyzed.  
Depletion of NDR kinases results in proliferation defects and G1-arrest (Figure 2). 
The activity of Cyclin-Cdk complexes important for G1-progression and S-phase 
entry is regulated the action of Cdk inhibitors (CKIs), such as p21 and p27 (1). 
Although depletion of NDR1/2 does not affect Cyclin levels (apart from a slight 
increase in Cyclin D1), the levels of the Cyclin-Cdk inhibitors p21 and p27 are 
significantly increased. The proto-oncogene c-myc has been shown to regulate both 
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Figure 7. Increased p21 level upon knock-down of NDR1/2 correlate with G1-arrest and mediate increased senescence.  
A: HeLa cells expressing shRNA against NDR1/2 were induced with tetracycline for the indicated time before harvest and 
lysis. Cells used for cell-cycle analysis were treated with 2.5μg/ml nocodazole for 14h before harvest. B: HeLa cells 
expressing shRNA against NDR1/2 were treated for 4 days with tetracycline and photomicrographs were taken. C: Cells 
treated as in B were stained for senescence-associated-beta galactosidase activity and counted. A total of 250 cells were 
counted for each condition and experiment (n=3). 
 
p21 and p27 level by repression of their respective promoters (21, 22). Depletion of 
NDR1/2 also results in decreased c-myc level. Indeed, the upregulation of p27 protein 
level is also reflected in increased p27 mRNA. However p21 mRNA levels are not 
elevated, indicating a regulation of p21 level independent of c-myc. Furthermore, 
overexpression of c-myc in NDR1/2 depleted cells affects p27 level, whereas p21 
levels remain unaffected. Importantly, the G1-block in NDR1/2 depleted cells is not 
affected by overexpression of c-myc, but by knock-down of p21. Furthermore, our 
experiments reveal, that the increase in p21 level is due to increased p21 protein 
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stability. The G1-arrest in NDR kinase depleted cells is therefore a consequence of 
increased p21 protein levels. 
Degradation of p21 is mediated by both ubiquitin-dependent and independent 
mechanisms (35). In addition, phosphorylation of p21 has been shown to modulate a 
variety of p21 functions by impacting on p21 localization, complex formation and 
degradation (28). We show that NDR1 and NDR2 phosphorylate p21 on S146 in vitro 
and in vivo identifying p21 as first in vivo substrate for human NDR1/2. 
Phosphorylation of p21 on serine 146 has been reported to both increase and decrease 
p21 protein stability, depending on the cellular context and whether endogenous or 
over-expressed p21 was analyzed (30, 36-38). In our setting we can confirm the 
destabilizing effect of phosphorylated serine 146 on p21 protein turnover. 
Overactivation of NDR1/2 results in increased p21 degradation, whereas knock-down 
of NDR1/2 increases p21 protein stability, resulting in G1-arrest and increased 
senescence. 
Although we can show that decreased NDR kinase level not only impact on p21 level, 
but also on c-myc, the effects of decreased c-myc level in our setting remain to be 
defined. NDR1 has been shown previously to bind to and increase c-myc stability. 
However, no studies have been performed to further analyze the mechanisms by 
which NDR impacts on c-myc stability (23). c-myc protein levels are strictly 
regulated in cells. Apart from a pronounced regulation on the level of transcription, 
protein levels of c-myc are controlled by the ubiquitin-ligases FBW-7 and Skp2 (39). 
Whereas the mechanisms regulating c-myc degradation by FBW7 proteins have been 
well described (26, 27, 40), factors regulating c-myc degradation by Skp2 remained 
elusive. Reports show, that Skp2 binds to c-myc on two sites in both the N-terminus 
and the C-terminus, thereby mediating ubiquitination and degradation (24, 25). Our 
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analysis suggests that NDR binding sites on c-myc overlap with those described for 
Skp2. NDR kinases possibly compete with Skp2 for c-myc binding, thereby reducing 
Skp2 mediated ubiquitination and degradation. Indeed, NDR kinases can reduce 
ubiquitination of c-myc by Skp2. Therefore our data suggest a model for the 
regulation of c-myc protein stability by NDR1/2. NDR kinases bind to c-myc 
dependent on its HM-phosphorylation. Increased phosphorylation of NDR on its HM 
by MST3 results in increased binding to c-myc competing with Skp2. Reduced 
binding of Skp2 results in increased c-myc stability. However, although Skp2 
mediates c-myc ubiquitination, it has also been shown, that mono-ubiquitination of c-
myc by Skp2 is important for efficient transcription of genes such as Cyclin D2 and 
ornithine decarboxylase important for S-phase entry (24, 25). Interestingly, although 
overexpression of NDR kinases reduces c-myc poly-ubiquitination and degradation, it 
seems as if the mono-ubiquitinated form of c-myc is stabilized. It remains to be 
addressed, whether the transcription of Cyclin D2 and ornithine decarboxylase is 
affected in this setting. Furthermore the functional role of NDR induced c-myc 
stabilization remains to be determined, as a role for c-myc in the G1-arrest induced by 
decreased NDR1/2 could be ruled out. It will be interesting to investigate, whether 
overexpression of NDR1/2 in combination with active MST3 could increase cellular 
transformation. Although the other members of the MST family (MST1/MST2) 
implicated in the regulation of NDR1/2 have been shown to functions as tumor 
suppressors as part of the HIPPO pathway (8), a role for MST3 in tumor biology has 
not been reported so far. Recently a role for NDR kinases in tumor suppression was 
described (Cornils, et al.; submitted). However, the finding that increased NDR kinase 
level could result in increased levels of the proto-oncogene c-myc seems 
contradictory. On the other hand, several established tumor suppressors have been 
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described to also function as oncogenes or facilitating tumor development in a context 
dependent manner (41). Interestingly, the other downstream factor identified in this 
study, p21, has been reported to function as a context dependent tumor-suppressor 
(41). Although loss of p21 predisposes mice to the development of tumors together 
with activating oncogenes such as RAS (42), loss of p21 also decreases cancer 
incidence in c-myc transgenic mice (43). This dualism has also been described on the 
cellular level. On the one hand, p21 regulates cell-cycle arrest for example after p53 
activation (44). On the other hand, it functions in an anti-apoptotic manner by binding 
to and inhibiting caspase3 (45, 46). Depending on the context p21 can act as a tumor 
suppressor by inhibiting growth or as oncogene by inhibiting apoptosis (41). It seems 
likely that also NDR kinases could function as context dependent tumor suppressors. 
As mentioned above, p21 represents the first substrate identified so far for mammalian 
NDR kinases. Interestingly, increased levels of p21 have also been described to 
inhibit apoptosis as well as centrosome duplication (45-47). It is tempting to speculate 
that the increased level of p21 upon knock-down of NDR1/2 could also be responsible 
for the defects in apoptosis and centrosome duplication described earlier. However 
this possibility remains to be addressed and together with the potential oncogenic 
function of the MST3-NDR1/2-c-myc connection provides an interesting field for 
future research. 
Taken together, in this study we identify a novel function for NDR1 and NDR2 in the 
regulation of G1-progression and S-phase entry. We provide evidence for the first 
functional context of NDR kinase activation by MST3. In addition the first 
mechanisms of signaling downstream of NDR kinases are defined: NDR kinases 
impact on both c-myc and p21 protein stability by different mechanisms. On the one 
hand NDR interacts with and stabilizes c-myc in a kinase-activity independent, but 
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HM-phosphorylation dependent manner. On the other hand p21 is defined as first in 
vivo substrate for NDR kinases. NDR kinases phosphorylate p21 resulting in 
decreased p21 protein stability. Decrease in NDR kinases results in accumulation of 
p21 and arrest of cells in G1, with subsequent accumulation of cells in senescence. 
Thus NDR kinases seem to play a pivotal role in regulating cellular proliferation by 
impacting on central players in G1-phase progression. 
 
3.2.5 Material and Methods 
Cell Culture, transfections and treatments 
HeLa, HeLa S3, HEK293, U2OS and HCT116 cells were maintained in DMEM 
supplemented with 10% fetal calf serum (FCS). Cells were transfected using Fugene 6 
(Roche), Lipofectamine2000 (Invitrogen) or jetPEI (Polyplus Transfection) as 
described by the manufacturer. For siRNA mediated knock-down of MST3 or p21 
cells were transfected with pre-designed siRNA (Qiagen) using Lipofectamine2000. 
Validated control siRNAs were from Qiagen and used according to the manufacturer's 
instructions. For rescue experiments targeting elevated p21 level, cells were 
transfected twice in 24h intervals with siRNA against p21 or control siRNA. HeLa 
cells expressing tetracycline inducible shRNA against NDR1 and NDR2 and U2OS 
cells stably expressing shRNA against NDR1 together with an NDR1wt rescue 
construct have been described elsewhere (12, 13). HeLa and U2OS cells stably 
expressing shRNA against NDR1 or NDR2 alone were generated as described in (12, 
13). To access protein stability, cells were treated with 50μg/ml cycloheximide (CHX) 
or 10μM MG132 for the indicated time. Staining for cellular senescence was 
performed as described in (15). 
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Reagents and Antibodies 
The generation of antibodies against T-444-P, NDR1, NDR2 and NDR1/2 have 
previously been described (13). Antibodies against Cyclin A, Cyclin E, Cyclin B1, 
cdc2, p27, gfp, c-myc (N262), HA (Y11) and actin were from Santa Cruz. Antibodies 
to detect p21, Cyclin D1, Cdk4 and myc-tagged proteins (71D10) were from Cell 
Signalling. Antibodies against HA-tag (12CA5, 42F13), Tubulin (Y1/2) and c-myc 
(9E10) were used as hybridoma supernatants. Additional antibodies used included: 
anti-P-p21-S146 (Abgent), anti-P-MST4-T178/-MST3-T190/-STK25-T174 (referred 
to as P-MST3; Epitomics), anti-MST3 (BD Bioscience) and anti-FLAG (M2) 
(Sigma). Nocodazole, Thymidine, PI and Cycloheximide were from Sigma. 
SB203580 and SB202190 were from Alexis. MG132 was from Calbiotech and the 
BrdU and the anti-BrdU antibody was from BD Bioscience. 
 
Construction of plasmids 
The construction of plasmids encoding cDNAs for tagged variants of NDR1, NDR2, 
MST1, MST2 and MST3 has been described elsewhere (13, 14, 16). RNAi-rescue 
constructs for NDR2 were obtained by introducing silent mutations into the shRNA 
target sites using PCR-mutagenesis. For constructs expressing cDNAs fused to an 
IRES-gfp, the IRES-gfp cassette was excised from the pMIG-vector (a kind gift from 
W. Hahn, Dana-Farber Cancer Institute, Boston) using XhoI/SalI digestion and 
inserted into pcDNA3 containing the indicated cDNAs using XhoI. Constructs for 
pGEX2T-GSTp21, pcDNA3-p21 and pcDNA-myc-p21 were obtained by PCR 
cloning attaching BamHI/XhoI sites to p21-cDNA (a kind gift from N. Lamb, Institut 
de Génétique Humaine, Montpellier) and insertion into the BamHI/XhoI sites of the 
respective vector. Mutation of T145, S146 and T145/S146 to alanine was done by 
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PCR-mutagenesis. cDNA encoding c-myc was a kind gift from N. Hynes (Friedrich-
Miescher Institute, Basel) and HA-tagged c-myc was obtained similar to myc-p21 by 
PCR-cloning into a pcDNA3-HA vector. HA-tagged variants of c-myc containing 
only the first 215 amino-acids (c-myc-ΔC) or the last 234 amino-acids (c-myc- ΔN) 
were obtained by PCR cloning. Deletion of the MB1 or MB2 domain was performed 
by mutagenesis-PCR. Primer sequences are available upon request. Vectors encoding 
cDNA for Skp2 or ubiquitin (Ub) were kind gifts from W. Krek (Institute of Cell 
Biology, ETH Zürich, Zürich) and W. Filipowicz (Friedrich-Miescher Institute, 
Basel). 
 
Protein extraction, immunoprecipitation, immunoblotting and ubiquitination analysis 
Proteins extraction from cultured cells, immunoprecipitation and immunoblotting 
were done as described previously (16). The following antibodies were used for 
immunoprecipitation: anti-HA (12CA5), anti-c-myc (9E10, N262) and a mixture of 
NDR1 and NDR2 specific antibodies to access endogenous NDR species. For 
quantification using the Licor Odyssey System, western blots were incubated with 
secondary antibodies conjugated with fluorescent dyes. Quantifications were carried 
out using the Licor Odyssey software. Analysis of c-myc ubiquitination was 
performed as described in (Cold Spring Harb. protocols; 2006, 
doi:10.1101/pdb.prot4616) 
 
Cell cycle analysis 
HeLa and HeLa S3 cells were synchronized using either a double thymidine block 
with subsequent nocodazole arrest and mitotic shake-off (17) or a single treatment 
with 100ng/ml nocodazole for 14h. Cells were washed free from nocodazole with ice-
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cold PBS and released into fresh medium for the indicated time before harvesting. 
Cell cycle distribution was accessed using either BrdU labeling, as described by the 
manufacturer or PI staining as described (12). To detect cells blocked in G1 a method 
described in (18) was used. In short, cells were seeded at defined densities into 10cm 
dishes. 24h later 2.5ug/ml nocodazole was added for 14-16h to terminally arrest cells 
at G2/M border. Cells were harvested by trypsination and processed for FACS 
analysis. 
 
Kinase Assays 
Methods to determine the activity of endogenous NDR kinases have been described 
earlier (13). To assay p21 phosphorylation by NDR1/2 in vitro, HEK293 cells were 
transfected with cDNAs encoding for HA-tagged NDR kinase isoforms and mutants. 
Cells were stimulated with 1μM okadaic acid for 60h prior to lysis and 
immunoprecipitation. In vitro kinases assay using purified GST-tagged p21 isoforms 
were performed as described (16) with minor modifications. Before adding 35P-
labelled ATP and GST-p21, the immuno-precipitated kinases were pre-incubated for 
90min at 30°C in reaction buffer without 35P-labelled ATP. The labeling reaction was 
stopped after 60’ by boiling the samples in sample buffer for 5’ at 95°C. Samples 
were resolved on SDS-PAGE, stained with Coomassie and exposed to a phosphor-
imager (Amersham Biosciences).  
 
Proliferation Assays 
For the analysis of cell proliferation, cells were seeded at defined densities in 
triplicates, for experiments including inducible shRNAs fresh tetracycline was added 
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each day starting with cell seeding. After the indicated time, cells were harvested by 
trypsination and counted using a ViCell-automated cell counter (Beckman-Coulter).  
 
RNA isolation and quantitative Real Time PCR 
Total RNA from cells was isolated with TRIzol reagent (Invitrogen) and further 
purified using RNeasy kit (Qiagen). cDNA from samples was generated from 2μg of 
total RNA using M-MuLV reverse transcriptase (NEB) and Oligo-dT primers. 
Quantitative RT-PCR to detect p21, p27 and c-myc (primer sequences upon request) 
was carried out using SYBR green technology in an ABI Prism 7000 detection system 
(Applied Biosystems).  
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3.2.7 Supplemental material 
 
Figure S1. Validation of siMST3 effect on NDR activation in G1-phase.  
A: HeLa cells were transfected with control siRNA (siC) or siRNAs against MST3 (siMST3-8/9 and 24h later arrested with 
nocodazole for 14h. Arrested cells were harvested or released into G1 for 8h before harvesting and analysis.  
 
Figure S2. Single NDR1 or NDR2 knock-down cells also show proliferation defects. 
A: HeLa cells expressing shRNA against NDR1 alone were seeded and treated with tetracycline for the indicated time. Cells 
were either processed for immuno-blotting (left panel) or counted using a Vicell-automated cell counter. B: HeLa cells 
expressing shRNA against NDR2 alone were treated and analyzed as in A. C: Validation of proliferation defects in different 
clones stably expressing shNDR1, shNDR2 or shNDR1/2 or shLUC (n=3). Experiments were performed as in A differences in 
proliferation were calculated as percentage of cells without tetracycline to cells with tetracycline counted on day6 after induction 
of shRNA expression. 
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Figure S3. Depletion of NDR1 and NDR2 results in an increase in G1-cells accompanied by a decrease in S-phase cells. 
A: HeLa cells expressing shRNA against NDR1/2 were induced for 4 days with tetracycline. BrdU was added directly to the cell 
medium for 30min before harvesting and processing for FACS analysis (n=3). 
 
Figure S4. Treatment of NDR1/2 depleted cells with inhibitors against p38 does not suppress G1-arrest. 
A: HeLa cells expressing shRNA against NDR1/2 were induced for 4 days with tetracycline. 24h before analysis SB203580 or 
SB202190 (10μM final) were added to the cells. G1-arrest analysis was performed as described. 
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Figure S5. Validation of the effects of depletion of NDR kinases on p21, p27 and c-myc level. 
A: Analysis of p21, p27 and c-myc level in a different HeLa clone expressing shRNA against NDR1/2. shRNA expression was 
induced for 72h before harvest and analysis. B: Analysis of p21, p27 and c-myc upon knock-down of NDR1 alone. Experiment 
was performed as in A. C: Analysis of p21, p27 and c-myc upon knock-down of NDR2 alone. Experiment was performed as in 
A. D: Analysis of p21, p27 and c-myc in a control clone expressing shLUC. Experiment was performed as in A. E: Validation of 
findings in HCT116 cells. Cells were transiently transfected with vectors expressing shLUC or shNDR1/2. Protein lysates were 
obtained 3 days after transfection. Cells were seeded in triplicates and counted after the indicated time using a Vicell-automated 
cell counter. F: Analysis of p21 level in U2OS cells expressing shNDR1. Cells were treated as described in A. G: Effects of 
NDR1 depletion on p21 and p27 level and on proliferation were rescued by re-expression of an NDR1wt rescue contruct. U2OS 
cells expressing shNDR1 and rescue constructs were described and validated in (12). Protein lysates were obtained 72h after 
tetracycline induction and cell counts were obtained as described in E. 
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Figure S6. NDR1/2 interact with c-myc both on over-expressed and endogenous protein.  
A: HEK cells were transfected with cDNAs for c-myc and HA-NDR1wt. NDR1 was immunoprecipitated using anti-HA 
antibodies and c-myc was immunoprecipitated using anti-c-myc (N262) antibody. Precipitates were analyzed by SDS-page. B: 
HEK cells were transfected with HA-NDR1, HA-NDR2 and c-myc and complexes were analyzed as in A. Note that the loading 
for the immunoprecipitations differed from the input. C: Endogenous NDR kinases or c-myc were precipitated from HeLa cell 
lysates and complex formation was analyzed using SDS-page. D: Effect of MST1 expression on NDR1 mediated c-myc stability. 
HEK cells were transfected and treated as described in Figure 3D. Fold change in c-myc level 120' after CHX addition upon 
MST1 co-expression were analyzed.  
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Figure S7. Validation of p21 as substrate for both NDR1 and NDR2 in vitro and in vivo. 
A: His-tagged NDR2 was purified from okadaic acid treated Sf9 cells using Ni-NTA sepharose and used for in vitro kinase assay 
using GST-p21 as a substrate. B: HA-tagged NDR1/2wt or HA-NDR1/2kd was immuno-precipitated from okadaic acid 
stimulated HEK cells and after pre-incubation with cold ATP used for in vitro kinase assays with GST-p21 as substrate. C: In 
vitro kinase assay to determine NDR phosphorlyation site on p21. GST-p21 with mutated T145, S146 or doubly mutated 
T145/S146 phospho-acceptor sites were used as substrates for in vitro kinase assays as described in B. Here NDR1 was 
immunoprecipitated from cells. D: Cold kinase assay confirming the results obtained from "hot" kinase-assays and characterizing 
P-p21-S146 antibody. HA-tagged NDR1/2wt or HA-NDR1/2kd was immuno-precipitated from okadaic acid stimulated HEK 
cells and used for in vitro kinase assays with GST-p21wt or GST-p21S146A as substrate. E: HeLa cells were transfected with the 
HA-tagged NDR2wt or NDR2kd together with myc-tagged p21. Samples were stimulated with OA for 1h before lysis where 
indicated. myc-tagged p21 was immunoprecipitated from lysates and P-p21-S146 levels were analyzed and quantified using the 
Licor Odyssey system (n=3). P-p21-S146 levels were normalized to –OA controls. 
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Figure S8. Characterization of siRNA against p21 in NDR1/2 depleted cells after one round of siRNA transfection. 
A: HeLa cells expressing shRNA against NDR1/2 were induced for 48h and transfected once with siRNAs against p21. 48h later 
G1-arrest and p21 level were analyzed. Note that although siRNAs reduce p21 level in NDR1/2 depleted cells, one round of 
siRNA transfection was not sufficient to reduce level to untreated cells. In addition, amount of G1-arrest seemed to depend on 
p21 level. si-p21_7 reduced p21 level the strongest and shows the highest relieve from G1 arrest. 
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4. General discussion 
The aim of this thesis was to characterize the consequences of NDR kinase deficiency 
in a mouse model and in cell culture systems. Addressing this question we were able 
to define a first in vivo function for NDR kinases in tumor suppression. Furthermore, 
using cell culture systems we characterized a novel function for NDR kinases in the 
regulation of G1-progression and S-phase entry. In addition, the first signaling 
mechanisms downstream of NDR1/2 could be defined.  
Concerning the role of NDR kinases in tumor suppression, we could show that loss of 
one or two alleles of NDR1 predisposes mice to the development of T-cell lymphoma, 
both upon age and upon carcinogen treatment (Figure 7). In addition, our analysis 
revealed that the role of NDR kinases in preventing tumor development seems to be 
mediated by the regulation of proper apoptotic responses to various pro-apoptotic 
signals. Indeed, we could identify a pattern of genes correlating to low NDR kinase 
levels in tumors. Further analysis revealed a significant enrichment for targets of the 
E2A gene products E12/E47 in our data-set. Mechanistic analysis provided further 
insight: Downregulation of NDR1/2 in cells resulted in decreased levels of E47. 
Furthermore, overexpression of E47 could partially suppress the defects in apoptosis 
observed in NDR1/2 depleted cells (Figure 7).  
A role of NDR kinases in tumor suppression was suggested before. First depletion of 
NDR1/2 in transformed cells resulted in defects to FAS mediated apoptosis (31). In 
addition decreased NDR activity has been shown to result in defects in centrosome 
duplication (92) and the alignment of mitotic chromosomes (32), with both processes 
being linked to genomic instability and tumor development. Secondly, it has been 
shown that several upstream regulators of NDR kinases in the above-mentioned 
contexts have been implicated in tumor suppression as components of the HIPPO 
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tumor suppressor pathway (61). Specifically, the proteins RASSF1A, MST1/2 (as 
Hippo homologues) and hMOB1 have been shown to function as part of the HIPPO 
pathway. Our data therefore confirms the proposed role for NDR1/2 in tumor 
suppression. It was shown earlier, that a given Ste20 like kinase could regulate two 
different NDR kinase family members in a given context (28). In the process of 
dendritic tiling and maintenance of neuronal connectivity in drosophila, Hippo was 
shown to regulate both the NDR1/2 homologue tricornered and the LATS1/2 
homologue LATS to control the outgrowth of neurites via trc and the maintenance of 
neurites via LATS (28). It is tempting to speculate that a similar mode of action exists 
in the context of apoptosis signaling. Whereas the HIPPO pathway controls the YAP 
oncogene and thereby the expression of anti-apoptotic genes such as cIAP via LATS, 
the HIPPO pathway could "split" on the level of the NDR kinases to also control YAP 
independent functions via NDR, possibly by regulating the levels of other 
transcription factors such as E47. Another possibility for NDR1/2 functioning as 
tumor suppressors was given by the analysis of MST1/2 deficiency in the liver (88). 
Figure 7. Model summarizing NDR kinase function as a tumor suppressor in T-cell lymphoma. Reduced levels of NDR kinases 
in cells of the T-cell lineage decrease the levels of the tumor suppressor protein E47, resulting in increased resistance to pro-
apoptotic stimuli. (Dashed lines indicate unknown involvement or unknown biochemical mechanisms.) 
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Deletion of both MST1 and MST2 as Hippo homologues resulted in the development 
of liver cancers dependent on YAP. However, the role of LATS1/2 as connection 
between MST1/2 and YAP was questioned in this setting (88). Firstly, LATS 
phosphorylation was not changed in this setting and secondly, although LATS 
correlated with a YAP kinase activity in fractionated liver extracts, this activity was 
not changed upon deletion of MST1/2. Could the other two NDR family members in 
mammals NDR1 and NDR2 fill this empty spot? It has been shown, that NDR1/2 
could phosphorylate YAP in vitro, but failed to phosphorylate YAP in cells upon 
overexpression (75). However, it has to be noted that overexpression of NDR1/2 in 
cells does not result in a significant increase in NDR kinase activity. Our data 
revealed a tumor suppressive function for NDR1/2 in vivo and it will be important for 
future studies to address the role of NDR1/2 in tumor suppression using mice doubly 
deficient for NDR1/2. For example it will be interesting to the test the effect of 
deleting NDR1/2 in liver and to analyze whether NDR1/2 would correspond to the 
MST1/2 responsive YAP-kinase activity defined earlier (88). Interestingly, analysis of 
animals doubly deficient for NDR1 and NDR2 revealed an embryonic lethality 
phenotype very similar to MST1/2 doubly deficient animals (Schmitz, et al.; 
unpublished). Taken together, our experiments revealed a tumor suppressive function 
for NDR kinases in T-cell lymphoma. It will now be important to further address this 
function in different organs and tumor-settings. It will also be important to investigate 
the relation of this finding to the HIPPO tumor suppressor pathway and also to further 
define downstream signaling mechanisms important for NDR kinases as tumor 
suppressors. 
Somewhat contradictory to the above described tumor suppressive function we 
observed that loss of NDR1/2 impairs cell proliferation by imposing a G1-arrest 
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mediated by increased p21 level (Figure 8). Furthermore, decreased NDR kinase 
levels result in reduced levels of the well known proto-oncogene c-myc, whereas 
overexpression of NDR1/2 results in increased c-myc protein levels. Could NDR 
kinases actually function as oncogenes under certain circumstances? Indeed this 
seems possible. Firstly, the impact of NDR1 on c-myc was also identified in B-cell 
lymphoma and B-cell leukemia samples, while analyzing possible novel factors 
regulating c-myc protein stability (93). In addition NDR2 has been found downstream 
of a pro-viral integration site in B-cell lymphoma (94). Another report identified 
NDR1 as a target gene of the tumor and metastasis promoting matrix-
metalloproteinase MT1-MMP (95). Interestingly no increase in NDR1 or NDR2 
mRNA levels in tumors deriving from the T-cell lineage have been described so far. 
Therefore our data and data from other labs indicate a possible oncogenic function for 
NDR kinases (Figure 9). How could a certain protein function both as tumor 
suppressor and as oncogene? Interestingly for several well known oncogenes and 
tumor suppressors this dual function has already been described (96). KLF4, p21, the 
Figure 8.  Model summarizing the role of NDR1/2 in cell cycle progression. Decrease in NDR1/2 levels results in G1-arrest due 
to upregulation of p21 levels (left panel). Over-expression/ -activation of NDR1/2 could potentially contribute to increased 
proliferation/ transformation by increased c-myc levels. (Dashed lines show unknown contribution to the indicated biological 
read-out) 
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TGF-beta pathway, Runx, NOTCH1, E2F1, RAS, LKB1 and VHL have all been 
shown to either promote or oppose tumor development in different contexts. For 
example, the tumor suppressor protein VHL has been identified as mutated in the von 
Hippel Landau syndrome in humans (97). In mice deletion of VHL causes vascular 
tumors and VHL deficient cells proliferate in low serum conditions (98, 99), however,  
deletion of VHL also results in decreased proliferation of cells via the upregulation of 
p21 and p27 (100). The TGF-beta pathway represents another example. In humans the 
TGF-beta pathway is inactivated in pancreatic and colon tumors, but also 
overexpressed in solid tumors, where it is implicated in epithelial to mesenchymal 
transition (EMT) and metastasis (101). In mice it has been shown, that inactivation of 
the pathway results in tumor development, whereas inactivation also impairs tumor 
invasiveness and metastasis (101). Furthermore, the Cyclin-Cdk inhibitor p21 has also 
been placed in this list (96, 102). Mutations in the p21 gene are rare in human tumors 
(103); however, polymorphisms in p21 have been associated with oral and breast 
cancer (104-106). In human pancreatic tumors increased p21 expression occurs during 
progression and re-localization of p21 to the cytoplasm is linked with poor prognosis 
(107-109). p21 targeted mice show an increased rate of spontaneous tumor 
development and deficiency in p21 also increases the rate of tumor development in 
the background of Apc heterozygosity and overexpressed oncogenic RAS (110-112). 
On the other hand, loss of p21 decreases tumor development in myc-transgenic mice, 
Atm deficient mice and upon gamma irradiation treatment (111, 113, 114). 
Interestingly, p21 has been shown to partially mediate the tumor suppressive effects 
of the TGF-beta pathway and the context dependent tumor suppressor Klf4 (96). 
Cellular analysis revealed the mechanisms behind this dual activity of p21. Upon 
overexpression of p21, cells arrest in the cell cycle due to an inhibition of Cyclin-Cdk 
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complexes (115). However, increased levels of p21 have also been shown to promote 
cell proliferation by increasing the assembly of CyclinD-Cdk 4/6 complexes (116). In 
addition an anti-apoptotic function for p21 has been described (117, 118). p21 has 
been shown to directly bind to caspase 3 and to interfere with caspase 3 cleavage and 
activation. However, so far the anti-apoptotic function of p21 has been limited to 
cytoplasmatic p21. Interestingly, in breast cancer cell lines overexpressing Her2, 
increased activity of PKB has been found to phosphorylate p21 on T145 resulting in 
cytoplasmatic localization, potentially increasing p21's anti-apoptotic activity (119). 
As we identified increased p21 level in NDR1/2 depleted cells as being responsible 
for cell cycle arrest, it is tempting to speculate that increased p21 also (at least 
partially) mediate the apoptotic resistance observed in NDR depleted cells and 
tumors. We already identified the E2A gene product E47 as being partially 
responsible for the apoptotic defects in NDR depleted cells and tumors. A functional 
connection between E47 and p21 in this setting remains to be addressed. Interestingly, 
our analysis also revealed that apart from E2A targets, targets of the G1-phase 
regulators Cdk4, Cyclin D1 and p21 were also significantly enriched in the genes 
correlating with low NDR levels in tumors. It will be important in future studies to 
Figure 9. Models summarizing the potential dual role of NDR kinases in tumor development. Decrease in NDR kinases results 
in decreased proliferation and increased apoptosis resistance (left panel). During tumor development additional aberrations in 
signaling pathways overcome the defects in proliferation. Overexpression of NDR potentially results in increased proliferation, 
but decreased apoptotic thresholds. Acquiring additional changes in anti-apoptotic pathways could result in tumor development 
under these conditions.  
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further dissect the interplay between NDR kinases, p21, c-myc and E47 in apoptosis 
signaling and proliferation. As the consequences of NDR kinase overexpression on 
apoptosis signaling, proliferation and transformation remain to be defined, future 
research is warrant to define a potential oncogenic function of NDR kinases (Figure 
9). Similar to the c-myc oncogene, which induces cellular proliferation, but also 
lowers the apoptotic threshold, decreased NDR lowers proliferation, but increases 
apoptotic resistance (Figure 9). Both proteins need a certain context to exert its tumor 
promoting or suppressing functions. Whereas c-myc overexpressing tumors depend 
on changes in signaling pathways to lower the apoptotic threshold (120), NDR 
deficient tumor cells need to overcome the proliferation defects resulting from low 
NDR kinase level. Indeed our analysis revealed that tumors with low NDR kinase 
levels did not show a consistent decrease in proliferation, whereas apoptosis was 
significantly decreased. Conversely, elevated levels of NDR could increase 
proliferation by stabilizing c-myc, but could also result in increased apoptosis. Pro-
apoptotic signaling in this context could therefore be the target of additional changes, 
while the proliferative response of elevated NDR level might prove advantageous for 
tumor development (Figure 9). Future research therefore could indeed define 
mammalian NDR kinases as true context dependent tumor suppressors and it will be 
of utter interest to further define the signaling pathways and mechanisms upstream 
and downstream of NDR under these conditions to gain insight into the functions of 
NDR kinases in vivo.  
Taken together, by further defining the consequences of NDR kinase deficiency in 
mammals, the results obtained during this thesis shed light onto the mechanisms of 
NDR1/2 function in the context of cell cycle regulation, apoptosis and tumor 
suppression, indicating an important role for NDR1 and NDR2 in signal transduction.  
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stimulation and promotes apoptosis" by Vichalkovsky, et al.; Current Biology 2008) 
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Hergovich, et al.; Current Biology 2009). The third manuscript contains work on 
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biochemical mechanisms regulating NDR kinases. Therefore this work is not 
intensively discussed in this thesis. 
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The NDR (nuclear Dbf2-related) family of kinases is highly conserved from yeast to human, and has been classified as a subgroup of the AGC
group of protein kinases based on the sequence of the catalytic domain. Like all other members of the AGC class of protein kinases, NDR kinases
require the phosphorylation of conserved Ser/Thr residues for activation. Importantly, NDR family members have two unique stretches of primary
sequence: an N-terminal regulatory (NTR) domain and an insert of several residues between subdomains VII and VIII of the kinase domain. The
kinase domain insert functions as an auto-inhibitory sequence (AIS), while binding of the co-activator MOB (Mps-one binder) proteins to the NTR
domain releases NDR kinases from inhibition of autophosphorylation. However, despite such advances in our understanding of the molecular
activation mechanism(s) and physiological functions of NDR kinases in yeast and invertebrates, most biological NDR substrates still remain to be
identified. Nevertheless, by showing that the centrosomal subpopulation of human NDR1/2 is required for proper centrosome duplication, the first
biological role of human NDR1/2 kinases has been defined recently. How far NDR-driven centrosome overduplication could actually contribute to
cellular transformation will also be discussed.
© 2007 Elsevier B.V. All rights reserved.Keywords: NDR/LATS protein kinase; Activation mechanism; MOB binding; Subcellular localization; Centriole duplication; Tumour suppressor; Cellular
transformation1. Introduction
Protein kinases are crucial for the regulation of various
cellular processes and have emerged as important therapeutic
targets over the last decade, since many protein kinases are
linked to human diseases. In human cells, 518 protein kinases
have been identified so far that could catalyse transfer of
phosphates (phosphorylation) to serine (Ser), threonine (Thr)Abbreviations: AGC, PKA/PKG/PKC-like; NDR, nuclear Dbf2-related;
MOB, Mps-one binder; LATS, large tumour suppressor; Trc, tricornered; SAX-
1, sensory axon guidance-1; PP2A, protein phosphatase type 2A; MST,
Mammalian Ste20-like kinase; SWH, Salvador/Warts/Hippo; Hpo, Hippo; Sav,
Salvador; Mer, Merlin; Ex, Expanded; Ft, Fat; Yki, Yorkie; RASSF1A, RAS-
association domain family protein 1A; PLK4, Polo-like kinase 4; Cdk2, cyclin-
dependent kinase 2; NTR, N-terminal regulatory; AIS, auto-inhibitory sequence;
SPB, spindle pole bodies (SPB); MEN, mitotic exit network; SIN, septation
initiation network
⁎ Corresponding author. Tel.: +41 61 69 74872; fax: +41 61 69 73976.
E-mail address: brian.hemmings@fmi.ch (B.A. Hemmings).
1570-9639/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbapap.2007.07.017and tyrosine residues, thereby defining protein kinases as one of
the largest superfamilies found in the human genome [1]. In
general, these enzymes have a catalytic domain of about 250 to
300 amino acids (in most cases combined with regulatory
domains) which contains conserved residues that contribute to
nucleotide binding, metal-binding, substrate binding, and
phosphoryl transfer. These conserved residues are located within
functional domains (subdomains) that can be used to describe
structural details of protein kinases [2]. The phosphorylation of
certain key residues – i.e. within the activation segment
(subdomain VIII) – can also result in the modulation of kinase
activity [3].
The human genome encodes about 70 protein kinases that are
classified as members of the serine/threonine AGC (protein
kinase A (PKA)/PKG/PKC-like) class of protein kinases.
Importantly, AGC kinases – such as PKA, protein kinase B
(PKB, also known as AKT), p70 ribosomal S6 kinase (S6K) or
p90 ribosomal S6 kinase (RSK) – require phosphorylation of a
conserved Ser/Thr residue within the activation segment for
4 A. Hergovich et al. / Biochimica et Biophysica Acta 1784 (2008) 3–15activation, and have crucial functions in the regulation of cellular
processes that are important for cell metabolism, proliferation
and survival.
2. Members of the NDR protein kinase family
Members of the NDR (nuclear Dbf2-related) family of
kinases are highly conserved from yeast to man [4]. The NDR
family has been classified as a subgroup of the AGC group of
protein kinases, based on the sequence of the catalytic domain
[1]. Human cells express four related NDR kinases, NDR1 (also
known as serine/threonine kinase 38 or STK38), NDR2 (or
STK38L), LATS1 (large tumour suppressor-1) and LATS2.
Members of the NDR family can also be found in Drosophila
melanogaster [Trc (tricornered) and Warts/Lats], Caenorhab-
ditis elegans [SAX-1 (sensory axon guidance-1) and LATS],
Saccharomyces cerevisiae (Dbf2p, Dbf20p and Cbk1p), Schi-
zosaccharomyces pombe (Sid2p and Orb6p), and some other
fungi, protozoan and plants [4].
While genetic studies have unraveled pathways (discussed in
Section 3.4) and functions (discussed briefly in Section 4) that
center around NDR kinases in yeast and invertebrates, the
precise mechanisms of NDR regulation have been established in
mammalian systems (summarized in Section 3). To date, NDR
kinases have been shown to regulate mitosis, cell growth,
embryonic development, and neurological processes [4].
Moreover, NDR kinases have recently been shown to control
centrosome duplication [5]. A brief description of key NDR
family members is included below. Table 1 provides a brief
summary of the available, functional information on selected
NDR kinases.
3. Regulation of the NDR family
In contrast to studies of the physiological roles of NDR
kinases (mainly undertaken in yeast and flies), the regulatory
mechanisms of NDR kinases at the molecular level have beenTable 1
NDR kinase family members
Kinase Species
Dbf2p S. cerevisiae
Cbk1p S. cerevisiae
Sid2p S. pombe
Orb6p S. pombe
TBPK50 T. brucei
SAX-1 C. elegans
Trc D. melanogaster
Lats/Warts D. melanogaster
LATS1 H. sapiens/M. musculus
LATS2 H. sapiens/M. musculus
NDR1/STK38 H. sapiens/M. musculus
NDR2/STK38L H. sapiens/M. musculusmostly studied in mammalian cells over the past decade [4].
Nevertheless, we summarize in this section our current
understanding of these processes with respect to the entire
NDR family, with particular focus on the role of phosphorylation
by Ste20-like kinases (Section 3.2) and the regulation of NDR
kinases through their association with MOB (Mps-One-Binder)
proteins (Section 3.3). At the end of this section, these
components are discussed in the context of signaling cascades
(Section 3.4).
3.1. Regulation by phosphorylation
All NDR kinases contain two main regulatory phosphoryla-
tion sites: the activation segment (Ser281 of human NDR1; or
Ser909 of human LATS1) and the hydrophobic motif phosphor-
ylation sites (Thr444 of human NDR1; or Thr1079 in human
LATS1). While in other AGC kinases the activation loop is
targeted by an upstream kinase (i.e. PDK1 phosphorylates
PKBα on Thr308), the activation of NDR kinases is regulated by
autophosphorylation on the activation segment [6,7]. Impor-
tantly, unlike other AGC kinases, NDR kinases also have a
unique insert of several residues between subdomains VII and
VIII of the kinase domain [4]. All kinase domain inserts contain
a region that is rich in basic residues, located near the C-terminal
end of this insert, hence this positively charged cluster
immediately precedes the activation segment. Interestingly,
this stretch of primary sequence seems to negatively affect NDR
kinase activity, since a significant increase in kinase activity of
human NDR1/2 was observed when the positive residues in the
kinase domain insert were mutated to alanines [8]. Therefore, the
insert motif is also referred to as an auto-inhibitory sequence
(AIS), a typical feature of NDR family members.
Similar to other AGC kinases, the hydrophobic motif of NDR
kinases is targeted by an upstream kinase (discussed in Section
3.2). The best illustration of the importance of this phosphor-
ylation event has been provided by a study of a distant relative of
NDR kinases, namely PKB [9]. Phosphorylation of theFunctional information
Controls mitotic exit and cytokinesis
Centerpiece of RAM network; couples cell
morphology with the cell cycle
Regulates septum formation and cytokinesis
Links morphological changes with the cell cycle
Coordinates cell shape and cell cycle
Important for neurite outgrowth and dendritic tiling
Controls epidermal outgrowths, and dendritic tiling and branching
Central player in the Hippo pathway; required for dendritic maintenance
Regulates G2/M cell cycle transition, apoptosis and mitotic progression;
part of the G1 tetraploidy checkpoint; the LATS1 cDNA can rescue the
loss of D. melanogaster Lats/Warts
Controls cell proliferation, genomic stability and mitotic progression;
linked to the G1 tetraploidy checkpoint; essential gene,
since LATS2 null mice die before embryonic day 12.5
Required for centriole duplication; the NDR1 cDNA can compensate
for the loss of D. melanogaster Trc
Functions in the regulation of neuronal growth and differentiation
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more specifically in a disorder-to-order transition. In contrast to
PKB, a single change of the phospho-acceptor Thr to a phospho-
mimicking residue is not sufficient to augment NDR kinase
activity [10], however, the exchange of the entire hydrophobic
motif of humanNDR2 by the hydrophobicmotif of PRK2 kinase
(that mimics hydrophobic motif phosphorylation) leads to a
constitutively active form of human NDR2 kinase [6]. Of note,
mutating either the activation segment or the hydrophobic motif
phospho-acceptor residue to alanine residues nearly completely
abolishes the kinase activity of yeast, fly, mouse and human
NDR kinases [4], thereby showing that the phosphorylation of
both the activation segment and the hydrophobic motif is
essential for NDR kinase activity. Furthermore, these activating
phosphorylation events can be removed by protein phosphatase
type 2A (PP2A) in mammalian, fly and yeast cells [4]. Overall,
current evidence strongly indicates that NDR kinases are
activated by multi-site phosphorylation and inactivated by
dephosphorylation.
3.2. Ste20-like upstream regulators
Several genetic studies have already shown that Ste20-like
kinases function upstream of NDR kinases (summarized in [4]).
However, MST3 (mammalian serine/threonine Ste20-like
kinase 3) was the first Ste20-like kinase shown to specifically
phosphorylate the hydrophobic motif, but not the activation
segment [11]. Another report provided further evidence that
MST1/2 phosphorylate human LATS1/2 [12].Moreover, several
yeast Ste20-like kinases have been demonstrated to operate
upstream of NDR kinases in budding and fission yeast. In flies,
Hpo (one of two Ste20-like kinase inD. melanogaster) has been
shown to function biochemically and genetically as a direct
upstream regulator of Lats and Trc [13]. Importantly, the Jan
laboratory could show that Hpo specifically phosphorylates the
hydrophobic motif of Lats and Trc. Therefore, considering that
human and fly NDR kinases are selectively phosphorylated on
their hydrophobic motif phosphorylation site by Ste20-like
kinases, it is very likely that the majority of NDR family
members are targeted on this motif by their respective Ste20-like
upstream regulators (i.e. phosphorylation of human LATS1 on
Thr1079 byMST1/2 or phosphorylation of Dbf2p on Thr544 by
Cdc15p). Studies are now needed that test whether this
prediction is valid in other model systems in order to allow a
full assessment of the conservation of the Ste20-like/NDR
pathway. Current open questions include whether Sid2p is
phosphorylated on Thr578 by Sid1p, or whether SAX-1 is
regulated by phosphorylation on Thr441 by any of the two
Ste20-like kinases in C. elegans. How far human LATS1/2 is
specifically targeted on the hydrophobic motif phosphorylation
site by MST1/2 also remains to be determined in cells.
3.3. MOB proteins as co-activators
Besides the unique insert between subdomains VII and VIII
of the kinase domain, all NDR kinases have an N-terminal
regulatory (NTR) domain that contains a number of conservedbasic hydrophobic residues [4]. This positively charged cluster
mediates the interaction between NDR kinases and a negatively
charged area on the surface of the co-activator MOB (Mps-one
binder). Genetic, structural, and biochemical studies strongly
indicate that this interaction is essential for the regulation of
NDR kinases. In S. cerevisiae and in S. pombe, Mob1p is crucial
for the localization and kinase activity of Dbf2p and Sid2p,
while Mob2p regulates Cbk1p and Orb6p, respectively
(summarized in [4]). In Drosophila, expression of human
hMOB1A can rescue the lethality associated with dMob1/Mats
loss of function [14], thereby restoring the tumour suppressor
activity of the Mats/Lats complex. However, different MOBs
(dMob1–4) have been shown to interact with Trc and Lats in
flies [15], whereby the Adler laboratory could demonstrate that
residues conserved between yeast Mob1p and fly dMob2 were
essential for the interaction of Trc with dMob2 [15]. Importantly,
the same conserved residues in Mob1p are also important for the
functionality of the Mob1p/Dbf2p complex in yeast [16].
Furthermore, substitutions of key residues by alanines in the
NTR domain of human NDR1/2 and human LATS1 completely
abolished their interaction with hMOB1A and severely impaired
kinase activity [8,17,18]. Taking into further consideration the
structures of human, yeast and frog MOB1 [16,19,20], together
with our knowledge of key residues in human NDR1/2 and
LATS1 that are required for hMOB1A association [8,18,21], it is
extremely likely that the positively charged NTR domain of
NDR kinases is responsible for the direct interaction with a
negatively charged surface on MOBs.
Current data actually suggest several functions for the
binding of MOBs to NDR kinases: (1) one study indicates that
this binding releases human NDR1/2 kinases from inhibition
mediated by the AIS within the kinase domain insert [8], (2)
MOBs are thought to activate NDR kinases by the disruption of
an inhibitory self-association in yeast [22], and (3) recent
evidence further suggests that the targeting of MOBs to the
plasma membrane is sufficient to fully activate human NDR1/2
and LATS1—most likely by allowing efficient autophosphor-
ylation on the activation segment, and simultaneously recruiting
NDR kinases into the proximity of its upstream kinase that
phosphorylates the hydrophobic motif phosphorylation site
[11,17,18]. However, more work is needed in order to
understand these regulatory processes in more detail. Neverthe-
less, it is intriguing that all NDR kinases contain the AIS motif
[4] and that hMOB1A contains also a cluster of positively
charged residues [16] which would allow its association with
negatively charged phospholipids in membranous structures.
Still, the mechanism(s) regulating the membrane association of
MOBs are yet to be elucidated.
3.4. Signaling cascades involving NDR kinases
Lats kinase is the centerpiece of a pathway that balances the
relationship between cell size, cell proliferation and cell death in
flies—the Hippo (Hpo) or SWH (Salvador/Warts/Hippo) sig-
naling cascade (please see also Section 4). In Drosophila, an
unknown extracellular stimulus transmits a signal through Ft
(Fat), Mer (Merlin) and Ex (Expanded) to a complex containing
6 A. Hergovich et al. / Biochimica et Biophysica Acta 1784 (2008) 3–15Hpo, Sav (Salvador), dMob1 and Lats, which in turn
phosphorylates and inactivates the transcriptional co-activator
Yki (Fig. 1). Normally, Yki stimulates the transcription of cyclin
E (a driver of cell proliferation), DIAP1 (an inhibitor of
apoptosis) and the bantam microRNA. Thus, loss of Hpo
signaling components results in tissue overgrowth that is
associated with increased cell proliferation and decreased cell
death. Current evidence strongly indicates that Hpo phosphor-
ylates and activates Lats in a Sav/Hpo/Lats complex by a Sav-
mediated manner (summarized in more detail by [4,23,24]).
Recent data further suggest that dMob1 associates with Hpo and
is phosphorylated by Hpo [25]. Phosphorylated dMob1 then has
a higher affinity for Lats, and this activated dMob1/Lats
complex (both molecules are phosphorylated by Hpo) can target
the downstream factor Yki more efficiently [25]. Interestingly,
further evidence suggests that the Hpo pathway can be activated
by radiation in a p53-dependent manner and that Hpo is required
for p53-induced cell death in flies [26]. Therefore, the Hpo
pathway might be kept in check by p53 under conditions of
aberrant activity in Drosophila cells.Fig. 1. NDR/LATS signaling pathways in yeast, flies and mammals. (A) The mitotic e
which phosphorylates Dbf2p (red) and Mob1p (green), whereby Nud1p (light yellow
the phosphate Cdc14. (B) The Hippo/SWH pathway inD. melanogaster [23,24]. Exp
yellow); Hpo (Hippo, yellow); Lats (red) and dMob1 (also termed Mats, green), wher
then inactivates Yorkie (Yki) by phosporylation. Consequently, Yki cannot stimu
proliferation and increased cell death. (C) The Hpo/Trc pathway in control of morpho
dMob1 (green) and Trc/dMob2 complexes are required for the control of dendritic tili
in mammals [4,23,24]. Mammalian sterile 20-like kinases 1 and 2 (MST1/2; yellow
activate LATS1/2 by phosphorylation. The LATS/hMOB1 (green; whereby hMOB1
expression programs through phosphorylation of YAP (the putative human ortholo
remains to be documented. (E) The NDR/MST pathway. MST3 (yellow) phosphoryla
centriole duplication and neurite outgrowths. Noteworthy, it is currently unclear whe
Question marks highlight unknown upstream and downstream factors.Of importance, it appears that the entire Ft/Ex/Mer/Sav/Hpo/
Lats/dMob1/Yki Drosophila cascade is conserved in mammals
as the FAT/NF2/hWW45/MST/LATS/hMOB1/YAP pathway
(Fig. 1). hWW45, MST1/2, and LATS1 (the human relatives of
Drosophila Sav, Hpo, and Lats, respectively) have been reported
to form a complex [12,27,28]. Furthermore, MST1/2 phosphor-
ylates and activates human LATS1/2 [12], and hMOB1A asso-
ciates with human LATS1 [18,21], LATS2 [29], as well asMST1
[25]. However, it remains to be determined whether the proto-
oncogene YAP (the human orthologue of Yki; [30]) is regulated
by the Hpo pathway in human cells, and whether the p53 tumour
suppressor protein is required for the activation of MST1/2 by
radiation. Of equal importance will be more studies that address
whether the tumour suppressor RASSF1A (RAS-association
domain family protein 1A) plays an activating or inhibiting role
in the Hpo/Sav/Lats complex. Current reports suggest that
dRASSF functions as an antagonist of the Hpo pathway in
Drosophila [31], while in human cells RASSF1A activates
MST2, thereby promoting the phosphorylation of LATS1 [28].
Overall, providing sound evidence for the conservation andxit network in S. cerevisiae [32,33]. Tem1p activates the kinase Cdc15p (yellow),
) serves as a scaffold. It is not known how the Dbf2p/Mob1p complex activates
anded (Ex) and Merlin (Mer) stimulate a complex containing Sav (Salvador, light
eby Hpo phosphorylates both Lats and dMob1. The active Lats/dMob1 complex
late the expression of DIAP1 and cyclin E, which results in decreased cell
logical changes. Hpo (yellow) activates Trc (tricornered; red), and the active Trc/
ng in sensory neurons and epidermal outgrowths. (D) The putative Hpo pathway
) associate with human Salvador (hSav also termed hWW45; light yellow) and
can also be phosphorylated by MST2) then potentially activates specific gene
gue of Yki). Of note, the existence of the entire mammalian signaling cascade
tes NDR1/2 (red), and the NDR/hMOB (green) complex then potentially controls
ther MST3 or hMOB1/2 contribute to any of those two NDR-related functions.
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significant challenge in mammals.
In the budding and fission yeast, the NDR kinases Dbf2p and
Sid2p are essential for the functionality of MEN (mitotic exit
network)/SIN (septation initiation network) networks [32,33]. In
S. cerevisiae, after the initial activation of Tem1p, the Cdc15p
protein kinase is stimulated, followed by increased activity of the
Mob1p/Dbf2p complex, consequent release of the protein phos-
phatase Cdc14p from the nucleolus into the cytoplasm, thereby
leading to a dephosphorylation wave through which cyclin B/
cdc34p is inactivated, finally allowing the exit from mitosis
(Fig. 1). A very similar pathway consisting of Spg1p, Sid1p,
Cdc7, Sid2,Mob1p, and Clp1p has also been described in fission
yeast. Strikingly, it seems that several components of the yeast
MEN/SIN pathway are conserved in human cells [4]. Some
human proteins (for example CDC14) are functionally so con-
served that they can compensate for the loss of their yeast
counterpart [34]. Furthermore, human LATS1 and LATS2 have
recently been reported to play a role in mitotic exit [21,29].
Nevertheless, any detailed analysis of mammalian MEN/SIN
pathways is yet to be undertaken.
4. Functions of NDR kinases in yeast and invertebrates
As already pointed out, extensive genetic studies in budding
and fission yeast have unraveled that NDR kinases play crucial
roles in the regulation of MEN in budding yeast and SIN in
fission yeast. Considering that both pathways (centering around
Dbf2p and Sid2p, respectively) have already been reviewed in
detail, we refer herein to selected reviews for further reading
[32,33].
The secondNDRkinase in yeast (Cbk1p in budding yeast and
Orb6p in fission yeast) is part of a morphogenesis network (see
also [4]). In S. cerevisiae, Cbk1p is an essential component of
the RAM (regulation of Ace2p activity and cellular morpho-
genesis) signaling cascade that regulates polarized growth. In
S. pombe, Orb6p is required for the coordination of morpho-
logical changes with cell cycle progression. Interestingly, the
existence of the RAM pathway with CBK1 as centerpiece has
also been described in the human pathogenic fungus Crypto-
coccus neoformans [35]. Whether such morphogenesis net-
works also function in multicellular eukaryotes is not clear,
although studies in the worm and fly showed that NDR family
members have important roles concerning morphological
changes in metazoans.
In D. melanogaster, the NDR Kinase Trc is important for the
integrity of outgrowths (such as epidermal hair) and essential for
the control of non-redundant innervations (dendritic tiling) and
branching of sensory neurons (summarized inmore detail in [4]).
The second NDR kinase in flies, Lats, has recently been reported
to regulate the maintenance of dendrites by genetically inter-
acting with Polycomb group genes [13,36]. The homologue of
Trc in C. elegans, termed SAX-1, is also important for neurite
growth and neurite tiling [37], indicating that NDR kinases play
important roles during dendritic outgrowth in invertebrates.
Lats is also part of a novel signaling network in Drosophila,
known as the Hpo/SWH pathway [23,24]. Some components ofthis kinase cascade are: Salvador (Sav), Lats (also known as
Warts), Hpo (a Sav binding partner that functions as upstream
kinase of Lats), dMob1 (also termed Mats; a co-activator of Hpo
and Lats), Yorkie (Yki; a substrate of Lats), as well as Expanded,
Merlin and Fat. Currently, eleven proteins have been implicated
as members of this pathway that are responsible for the
coordination of cell growth, survival, and proliferation in D.
melanogaster [23,24].
5. Roles of mammalian NDR kinases
Mammalian cells express four related NDR kinases, NDR1,
NDR2, LATS1 and LATS2, whereas the latter two kinases have
been shown to function as tumour suppressor proteins. LATS1-
deficient mice exhibited ovarian and soft-tissue tumours, in
addition to hypersensitivity to carcinogenic treatments [38].
Downregulation of LATS1/2 mRNA levels has been reported in
association with human sarcomas, ovarian carcinomas, aggres-
sive breast cancers, human astrocytomas and acute lymphoblas-
tic leukemia [39–42]. Furthermore, LATS1 overexpression
suppressed growth of MCF-7 cells in soft agar and tumour
formation in nude mice [43]. In addition, the ectopic expression
of LATS2 in v-Ras transformed NIH/3T3 cells suppressed the
development of tumours in nude mice and inhibited cell
proliferation in vitro [44]. The tumour suppressor activity of
LATS2 has as yet not been addressed in knock-out animals, since
LATS2-null mice die before embryonic day 12.5 due to
proliferation defects and genomic instability [29,45]. In contrast,
LATS1-deficient animals can develop normally and be fertile,
although about 60% of female knock-out animals displayed
infertility [38]. Moreover, male LATS1-null mice also appear to
have reduced fertility [38].
Mammalian NDR1 is also not essential for development
because NDR1-deficient mice are viable and fertile. However,
loss of NDR1 seems to be compensated by the elevation of
NDR2 protein levels in a tissue-specific manner (Cornils, H.,
Stegert, M.R., Dirnhofer, S., and Hemmings, B.A., unpublished
data). Nevertheless, aged NDR1-null animals develop T-cell
lymphomas, and preliminary results suggest that knock-out
animals might be hypersensitive to carcinogenic treatment
(Cornils, H., Stegert, M.R., Dirnhofer, S., and Hemmings, B.A,
unpublished data). The ongoing generation of NDR2-null and
NDR1/NDR2 double knock-out mice will be essential to
elucidate the full spectrum of the physiological roles of
NDR1/2 kinases in mammals.
Overall, LATS1/2 and NDR1 appear to be tumour suppressor
proteins, although some evidence indicates that mammalian
NDR1/2 kinases could function as proto-oncogenes. NDR1
mRNA levels are up-regulated in progressive ductal carcinoma
in situ [46], lung adenocarcinoma [47,48], and ovarian cancer
[49,50]. NDR2 mRNA levels are elevated in germ cell tumours
[51,52], ovarian cancer [53], and a highly metastatic, non-small
cell lung cancer cell line [54]. In addition, human NDR protein
levels are increased in some melanoma cell lines [55], and the
upstream integration of a retrovirus in the murine NDR2 locus
resulted in B-cell lymphoma [56]. In contrast, NDR1 and NDR2
mRNA levels have been reported to be down-regulated in
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Therefore, mammalian NDR1/2 kinases might have opposing
roles in cancer, by either functioning as tumour suppressor
proteins or oncogenes, as already reported for factors such as
KLF4, CDKN1A, TGFβ, NOTCH1 or Ras [61]. Many more
studies are now needed to tackle the role(s) of mammalian NDR
kinases in cancer biology, in order to fully comprehend the
potential importance of these kinases in cellular transformation.
Perhaps already described functions of mammalian LATS/NDR
kinases could be translated into the analysis of cancer
development, in particular roles of mammalian LATS1/2 kinases
that have been studied more intensively over the past years.
On the cellular level, LATS1 has been shown to regulate the
G2/M cell cycle transition and apoptosis [43,62], and to interact
with the serine protease Omi/HtrA2 that can control cell
proliferation and cell death [63,64]. Recently, it was reported
that LATS1 seems to play a role in cellular senescence [65]. The
LATS1 kinase has also been implicated in the regulation of
mitotic progression [66], whereby evidence was provided that
LATS1 regulates both mitotic exit [21] and cytokinesis [67].
Strikingly, LATS2 knock-out cells exhibit also acceleration of
exit from mitosis [29], as well as defects in cell proliferation
control and maintenance of genomic stability [45]. Similar to
LATS1, LATS2 also controls cell cycle progression and
apoptosis [44,68]. Both, LATS1 and LATS2, have further been
linked to the G1 tetraploidy checkpoint [66,69], whereas LATS2
has been shown to be part of a positive feedback loop between
p53 and LATS2 in order to prevent tetraploidisation [69]. Oren
and colleagues reported that LATS2 protects p53 from Mdm2-
mediated degradation in a kinase activity dependent manner,
while elevated p53 protein levels stimulated the expression of
LATS2 [69]. Interestingly, another study has documented that
two microRNAs, miR-372 and miR-373 (that can function as
novel oncogenes in the development of human testicular germ
cell tumours), are implicated in the p53-mediated inhibition of
Cdk (cyclin-dependent kinase), possibly by down-regulating the
expression of LATS2 [70]. These findings suggest that the
LATS2 and p53 tumour suppressor pathways can strongly
interact and are also dependent on each other (at least to a certain
degree). However, how far the putative mammalian Hpo
pathway is involved in this collaboration with the p53 signaling
cascade is as yet unclear (please see also Section 3.4 for a
discussion of this point).
In contrast to our detailed understanding of mammalian
LATS1/2 kinases, only two functions have so far been attributed
to mammalian NDR1/2 kinases: (1) mammalian NDR2 has been
implicated in fear conditioning [71], and (2) human NDR1/2
kinases play a role in the regulation of centrosome duplication
(discussed in detail in Section 6). Stork and colleagues observed
that mouse NDR2 was up-regulated in the amygdala of fear-
conditioned animals and proposed that NDR2 contributes to the
coupling of morphological changes of neurons with fear-
memory consolidation [71]. At least in cultured cells, they
could show that the overexpression of NDR2 alters neuronal
growth and differentiation, as well as facilitates neurite
outgrowth. Therefore, mammalian NDR2 could potentially
regulate dendritic tiling and branching, as already reported forinvertebrate NDR kinases, Trc [72] and SAX-1 [37]. However,
the physiological role(s) of mammalian NDR family members
remain to be studied with respect to such dendritic interactions.
6. Centrosome duplication and NDR kinases
In animal cells, the centrosome (comprised of two centrioles
surrounded by pericentriolar material) functions as a primary
microtubule-organising center, regulates cell polarity, motility
and adhesion, is required for cilia/flagella formation, and also
plays a role in cell cycle regulation [73]. Centrosomal abnor-
malities occur in many cancer types and have been observed in
association with genomic instability [74,75]. In addition, several
centrosomal components are required for the assembly of cilia
and flagella, which have essential functions in development and
physiology [76–78]. Therefore, it is crucial for a healthy
organism to maintain centrosomes and centriole numbers under
strict control. However, little is known about the co-ordination
and control of centriole duplication.
Electron microscopy studies have defined the main phases of
the centrosome cycle: (1) centriole disengagement, (2) centriole
duplication/formation of procentrioles, (3) elongation of pro-
centrioles, (4) centrosome separation [73,74]. Genetic and
proteomic screens have allowed the identification of proteins
including ZYG-1, SPD-2 SAS-4, SAS-5, and SAS-6, that are
part of a conserved centriole assembly protein module [73,79].
Recent evidence strongly indicates that PLK4 (Polo-like kinase
4; the mammalian homologue of ZYG-1) and SAS-6 are key
regulators of centriole duplication since their absence abolishes
centriole duplication, while their overexpression results in an
increase of centrosome/centriole numbers in human and
invertebrate cells [80–86]. The depletion or inhibition of
cyclin-dependent kinase 2 (Cdk2) also results in a block of
centrosome (re-)duplication [87–92]. Therefore, centriole
duplication is orchestrated by different protein kinases.
Interestingly, NDR family members have been detected on
spindle pole bodies (SPB; the equivalent of centrosomes in
lower eukaryotes) and centrosomes. In yeast, Dbf2p and Sid2p
reside on the SPB and at the cell division site (summarized in
[4]), and in mammals, LATS1 and LATS2 have been detected
on interphase and mitotic centrosomes [45,93–97]. Further-
more, mammalian NDR1/2 kinases have been found on
centrosomal structures throughout the entire cell cycle [5].
Noteworthy, phospho-species of NDR1/2 were detectable on
one out of two centrioles/centrosomes in G1/S phase, while
NDR species were equally distributed between both centro-
somes in G2/M phase (Fig. 2). Although NDR family members
might utilize the SPB/centrosome “only” as signaling platforms
[98,99], LATS2 knock-out cells displayed centrosome frag-
mentation and amplification [29,45]. Nevertheless, mammalian
LATS1/2 kinases are most likely not directly involved in the
control of centrosome duplication, because (1) the overexpres-
sion of LATS1/2 wild-type kinases did not cause an increase in
centrosome numbers, and (2) the overproduction of LATS1/2
kinase-dead forms (which can function as dominant-negative
molecules) did not interfere with centrosome overamplification
[5].
Fig. 2. Cell cycle-dependent localization of phospho-NDR1/2 species. U2-OS
cells were processed for immunofluorescence using indicated markers.
Phospho-NDR1/2 molecules are shown in green, and centrosomes are indicated
in red. DNA is stained in blue. Insets show enlargements of centrosomes. White
arrowheads indicate midzone staining of phospho-NDR1/2. (Figure originally
published in Hergovich et al., Molecular Cell [5]).
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lian NDR1/2 kinases has been defined as regulators of centriole
duplication [5]. Overexpression of NDR1/2 resulted in centro-
some/centriole overduplication in a kinase-activity-dependent
manner, while expression of kinase-dead NDR1/2 or depletion
of NDR1/2 by small interfering RNA (siRNA) negatively
affected centrosome duplication (Fig. 3). Furthermore, by
selectively targeting NDR species to the centrosome, our
laboratory could show that the centrosomal pool of active
NDR is sufficient to generate supernumerary centrosomes. In
addition, our study revealed that NDR-driven centrosome
duplication requires Cdk2 activity and that Cdk2-induced
centrosome amplification is affected upon reduction of NDR
kinase activity. Altogether, our recent data indicate that
mammalian NDR1/2 kinase activity regulates centriole dupli-
cation directly on the centrosome in a Cdk2-dependent manner.
Studies are now needed that address the mechanism of this
function by testing the co-operation of NDR1/2 with other
known regulators of centriole duplication. Possibly, tackling the
relationship of NDR1/2 with the two master regulators of
centriole duplication, PLK4 and SAS-6, will be of great interest.
Considering that NDR1 immobilised on centrosomes still is able
to affect centrosome duplication [5], it is very likely that direct
substrates of NDR1/2 are present on centrosomes. Potentially,
the identification and characterization of such substrates could
reveal novel regulators of centriole duplication. However, any
physiological substrates of mammalian NDR kinases remain to
be defined [4]. Furthermore, it is as yet unclear at which step
NDR1/2 kinases control centrosome duplication: (1) directly at
the centrosome duplication machinery, (2) as licensing mole-
cules, (3) or by co-coordinating DNA and centriole duplication
[73]. Potentially, mammalian NDR1/2 are “general” regulators
of cell cycle progression and DNA replication. Therefore,
several different lines of research are now necessary to establish
the precise role(s) of mammalian NDR1/2 at the molecular level.
7. NDR kinases as therapeutic targets
Abnormal centrosome amplification occurs frequently during
cellular transformation (summarized in [100,101]), hence,
factors contributing to the regulation of centriole duplication
are likely to play a role in cancer development [74,102].
Furthermore, the deregulation of some regulators of centrosome
duplication has already been shown to contribute to tumour
formation. Elderly PLK4 heterozygote mice are prone to
develop liver and lung cancers [103], while PLK4 null mice
die very early at E7.5 during embryogenesis [104]. PLK4 knock-
out embryos displayed increased cell death and an elevated
mitotic index [104], similar to human cells depleted of PLK4
[80]. Interestingly, mitotic abnormalities and an increase in cell
death were also reported after depletion of SAS-6 in human cells
[82]. Furthermore, this link between centrosome duplication,
embryonic survival, and haplo-insufficiency for tumour sup-
pression has also been observed with nucleophosmin [105],
another regulator of centrosome duplication [106,107]. NDR1+/
− animals also develop tumours with increased age (Cornils, H.,
Stegert, M.R., Dirnhofer, S., and Hemmings, B.A., unpublished
Fig. 3. Defective centriole duplication after knock-down of NDR1 by RNAi in human cells. (A) U2-OS cells expressing tetracycline-inducible short-hairpin RNA
(shRNA) directed against human NDR1 were incubated without (−) or with (+) tetracycline for 4 days, before analysis by immunofluorescence. Centrioles are shown
in green, the tubulin network in red, and DNA is stained blue. Insets show enlargements of centrioles. (B) Histograms show the percentage of mitotic cells (prophase
and prometaphase) that displayed the indicated numbers of centrioles. Noteworthy, nearly 50% of cells with decreased NDR1 levels lacked at least one centriole, while
less than 10% of control cells displayed such a characteristic. (Figure originally published in Hergovich et al., Molecular Cell [5]).
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centriole duplication [5] contributes to this phenotype. Never-
theless, current data suggest that studies of mammalian NDR1/2
kinases might provide a further link between centrosome
duplication and haploinsufficiency for tumour suppression.
Altogether, these studies strongly support a link between
centrosome defects and oncogenesis (summarized in Table 2)
that has already been proposed nearly a century ago [108].
However, whether centrosome alterations are a cause or
consequence of tumour development is as yet unclear [74,102].
Although, one is tempted by our recent work to speculate that
NDR kinases can function as oncogenes by driving centrosome
overduplication [5], the existing animal data rather suggest that
mammalian NDR1 has a role as a tumour suppressor protein
(Cornils, H., Stegert, M.R., Dirnhofer, S., and Hemmings, B.A.,
unpublished data). However, since the loss of NDR1 appears toTable 2
Regulators of centrosome duplication and oncogenesis in mammals
Protein Species Study
PLK4 H. sapiens RNAi
Overex
PLK4/SAK M. musculus Knock
SAS-6 H. sapiens RNAi
Overex
NPM1/B23 H. sapiens/M. musculus RNAi
Overex
NPM/B23 M. musculus Knock
p53 H. sapiens Mutati
p53 M. musculus Knock
NDR1/STK38 H. sapiens RNAi
Overex
NDR1/STK38 M. musculus Knockbe compensated by the elevation of NDR2 protein levels in
some, but not all, tissues (Cornils, H., Stegert, M.R., Dirnhofer,
S., and Hemmings, B.A., unpublished data), one cannot yet
exclude the possibility that the development of T-cell lympho-
mas in homo- and heterozygote NDR1 animals is simply the
result of overcompensation by increased NDR2 protein levels.
The analysis of NDR2-null and NDR1/NDR2 double knock-out
mice will be essential to analyse this role of mammalian NDR1/2
as potential tumour suppressor proteins in more detail.
Altogether, it will be crucial to address the role(s) of NDR1/2
kinases in cancer biology by taking into account that these
kinases might show context-dependent, opposing roles in
cellular transformation, as already reported for factors such as
TGFβ, Notch, or Ras [61].
Irrespective of its direct role in cellular transformation,
mammalian NDR1/2 kinases might also be a useful target inPhenotype
No centriole duplication
pression Centriole amplification
-out Null mice die at E7.5; heterozygotes
develop liver and lung cancers
No centriole duplication
pression Centriole amplification
Centrosome amplification
pression No centrosome duplication
-out Null mice die at E11.5–E16.5;
heterozygotes develop blood disorders
ons Centrosome amplification
-out Centrosome amplification in p53 null cells
Impaired centriole duplication
pression Centriole amplification
-out Hetero- and homozygote mice develop lymphomas
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earlier with respect to PLK4 [80,81], inhibition of a kinase that
is involved in centriole duplication most likely will prove
incompatible with cell proliferation. Therefore, our finding that
human NDR1/2 kinases are required for proper centriole
duplication [5] has potential implications for the development
of anti-cancer compounds. However, two points are to be taken
into consideration with respect to this approach: (1) murine
NDR1 is not essential for development, because NDR1-
deficient mice are viable and fertile [however, due to the
potential compensation by NDR2 a full assessment of the role
of mammalian NDR1/2 kinases in development will require the
analysis of NDR1/NDR2 double knock-out animals], and (2)
the increased tumourigenesis in NDR1 homo- and heterozygote
mice may raise concerns as to the safety of an NDR kinase
inhibitor. Nevertheless, we believe that it is worth testing
whether diminished centriole duplication due to the down-
regulation of human NDR1/2 kinases negatively interferes with
tumour cell proliferation. Experiments addressing the con-
sequences of NDR1/2 knock-down on cell proliferation are
currently ongoing in tumour-derived cell lines, in order to
determine the potential value of NDR1/2 kinases as targets in
cancer treatment. Another challenge is going to be whether
researchers trained in drug design will be able to take
advantage of the unique structure of NDR kinases (see Section
3). Furthermore, additional studies are to be undertaken that
address the long-term consequences of blocked centriole
duplication in normal and tumour tissues. Before the
investment of more resources, one will first have to exclude
the following scenario. After an initial wave of cell death and
cell cycle arrest due to blocked centriole duplication, some cells
with increased DNA content (possibly generated by abortion of
mitosis or ongoing DNA replication) survive and proliferate
even faster than the tumour cells before drug treatment. As a
consequence of DNA amplification during the “centriole
arrest”, cells might also have acquired an increased potential
to form metastasis. In spite of these concerns, inhibitors of
kinases that regulate centriole duplication might prove to be
valid anti-cancer therapeutics in the future, in particular when
applied in combination with other anti-proliferative cancer
drugs.
Besides being a potential drug target in human disease,
another NDR family member could serve as target for anti-
parasitic agents [109]. TBPK50, the NDR kinase in Trypano-
soma brucei, has been shown to co-ordinate cell shape and
division [110], whereby this function appears to be performed
together with MOB1 [111]. Mottram and colleagues reported
that TBPK50 forms an active complex with MOB1 in vivo, and
more importantly, could show that MOB1 is required for
cytokinesis in blood stream forms of T. brucei [111]. This
finding that the TBPK50/MOB1 complex is essential for
efficient proliferation makes the TBPK50 kinase a promising
drug target candidate in trypanosomes. Therefore, further
research on NDR kinases from different species could provide
important leads in the discovery and validation of NDR kinases
as targets for the development of anti-cancer as well as anti-
parasitic therapeutics.8. Conclusions and perspectives
Over the past decade, studies of NDR family members have
revealed essential functions for NDR kinases in uni- and multi-
cellular organisms. In yeast, NDR kinases regulate mitotic exit
and cytokinesis, and their mammalian relatives appear to have
similar roles. In flies, the Hpo/SWH signaling pathway coor-
dinates cell death and proliferation, and this essential signaling
cascade in Drosophila might also be conserved in vertebrates.
Furthermore, NDR kinases have been shown to regulate mor-
phological changes on the cellular level, in particular SAX-1
and TRC are important regulators of dendritic outgrowth in
invertebrates. The corresponding physiological function, how-
ever, is yet to be addressed in more detail in mammals.
The regulation of NDR kinases at the molecular level has
also been studied in much detail over the past decade.
Phosphorylation events on the activation segment and the
hydrophobic motif have been shown to be essential for kinase
activity as well as functionality of various NDR family
members. The phosphorylation on the activation segment is
controlled by two stretches of primary sequence that are unique
for NDR kinases: (1) binding of MOB proteins to the NTR
domain stimulates autophosphorylation, and (2) basic residues
in close proximity to the activation segment phosphorylation
site contribute to inhibition of phosphorylation. In contrast,
genetic and biochemical evidence strongly indicates that the
hydrophobic motif is targeted by members of the Ste20-like
kinase family. Nevertheless, several lines of research are still
necessary to define the precise roles of these NDR interactors.
In particular, all five MST kinases and six MOB proteins are to
be tested with respect to their involvement in the regulation of
mammalian NDR/LATS kinases. Moreover, in spite of our
advanced understanding of the molecular activation mecha-
nism and function(s) of NDR kinases, the biological substrates
still remain to be identified. Only one substrate of the entire
NDR family is currently known, namely Drosophila Yki.
Potentially, molecular studies of Yki phosphorylation by Lats
will be able to provide general insights into the substrate
specificity of NDR kinases, but many more NDR/LATS
substrates are to be identified and characterized in order to
complement our understanding of NDR-regulated morpholog-
ical changes, mitotic exit or centrosome duplication. Any
extracellular stimulus that activates NDR kinases is also
unknown to date. In particular, research addressing the
activating trigger for the Hpo/SWH pathway is currently of
great interest.
Altogether, one challenge is to identify more components of
the already established Hpo/SWH and MEN/SIN networks in
uni- and multicellular model organisms such as yeast, worms or
flies. A second task is the translation from our knowledge gained
in yeast and invertebrates to mammals. Studies addressing the
regulation of dendritic outgrowth by NDR/LATS kinases as well
as the composition of the still putative mammalian Hpo/SWH
or MEN/SIN signaling cascades will be essential in order to
broaden our knowledge with respect to mammalian NDR/LATS
kinases. The phenotypical analysis of NDR1 and NDR2 single
and double knock-out animals is also to be reported. The
12 A. Hergovich et al. / Biochimica et Biophysica Acta 1784 (2008) 3–15generation and detailed characterization of mice that carry a
tissue-specific deletion of the desired kinase gene (i.e. LATS2)
should be of great help in this respect. Considering the important
role of NDR family members play in the control of mitotic
events, cell death and proliferation in yeast and invertebrates, it
is likely that their human counterparts play similar roles in the
control of these central processes. Actually, ongoing cancer
research is aiming to identify and characterize novel regulators
of cell survival and proliferation that are dysfunctional in
transformed mammalian cells. However, studies testing the
contributions of mammalian NDR/LATS kinases (in particular
of NDR1/2) and their regulators (i.e. MOB proteins) to human
diseases such as cancer appear only now on the horizon. Over the
coming years, it will be essential to understand where, how and
why mammalian NDR1/2 and LATS1/2 kinases are required in
embryonic development and tissue homeostasis, in order to
establish how far NDR/LATS pathways are suitable therapeutic
targets in the fight against human diseases.
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Summary
Human NDR1 and 2 (NDR1/2) are serine-threonine protein ki-
nases in a subgroup of the AGC kinase family [1]. The mech-
anisms of physiological NDR1/2 activation and their function
remain largely unknown. Here we report that Fas and TNF-a
receptor stimulation activates human NDR1/2 by promoting
phosphorylation at the hydrophobic motif (Thr444/442).
Moreover, NDR1/2 are essential for Fas receptor-induced ap-
optosis as shown by the fact that NDR knockdown signifi-
cantly reduced cell death whereas overexpression of the
NDR1 kinase further potentiated apoptosis. Activation of
NDR1/2 by death receptor stimulation is mediated by the tu-
mor suppressor RASSF1A. Furthermore, RASSF1A-induced
apoptosis largely depends on the presence of NDR1/2. Fas
receptor stimulation promoted direct phosphorylation and
activation of NDR1/2 by the mammalian STE20-like kinase 1
(MST1), a downstream effector of RASSF1A. Concurrently,
the NDR1/2 coactivator MOB1 induced MST1-NDR-MOB1
complex formation, which is crucial for MST1-induced
NDR1/2 phosphorylation upon induction of apoptosis. Our
findings identify NDR1/2 as novel proapoptotic kinases
and key members of the RASSF1A/MST1 signaling cascade.
Results and Discussion
Apoptotic pathways, including those induced by death recep-
tors, are often suppressed in cancer cells through the inactiva-
tion of corresponding tumor suppressors, which normally
resist cell overgrowth [2–4]. RASSF1A (Ras association do-
main family 1 isoform A) is a well-known tumor suppressor
protein encoded by a gene on human chromosome 3 at
p21.3 and is often silenced by promoter hypermethylation in
a wide variety of human cancers [2, 5]. Reintroduction of
RASSF1A was reported to induce cell-cycle inhibition via inac-
tivation of the APC/Cdc20 complex [6] or apoptosis via MST1
or MST2 [7, 8]. Although MST2 is known to signal through
LATS1/2 [8–10], the apoptotic signaling cascade downstream
of MST1 in mammalian cells remains obscure.
NDR1/2 are serine-threonine protein kinases belonging to an
AGC kinase subfamily implicated in many essential processes
such as cell division and proliferation [1]. So far the only known
function implicates NDR1 in the regulation of centrosome du-
plication [11]. Two phosphorylation sites of human NDR1/2,
Ser281/282 and Thr444/442, are essential for full kinase
*Correspondence: brian.hemmings@fmi.ch
2These authors contributed equally to this workactivation in vitro and in vivo [12, 13]. The binding of coactiva-
tor MOB1A to the N terminus of NDR1/2 stimulates kinase ac-
tivity, which results in autophosphorylation on Ser281/282 at
the activation segment [14].
We reported earlier that MST3 kinase can phosphorylate
NDR1/2 at Thr444/442 in the hydrophobic motif [15]. Although
no physiological stimulus has been reported for the MST3
kinase, close members within the MST kinase family, such as
MST1 and MST2, are actively involved in apoptosis and stress
response [16–20]. To determine whether NDR1/2 are regulated
by apoptotic stimuli, we treated HeLa cells with the Fas anti-
body or TNF-a. We observed a robust induction of NDR1/2
phosphorylation at Thr444/442, but total NDR1/2 did not
change. This NDR1/2 phosphorylation was paralleled by acti-
vation of MST1/2 and by PARP cleavage, confirming the onset
of apoptosis (Figure 1A, top). Similar results were obtained
with Jurkat cells (Figure S1A available online). The kinase ac-
tivity of endogenous NDR1/2 increased significantly (more
than 8-fold) in cells undergoing Fas and TNF-a receptor stim-
ulation, indicating NDR1/2 activation during apoptosis
(Figure 1A, bottom). These data are the first indication of
a physiological stimulation of NDR kinases.
It has been reported that Fas receptor stimulation triggers
RASSF1A-dependent activation of the downstream signaling
cascade [7, 8]. Indeed, expression of RASSF1A was sufficient
to promote NDR1/2 activation, comparable to induction by the
Fas receptor (Figure 1B, top). Moreover, localization of activated
NDR1/2 and RASSF1A partially overlapped in the cytoplasm
(Figure 1B, bottom). Decreased levels of RASSF1A protein in
cells treated with the Fas antibody resulted in impaired NDR
Thr444/442 phosphorylation, indicating that the Fas-depen-
dent apoptotic signaling cascade activating NDR kinases is
mediated by RASSF1A (Figure 1C).
RASSF1A protein was shown to exert its proapoptotic
effects via MST1 and MST2 kinases [7, 8, 21]. In Fas receptor-
induced apoptosis, MST2 transmits an apoptotic signal to
LATS1; however, no downstream target of MST1 has yet
been proposed. To investigate whether MST1 is involved in
the regulation of NDR Thr444/442 phosphorylation, the level
of the endogenous MST1 kinase was decreased by shRNA.
Stimulation of NDR Thr444/442 phosphorylation upon Fas an-
tibody treatment failed in cells with low MST1 content
(Figure 1D), demonstrating the importance of MST1 for the
NDR1/2 activation during apoptosis. Transient knockdown of
MST2 resulted in only moderate downregulation of NDR1/2
phosphorylation under the same experimental conditions
(Figure S1B). Consistent with these data, we also found re-
duced NDR Thr444/442 phosphorylation triggered by the ex-
pression of RASSF1A in MST1 knockdown cells (Figure 1E).
In addition, NDR1/2 kinase activity was stimulated by the non-
specific inducer of apoptosis, actinomycin D (Figure S1C).
Knockdown of MST1 efficiently prevented NDR1/2 phosphor-
ylation, induced by actinomycin D, whereas knockdown of
MST3 did not change the level of phosphorylated NDR
(Figure S1D).
Because MST1 kinase was crucial for the activation of
NDR1/2 during apoptosis, we tested its ability to induce
NDR1 activation in a series of kinase assays. MST1, but
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Figure 1. Death Receptor-Induced NDR Activation Is Mediated by RASSF1A and MST1
(A) Top: HeLa cells were treated with cycloheximide (CHX) alone or in combination with Fas antibody or TNF-a for the indicated time periods. Cell lysates
were analyzed for the phosphorylation of NDR1/2 (Thr444/442) and MST1/2 (Thr183/Thr180) and PARP cleavage by western blotting. Bottom: Immunopre-
cipitated NDR1/2 from HeLa cells treated with CHX, Fas antibody, or TNF-a for 6 hr was assayed for kinase activity. The results are from duplicate assays
from two independent experiments; data show mean 6 standard deviation.
(B) GFP-RASSF1A was overexpressed in H1299 cells with subsequent analysis of NDR Thr444/Thr442 phosphorylation either by western blotting with
Odyssey quantification (top) or by confocal microscopy (bottom). Note that cells expressing GFP-RASSF1A stained more intensely for Thr444/442 phos-
phorylated NDR1/2 than did untransfected cells (arrows).
(C) HeLa cells expressing shRNA against RASSF1A and treated with a combination of CHX and Fas antibody for 6 hr were lysed and processed for west-
ern blotting. The results are from three independently quantified experiments; data show mean 6 standard deviation.
(D) HeLa cells expressing shRNA against MST1 and treated with a combination of CHX and Fas antibody for 6 hr were lysed and assessed by western
blotting for the occurrence of the indicated proteins.
(E) GFP-RASSF1A was overexpressed in H1299 cells along with the shRNA against MST1, NDR Thr444/Thr442 phosphorylation was analyzed by western
blotting.not its kinase dead variant, phosphorylated MBP-NDR1 pro-
tein in vitro (Figure 2A, left). Next, we confirmed that MST1
was able to directly phosphorylate MBP-NDR1 at the hydro-
phobic motif (Thr444) (Figure 2A, top right), raising the ques-
tion of whether this phosphorylation also induced NDR1/2
activation. Indeed, NDR1 phosphorylated at Thr444 by
MST1 displayed greatly (7-fold) enhanced protein kinaseactivity (Figure 2A, bottom right). In order to verify the spec-
ificity of the kinase reaction, we performed experiments with
recombinant MST1 (Figures S2A and S2B). Finally, we deter-
mined whether MST2 and MST4 are also potential upstream
kinases for NDR. Although MST1, MST2, and MST3 potently
activated NDR1 in vitro, MST4 had only a minor effect
(Figure S2C).
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Figure 2. MST1 Phosphorylates and Activates NDR In Vitro and In Vivo
(A) MBP-NDR1 was in vitro phosphorylated in the presence of [g-32P]ATP by Flag-MST1 and its kinase dead variant (MST1KD) immunoprecipitated from
HEK293 lysates. Kinase reactions were resolved on the SDS-PAGE (left). Experiment performed as above but in the absence of radiolabelled ATP and
NDR1 Thr444 phosphorylation was analyzed by western blotting (right). MBP-NDR1 activated by MST1 was used in a subsequent in vitro kinase assay
on the NDR substrate peptide (right). The results are from duplicate assays from two independent experiments: data show mean 6 standard deviation.
(B) HEK293 cells were transfected with Flag-MST1 or Flag-MST1KD, cell lysates were analyzed for phosphorylated active NDR1/2 by western blotting and
quantified.
(C) HA-RASSF1A and Flag-MST1 as well as their SARAH domain deletion mutants were expressed in H1299 cells; western blotting of the indicated proteins
is shown.
(D) Putative phosphorylation sites (Thr202Ser203) in the sequence of RASSF1A are displayed (top). HA-MST1, immunoprecipitated from the HEK293 cells,
was used in an in vitro radioactive kinase assay with MBP-RASSF1A or its phospho-deficient mutant Thr/Ala202Ser/Ala203.
(E) HeLa cells were transfected with wild-type HA-RASSF1A or phosphorylation-deficient mutant, and activation of NDR1/2 by Thr444/Thr442 phosphory-
lation was assessed by western blotting.
(F) Apoptosis of HeLa cells expressing wild-type RASSF1A versus a RASSF1A-Thr/Ala202Ser/Ala203 mutant upon Fas antibody treatment. Data including
standard deviations from three independent experiments are displayed.The contribution of MST1 to in vivo phosphorylation and ac-
tivation of NDR was studied by expressing the kinase in
HEK293 cells. MST1 induced significant phosphorylation of
NDR1/2 on Thr444/442 (Figure 2B), comparable with that in-
duced by RASSF1A expression (Figure 1B), Fas antibody, or
TNF-a treatment (Figure 1A). Next, we examined whether theobserved increase in NDR Thr444/442 phosphorylation was
mediated by RASSF1A-MST1 binding via their SARAH do-
mains [7, 22]. As expected, wild-type MST1 coimmunoprecipi-
tated with RASSF1A, whereas the MST1 mutant lacking the
SARAH domain (DSAR) as well as MST3 (naturally lacking
a SARAH domain) failed to bind RASSF1A (Figure S2D).
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1892Comparison of NDR1/2 phosphorylation in cells expressing
wild-type or SARAH domain-deletion variants (DSAR) of
RASSF1A, MST1, or their combination showed that interaction
of RASSF1A and MST1 is required for a positive effect on NDR
Thr444/442 phosphorylation (Figure 2C).
Our data place mammalian NDR1/2 directly downstream of
the MST1 kinase. In Drosophila, the ortholog of NDR (Trc), as
well as of LATS (Warts/Lats), are also regulated by MST
(Hpo), a core member of Hippo tumor suppressor pathway [23].
We examined whether RASSF1A may be a substrate of NDR
or MST1. The direct phosphorylation of MBP-RASSF1A fusion
protein in in vitro kinase assays with the wild-type or kinase
dead variants revealed a marked effect of MST1 but not of
NDR1 (Figure S2E). We then mutated two putative phosphory-
lation sites in the MBP-RASSF1A construct (Figure 2D, top).
MST1 efficiently phosphorylated MBP-RASSF1A, whereas
MBP-RASSF1A Thr/Ala202Ser/Ala203 displayed only a residual
signal (Figure 2D, bottom). To investigate the effects of puta-
tive RASSF1A phosphorylation in vivo, mutant RASSF1A was
expressed along with the wild-type species. Interestingly,
analysis of NDR Thr444/442 phosphorylation demonstrated
a reduced capacity of the RASSF1A mutant to activate
NDR1/2 (Figure 2E). It has been reported previously that over-
expression of RASSF1A is sufficient to induce apoptosis [4, 7,
8]. We found that the mutant RASSF1A was less potent in trig-
gering apoptosis than the wild-type protein (Figure 2F). MST1
and RASSF1A form a complex via association of their SARAH
domains [24]. This interaction could facilitate MST1-mediated
RASSF1A phosphorylation upon induction of apoptosis [25].
The same motif (Thr202Ser203) was previously shown to be tar-
geted by Aurora-A [26] and CDK4 [27]. However, phosphoryla-
tion of RASSF1A by these kinases results mostly in effects on
the cell cycle and no apoptotic function has been proposed.
Previously, we established that full activation of NDR1/2 de-
pends on the MOB1 coactivator, which elicits its effect through
direct binding to the N termini of NDR1 and NDR2 [14, 28]. Hu-
man MOB1 protein exists in two isoforms that share more than
95% sequence similarity: MOB1A and B (collectively termed as
MOB1 hereafter). In order to study the role of MOB1 in NDR ac-
tivation during apoptosis, we knocked down both MOB1 iso-
forms in HeLa cells and treated with the Fas antibody. In these
experimental settings, a decrease in MOB1 protein level corre-
lated with reduced Thr444/442 phosphorylation of NDR1/2
(Figure 3A). Further, coexpression of MOB1A and MST1 re-
sulted in enhanced NDR1 activity (Figure 3B). In vitro kinase
assays with MBP-NDR1 as a substrate revealed a stimulatory
effect of MOB1A on MST1-induced NDR phosphorylation
(Figure S3A).
We showed earlier that MOB1A binds to NDR1 kinase and
that this association is increased upon okadaic acid (OA) treat-
ment, which preferentially inhibits protein phosphatase 2A
[14]. Recent studies also demonstrated association of Dro-
sophilaMats (MOB) and Warts/Lats (LATS) when Mats is phos-
phorylated by Hpo (MST) [29]. Based on these results, we
examined whether human MOB1A and MST1 interact in the
presence of OA. Indeed, MOB1A, MST1, and activated
NDR1/2 were found in a complex upon OA treatment (Figures
S3B and S3C). Moreover, all three proteins displayed cytoplas-
mic colocalization visualized by confocal microscopy
(Figure 3C, top). The inducible knockdown of MOB1 almost
completely abolished binding between endogenous MST1
and HA-NDR1 (Figure 3C, bottom).
Because Fas receptor stimulation activated both MST1 and
NDR1/2, we examined whether this stimulus could serve asa physiological signal for complex formation. Indeed, we ob-
served association of endogenous MOB1-MST1-NDR pro-
teins, triggered by the Fas antibody treatment. In addition,
shRNA against MOB1 was sufficient for disruption of the com-
plex (Figure 3D), implying that MOB1 was its driving force. Our
results support a model in which MOB1 binding not only re-
leases the autoinhibitory conformation of NDR1/2 [14, 30],
but also promotes maximal activation by inducing a triple
complex formation, essential for MST1-mediated phosphory-
lation. During the preparation of this manuscript, a report
was published that describes the association between
MST2, MOB1, and NDR1 [31]. However, it is not known
whether these proteins form an endogenous complex or which
physiological stimulus is required for this association.
Given that activation of NDR1/2 occurred in response to
death receptor stimulation and involved several prominent
proapoptotic molecules, we were prompted to investigate
the functional relevance of NDR1/2 in the apoptotic process.
To address this issue, we made use of HeLa cells expressing in-
ducible shRNA directed against NDR1/2. Cells depleted of
NDR1/2 were more resistant in developing morphological signs
of apoptosis such as membrane blebbing and cellular shrink-
age upon addition of the Fas antibody (Figure 4A, top). In the
same experimental settings, knockdown of NDR1/2 resulted
in a significant reduction of cleaved PARP and cytochrome c
release in cells undergoing apoptosis (Figure 4A, bottom).
The proapoptotic effect of NDR1/2 was further confirmed by
assessing the mitochondrial membrane potential (DJ), which
is a critical factor in the irreversible phase of apoptosis. Loss
of DJ induced by the Fas antibody was significantly lower in
cells depleted of NDR1/2 than in control HeLa cells
(Figure 4B). Transient knockdown of NDR1/2 in HeLa and
MCF7 cells had a similar effect (Figures S4A and S4B). The ex-
pression of siRNA-resistant wild-type NDR1 or NDR2 allowed
Fas-induced apoptosis, whereas reintroduction of siRNA-
resistant kinase dead (or even more so Thr444Ala) mutants
did not restore efficient induction of apoptosis (Figure 4C).
These data confirm that phosphorylation of the hydrophobic
motif as part of NDR activation mechanism is crucial for proa-
poptotic function of NDR kinases. In addition, it shows that
bothNDR1and NDR2 isoformsmediate Fas-induced apoptosis.
We addressed the relevance of NDR1/2 for RASSF1A-medi-
ated apoptosis. Even though both NDR1/2 knockdown and
control cells expressed comparable RASSF1A levels, apopto-
sis was not efficiently induced in the absence of NDR1/2, indi-
cating that these kinases are essential for RASSF1A-mediated
cell death (Figure 4D). Overexpression of NDR1 significantly
enhanced the release of the apoptotic markers, in particular
cytochrome c (Figure S4C, top), and further potentiated apo-
ptosis triggered by the Fas antibody (Figure S4C, bottom). Fur-
thermore, overexpression of NDR1wt but not NDR1Thr444Ala
mutant promoted apoptosis in MCF7 cells (Figure S4D). Signif-
icantly, depletion of endogenous MOB1 resulted in similar re-
duction in apoptotic response as knockdown of NDR (Figures
S4A and S4B). Our data identify NDR1/2 as key apoptotic
players downstream of RASSF1A/MST1/MOB1 and provide
evidence for this novel NDR kinase function, as summarized
schematically in Figure 4F.
Our results, together with the data on MST2-mediated acti-
vation of LATS [8, 10], suggest that the analog of the Hippo
pathway in mammals splits at the level of MST kinases to acti-
vate LATS and NDR.
Whereas MST1 and 2 have been assigned a proapoptotic
function and MOB1 and LATS1/2 are known tumor
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Figure 3. MOB1 Is Required for the Association of NDR and MST1 and for NDR Activation during Fas-Induced Apoptosis
(A) HeLa cells expressing shRNA against MOB1 and treated with a combination of CHX and Fas antibody for 6 hr were lysed and processed for western
blotting with the indicated antibodies. The results are from three independently quantified experiments: data show mean 6 standard deviation.
(B) HA-NDR1 precipitated from HEK293 cells transfected with either MST1 and MOB1A alone or their combination and was assayed for kinase activity on
NDR substrate peptide. The results are from duplicate assays from two independent experiments; data show mean 6 standard deviation.
(C) Indicated proteins were expressed in HeLa cells and their colocalization analyzed by confocal microscopy (top). HA-NDR1 expressed in U2OS with
tetracycline-regulated shRNA against human MOB1 stimulated with okadaic acid (OA) was coimmunoprecipitated with endogenous MST1 in the absence
of inducible MOB1 knockdown (bottom).
(D) Endogenous NDR1/2 were coimmunoprecipitated with endogenous MST1 after stimulation with Fas antibody from U2OS cells expressing inducible
knockdown of MOB1 (compare lines 3 and 6).
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Figure 4. NDR Mediates Fas-Induced Apoptosis
(A) Images of HeLa cells expressing tet-inducible shRNA against NDR1/2 after 6 hr of stimulation with CHX alone or in combination with Fas antibody. Cells
were lysed and analyzed by quantitative western blotting with the antibodies against total and active NDR1/2 (phospho-Thr444/Thr442), cleaved PARP, and
cytochrome c. The results are from three independent experiments; data show mean 6 standard deviation.
(B) Cells treated as in (A) were analyzed for depolarization of mitochondrial membrane potential by flow cytometry. Note that knockdown of NDR1/2 signif-
icantly reduced the number of cells undergoing apoptosis. Data including standard deviations from three independent experiments are displayed;
*p < 0.005.
(C) HeLa cells expressing tet-inducible shRNA against NDR1/2 were transfected with empty vector, HA-NDR1 wild-type, kinase dead, Thr444Ala mutant, or
HA-NDR2 wild-type that is refractory to siRNA [1wt(6N), 1kd(6N), 1T444A(6N), or 2wt(6N)]. Cells were treated as in (A) and analyzed for depolarization of
mitochondrial membrane potential by flow cytometry. Data including standard deviations from three independent experiments are displayed.
(D) Apoptotic response to HA-RASSF1A overexpression was measured by flow cytometry in HeLa cells expressing tet-inducible shRNA against NDR1/2.
Knockdown of NDR1/2 and expression levels of HA-RASSF1A were monitored by western blotting. Data including standard deviations from three indepen-
dent experiments are displayed; *p < 0.005.
(E) Schematic representation of the signaling pathway triggered by Fas receptor stimulation with the subsequent activation of NDR1/2 via the RASSF1A/
MST1.suppressors [32–34], the possible involvement of NDR1/2 in
cell transformation has not yet been addressed. The pathway
we describe highlights the importance of NDR1/2 in theregulation of apoptosis and contributes to the mechanism of
death receptor signaling, which is a part of antitumor defense
and is often compromised in cancer.
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Summary
Background: Human MST/hSAV/LATS/hMOB tumor suppres-
sor cascades are regulators of cell death and proliferation;
however, little is known about other functions of MST/hMOB
signaling. Mob1p, one of two MOB proteins in yeast, appears
to play a role in spindle pole body duplication (the equivalent
of mammalian centrosome duplication). We therefore investi-
gated the role of human MOB proteins in centrosome duplica-
tion. We also addressed the regulation of human centrosome
duplication by mammalian serine/threonine Ste20-like (MST)
kinases, considering that MOB proteins can function together
with Ste20-like kinases in eukaryotes.
Results: By studying the six human MOB proteins and five
MST kinases, we found that MST1/hMOB1 signaling controls
centrosome duplication. Overexpression of hMOB1 caused
centrosome overduplication, whereas RNAi depletion of
hMOB1 or MST1 impaired centriole duplication. Significantly,
we delineated an hMOB1/MST1/NDR1 signaling pathway
regulating centrosome duplication. More specifically, analysis
of shRNA-resistant hMOB1 and NDR1 mutants revealed that
a functional NDR/hMOB1 complex is critical for MST1 to phos-
phorylate NDR on the hydrophobic motif that in turn is required
for human centrosome duplication. Furthermore, shRNA-
resistant MST1 variants revealed that MST1 kinase activity is
crucial for centrosome duplication whereas MST1 binding to
the hSAV and RASSF1A tumor suppressor proteins is dispens-
able. Finally, by studying the PLK4/HsSAS-6/CP110 centriole
assembly machinery, we also observed that normal daughter
centriole formation depends on intact MST1/hMOB1/NDR
signaling, although HsSAS-6 centriolar localization is not
affected.
Conclusions: Our observations propose a novel pathway in
control of human centriole duplication after recruitment of
HsSAS-6 to centrioles.
Introduction
Centrosomes function as the main microtubule-organizing
centers in animal cells. Each centrosome is composed of
two centrioles surrounded by pericentriolar material [1–3].
They play an important part in organizing the bipolar spindle
during mitosis, ensuring equal distribution of genetic material
between the two daughter cells. Centrosomal components are
further required for the assembly and maintenance of cilia and
flagella, two structures with essential functions in mammalian
development and physiology [4, 5]. Therefore, the doubling of
centrosomes during S phase (termed centrosome duplication)
*Correspondence: hergo@fmi.chis under strict control. Studies with mammalian cells have
shown that centriole duplication is orchestrated by different
protein kinases, such as polo-like kinase 4 (PLK4), cyclin-
dependent kinase 2 (Cdk2), and NDR kinases [6–9].
The NDR/LATS family is a subgroup of AGC serine/threonine
protein kinases and consists of four related kinases (NDR1/
STK38, NDR2/STK38L, LATS1, and LATS2) in the mammalian
genome [10]. Although members of the NDR family have
been detected on spindle pole bodies (SPB) and centrosomes,
only human NDR1/2 kinases have been attributed a role in
centrosome duplication [11]. Although LATS1/2 kinases are
found on centrosomes, they are not involved directly in the
regulation of centrosome duplication in human cells [9]. In
multicellular organisms, LATS kinases play a central role in
Hippo/SWH (Salvador/Warts/Hippo) signaling, which coordi-
nates cell proliferation and apoptosis [12–14]. Initially delin-
eated in flies as the Hpo/Sav/Lats/dMOB1/Yki network,
mammalian MST/hSAV/LATS/hMOB/YAP tumor suppressor
signaling was also defined recently [15]. In mammalian cells,
this machinery regulates tissue homeostasis by balancing
cell proliferation and apoptotic events, where hSAV, MST1/2,
LATS1/2, and hMOB1 form complexes (summarized in [11]).
However, very little is known about other molecular functions
of MST/hMOB signaling.
Intriguingly, one study has already suggested that Mob1p
(the yeast counterpart of human hMOB1A/B proteins) plays
a role in SPB duplication [16]. Therefore, we analyzed in this
study all six human MOB proteins (hMOBs: hMOB1A,
hMOB1B, hMOB2, hMOB3A, hMOB3B, and hMOB3C) for a
potential involvement in centrosome duplication. Given that
MOB proteins can function together with Ste20-like kinases
in yeast, fly, and human cells [10], we further expanded our
study by addressing all human mammalian serine/threonine
Ste20-like kinases (MSTs: MST1, MST2, MST3, MST4, and
SOK1) in centrosome duplication. Significantly, we found that
MST1/hMOB1 signaling is required for centrosome duplica-
tion. Furthermore, we show here that centriole formation
depends on intact MST1/hMOB1/NDR signaling, although
the association of HsSAS-6 with centrioles appears to be
normal.
Results
Overexpression of hMOB1A/B Results in Centrosome
Overduplication
Given the intriguing observation with Mob1p [16], we initially
addressed hMOBs in human centrosome duplication by over-
expression studies (Figure 1). All six human MOB proteins
were overexpressed and the numbers of centrosomes per
mononucleated cell were determined by immunofluorescence
microscopy (Figure 1A). Except for hMOB2, all hMOBs were
detected mainly in the cytoplasm (Figure 1A). Overexpression
of hMOB1A/B caused a significant increase in cells displaying
extra centrosomes (three or more centrosomes per cell),
whereas expression of hMOB2, hMOB3A, and hMOB3B had
no effect (Figure 1B). Overexpression of hMOB3C resulted in
slightly increased centrosome amplification in U2-OS cells
(Figure 1B) but did not cause centrosome amplification in
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(A and C) U2-OS expressing indicated human MOB proteins (1A, 1B, 2, 3A, 3B, or 3C) for 48 hr were processed for immunofluorescence (A) or immunoblot-
ting (C) with the indicated antibodies.
(A) Insets show enlargements of centrosomes in green. DNA is stained blue.
(B) Histograms showing percentages of cells with excess centrosomes (more than three per mononucleated cell;R3). Cumulative data from two indepen-
dent experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard deviations.
(D) Histograms showing percentages of cells with supernumerary centrosomes in HeLa cells. Cells were incubated with aphidicolin (2 mg/ml) for 8 hr before
being transfected with indicated cDNAs. Cells were incubated for a further 48 hr before processing for immunofluorescence. Cumulative data from two
independent experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard deviations.
(E) Staining of U2-OS cells expressing HA-hMOB1A(wt) with antibodies against Cep170 (green), centrin (red), and HA (blue). Enlargements of centrioles
are shown.
(F) Quantification analysis of the experiment shown in (E). Cumulative data from three independent experiments with at least 100 cells counted per
experiment. Error bars indicate standard deviations.HeLa cells (Figure 1D). Notably, of the six hMOBs, expression
levels of hMOB1A and hMOB1B were consistently the lowest
for unknown reasons (Figure 1C; data not shown).
To investigate whether the generation of supernumerary
centrosomes resulting from hMOB1A/B overexpression is
a consequence of centriole/centrosome overduplication or
failure of cytokinesis, we arrested HeLa cells in S phase by
aphidicolin treatment and compared the induction of centro-
some amplification to that in untreated normally cyclingcells. Significantly, hMOB1A/B overexpression triggered
centrosome amplification regardless of the presence or
absence of aphidicolin (Figure 1D; data not shown). Centro-
somes do not overduplicate spontaneously during prolonged
S phase arrest in HeLa [17, 18], so these data suggest that
hMOB1A/B overexpression causes centrosome amplification
by an overduplication mechanism. To verify this finding, we
analyzed hMOB1A-overexpressing cells with increased
centrosome number for Cep170 staining (Figure 1E). If
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the majority of cells should contain only one Cep170-positive
centriole, whereas failure of cell division would cause the
accumulation of at least two mature Cep170-positive centri-
oles [19]. As seen in Figures 1E and 1F, the majority of
hMOB1A-expressing cells with supernumerary centrioles dis-
played only one Cep170-positive centriole, suggesting that
hMOB1A/B overexpression causes centrosome overduplica-
tion in our experimental system.
Endogenous hMOB1A/B Is Required for Centrosome
(Over)duplication
To study endogenous hMOB1A/B, centrosome overduplica-
tion assays [20] were performed in U2-OS cells depleted of
hMOB1A/B (Figure 2). In parallel to the generation of a
hMOB1A/B antibody that selectively recognized hMOB1A
and hMOB1B (Figure S1 available online), stable cell lines
were generated expressing tetracycline-inducible short hairpin
RNA (shRNA) directed against hMOB1A/B (Figure 2A). Of note,
hMOB1A and hMOB1B mRNAs had to be targeted simulta-
neously by two different shRNAs, to allow efficient knockdown
of total hMOB1A/B protein levels (Figure 2A). Significantly,
centrosome amplification was altered in hMOB1A/B-depleted
cells upon S phase arrest (Figures 2B and 2C). To ensure the
specificity of our RNAi experiments, wild-type hMOB1A cDNAs
refractory to shRNA were introduced into U2-OS cells express-
ing inducible vector-based RNAi (Figure 2D). Expression of
shRNA-resistant hMOB1A restored centrosome overduplica-
tion upon depletion of endogenous hMOB1A/B (Figure 2E),
indicating that the failure of hMOB1A/B-depleted cells to
efficiently overduplicate centrosomes is due to specific
knockdown of endogenous hMOB1A/B.
To address hMOB1A/B in normal centriole duplication, we
analyzed centriole numbers at the end of the centriole duplica-
tion cycle [9, 21]. Nearly 50% of hMOB1A/B-depleted cells
lacked at least one centriole in early mitotic stages (Figures
2F and 2G; control: 9.3% 6 1.7%; hMOB1A/B knockdown:
47.2% 6 8.7%). About 34% of hMOB1A/B-depleted cells
displayed bipolar spindles containing only three centrioles
instead of the normal four centrioles per cell (untreated control
background: 8%), and 13% of hMOB1A/B-depleted cells con-
tained only one or two centrioles (control: 2%). Depletion of
endogenous hMOB1A/B in HeLa and diploid untransformed
RPE1 cells also resulted in decreased centriole numbers
(Figure S2). U2-OS cells expressing shRNA-resistant hMOB1A
did not display a significant loss of centrioles upon depletion of
endogenous hMOB1A/B (Figure 2G; control: 10.2% 6 2.9%;
hMOB1A/B knockdown with shRNA-resistant hMOB1A:
13.5% 6 4%), suggesting that endogenous hMOB1A/B
contributes to normal centriole duplication in human cells.
hMOB1A/B Regulates Hydrophobic Motif Phosphorylation
of NDR Kinase
hMOB1A/B proteins have already been reported to interact
with NDR kinases [22–27]; hence, NDR1/2 protein levels were
analyzed in hMOB1A/B-depleted cells upon S phase arrest.
Significantly, phosphorylation of NDR1/2 on Thr444 (the
hydrophobic motif of NDR1) was strongly diminished upon
hMOB1A/B knockdown (Figure 2A) and partially restored by
expression of shRNA-resistant hMOB1A (Figure 2D). This
finding was surprising, because recombinant hMOB1A did
not cause an increase in NDR1/2 phosphorylation on Thr444
in vitro [22] and hMOB1A/B is not required for hydrophobic
motif phosphorylation of LATS1 in cells [26]. Nevertheless,our findings suggest that hMOB1A/B regulates the phosphor-
ylation of NDR1/2 on Thr444 by upstream kinase(s) upon S
phase arrest of cells.
hMOB1/NDR Complex Formation Is Essential for Efficient
Centrosome Duplication and NDR Phosphorylation
Before addressing the nature of the upstream kinase(s), we
determined whether the interaction of hMOB1A/B with NDR1/
2 is required for the regulation of centrosome duplication. First,
the effects of selected NDR1 mutants (initially defined in
[22, 25]) on the centrosome cycle were examined (Figure 3).
These NDR1 mutants displayed intact hMOB2 binding,
although interactions with hMOB1A/B (also termed hMOB1)
were undetectable (Figure S3; data not shown). All NDR1 vari-
ants expressed at comparable levels and displayed similar
subcellular distribution (Figures 3A and 3B; data not shown).
However, only overexpression of NDR1(wt) resulted in centro-
some amplification (Figure 3C). Overexpression of NDR1
kinase-dead (kd) or NDR1 deficient in hMOB1 binding did not
increase centrosome numbers (Figure 3C). Expression of
shRNA-resistant NDR1 mutants did not restore centrosome
overduplication upon depletion of endogenous NDR1 (Fig-
ure 3E). These mutants also displayed dramatically decreased
phosphorylation on Thr444 (Figure 3D), suggesting that NDR1/
hMOB1 complex formation is required for Thr444 phosphoryla-
tion and centrosome amplification.
To further address the role of hMOB1/NDR complex forma-
tion, we generated a hMOB1A(E51K) mutant deficient in
NDR1/2 binding (Figure S4). Overexpression of hMOB1A(E51K)
did not lead to centrosome overduplication, even though
expression and localization were not significantly changed
(Figure S5). Moreover, shRNA-resistant hMOB1(E51K) did not
compensate for the depletion of endogenous hMOB1A/B (Fig-
ure S5). Furthermore, although NDR1 expression and subcel-
lular localization were not obviously affected upon knockdown
of hMOB1A/B, NDR1-driven centrosome overduplication was
impaired in hMOB1A/B-depleted cells (Figure S6; data not
shown). Inversely, centrosome amplification resulting from
overexpression of hMOB1A was decreased in NDR1-depleted
cells (Figure S6; data not shown). Overall, the findings
described in Figure 3 and Figures S5 and S6 strongly suggest
that a functional hMOB1/NDR complex is indispensable for
centrosome overduplication.
MST1Kinase Regulates Centrosome (Over)duplication and
NDR Phosphorylation in a hMOB1A/B-Dependent Manner
Our data shown in Figure 2 and Figure S5 suggested that
hMOB1A/B regulates the phosphorylation of NDR1/2 by
upstream kinase(s). Therefore, we investigated whether any
of the postulated upstream activators (the entire group of
MST kinases [10]) is responsible for Thr444 phosphorylation
in a hMOB1A/B-dependent manner (Figure 4). In U2-OS cells,
overexpression of MST1(wt) increased phosphorylation of
endogenous NDR1/2 the most efficient (Figure 4A and
Figure S7), although MST1, MST2, and MST3 can phosphory-
late NDR1/2 on Thr444 in vitro [27, 28]. This increase in
NDR1/2 phosphorylation was dependent on MST1 kinase
activity (Figure 4A) and was blocked in hMOB1A/B-depleted
cells but restored by expression of shRNA-resistant
hMOB1A(wt) upon hMOB1A/B knockdown (Figure 4B). In full
agreement with our previous observations (Figure 2 and
Figure S5) these results suggest that MST1 phosphorylates
NDR1/2 on Thr444 in a hMOB1A/B-dependent manner.
Furthermore, they suggest that MST1 kinase might be involved
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(A and B) U2-OS cells stably expressing tetracycline-regulated short-hairpin RNA (shRNA) directed against hMOB1A/B were incubated for 72 hr without (2)
or with (+) tetracycline (2 mg/ml) and for a further 72 hr with aphidicolin (2 mg/ml), before processing for immunoblotting (A) or immunofluorescence (B) with
the indicated antibodies.
(B) DNA is in blue. Insets show centrosome enlargements in red.
(C) Histograms showing percentages of cells with excess centrosomes (R3) incubated without (2) or with (+) tetracycline, followed by incubation with aphi-
dicolin. Cumulative data from three independent experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard
deviations.
(D) U2-OS stably expressing shRNA against hMOB1A/B were infected with empty vector (lanes 1–4) or HA-hMOB1A wild-type cDNA (lanes 5–8) that is
refractory to shRNA [wt_9N]. After incubation for 72 hr with (+) or without (2) tetracycline and for an additional 72 hr with aphidicolin, cells were processed
for immunoblotting with the indicated antibodies.
(E) In parallel, cells were processed for immunofluorescence to determine centrosome numbers per cell. Histograms show the percentage of cells with
excess centrosomes (R3) incubated without (2) or with (+) tetracycline, followed by incubation with aphidicolin. Cumulative data from two independent
experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard deviations.
(F) U2-OS cells expressing shRNA directed against hMOB1A/B were incubated without (2) or with (+) tetracycline for 96 hr, before processing for immuno-
fluorescence with centrin (green) and a-tubulin (red) antibodies. DNA is shown blue.
(G) Histograms showing percentages of mitotic cells in prophase and prometaphase that displayed the loss of at least one centriole (%3 centrioles per cell)
in the presence (+) or absence (2) of tetracycline. Cumulative data from three independent experiments with at least 100 cells counted per experiment. Error
bars indicate standard deviations.
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1696Figure 3. NDR1 Kinase Deficient in hMOB1A/B Binding Does Not Support Centrosome Amplification
(A and B) U2-OS cells expressing HA-NDR1 wild-type(wt), kinase-dead(kd), or hMOB1A/B binding mutants (Y31A, R41A, or T74A) for 48 hr were processed
for immunoblotting (A) or immunofluorescence (B) with the indicated antibodies.
(B) Insets show enlargements of centrosomes in green. DNA is stained blue.
(C) Histograms showing percentages of cells with excess centrosomes (R3). Cumulative data from three independent experiments, with at least 150 cells
counted per experiment. Error bars indicate standard deviations.
(D and E) U2-OS cells stably expressing tetracycline-regulated short-hairpin (shRNA) directed against human NDR1 were infected with empty vector (lanes
1–3), HA-NDR1 wild-type (lanes 4 and 5), or hMOB1A/B binding mutants (lanes 6–11) that are refractory to shRNA [HA-NDR1(6N)]. After incubation for 72 hr
without (2) or with (+) tetracycline and for a further 72 hr with aphidicolin, cells were analyzed by immunoblotting with the indicated antibodies (D) or by
immunofluorescence for centrosome numbers (E).
(E) Histograms showing percentages of cells with excess centrosomes (R3). Cumulative data from two independent experiments, with at least two
replicates of 100 cells counted per experiment. Error bars indicate standard deviations.in the regulation of centrosome (over)duplication and Thr444
phosphorylation upon S phase arrest.
To address this experimentally, stable cell lines were
generated expressing tetracycline-inducible shRNA directed
against MST1 (Figure 4C). Phosphorylation of NDR1/2 onThr444 was decreased in MST1-depleted cells (Figure 4C), indi-
cating that MST1 is the main upstream kinase under these
conditions. Significantly, centrosome overduplication was
decreased upon MST1 knockdown (Figure 4D). By analyzing
the number of centrioles at the end of the centriole duplication
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(A) U2-OS transfected with indicated cDNAs for 20 hr were processed for immunoblotting with the indicated antibodies.
(B) U2-OS stably expressing shRNA against hMOB1A/B (lanes 1–3), or the same cells infected with empty vector (lanes 4–6) or shRNA-resistant HA-hMOB1A
(wt_9N) (lanes 7–9) were incubated without (2) or with (+) tetracycline for 72 hr before being transfected with HA-MST1(wt) overnight. Subsequently, cells
were processed for immunoblotting with the indicated antibodies.
(C) U2-OS cells stably expressing tetracycline-regulated short-hairpin RNA (shRNA) directed against human MST1 were incubated for 72 hr without (2) or
with (+) tetracycline and for a further 72 hr with aphidicolin, before processing for immunoblotting.
(D) In parallel, cells were analyzed by immunofluorescence microscopy. Histograms show the percentages of cells with excess centrosomes (R3) incubated
without (2) or with (+) tetracycline, followed by incubation with aphidicolin. Cumulative data from three independent experiments with at least two replicates
of 100 cells counted per experiment. Error bars indicate standard deviations.
(E) U2-OS stably expressing shRNA against MST1 were analyzed after 96 hr with (+) or without (2) tetracycline. Histograms show the percentage of mitotic
cells in prophase and prometaphase that lost at least one centriole (%3 centrioles per cell). Cumulative data from three independent experiments with at
least 100 cells counted per experiment. Error bars indicate standard deviations.
(F and G) U2-OS cells expressing the indicated cDNAs were processed for immunoblotting (F) or immunofluorescence (G) with indicated antibodies.
(G) Insets show centrosome enlargements in green. DNA is shown blue.
(H) Histograms showing percentages of cells with excess centrosomes (R3). Cells expressing the indicated kinase-dead(kd) MST kinases were incubated
with aphidicolin for 72 hr. Cumulative data from four independent experiments with at least two replicates of 100 cells counted per experiment. Error bars
indicate standard deviations.cycle (see Figure 2F), we found that 32%of MST1-depleted cells
lacked at least one centriole (Figure 4E; control: 10.1%6 0.7%;
MST1 knockdown: 32.3%6 4.5%). Knockdown of endogenousMST1 in HeLa and RPE1 cells also caused loss of centrioles
(Figure S2), indicating that endogenous MST1 contributes to
normal centriole duplication in different human cells.
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(kd) overexpression (Figures 4F–4H), because MST1(kd) can
function as a dominant-negative kinase [29]. Significantly,
centrosome overduplication was impaired in U2-OS cells ex-
pressing MST1(kd), whereas overexpression of MST2(kd),
MST3(kd), MST4(kd), or YSK1/SOK1(kd) had no effect, despite
similar expression and subcellular localization patterns (Fig-
ures 4F–4H; data not shown). Because MST2(kd), MST3(kd),
MST4(kd), and SOK1(kd) can also function as dominant-nega-
tive kinases [30], these findings suggest that mainly MST1
contributes to centrosome overduplication in our settings.
However, although MST1 plays a role in NDR1/2 phosphoryla-
tion and centrosome duplication (Figure 4), these findings did
not necessarily demonstrate that NDR-driven centrosome
duplication requires MST1. Thus, we determined the effect of
NDR1(wt) or hMOB1A overexpression on centrosome amplifi-
cation in MST1-depeleted cells, revealing that NDR1- or
hMOB1A-driven centrosome overduplication was impaired in
MST1-depleted cells (Figure S8). Therefore, it is very likely
that centrosome duplication is regulated by MST1/hMOB1/
NDR signaling in our experimental systems.
MST1 Kinase Activity, but Not RASSF1A or hSAV Binding,
Is Required for Centrosome Amplification
MST1 kinase is controlled by various mechanisms [30], most
importantly by binding to RASSF1A, hSAV, or to itself via a
C-terminally located SARAH (Sav/Rassf/Hippo) domain [31–
35]. Therefore, we generated a C-terminally truncated form of
MST1 (residues spanning 1–433; termedDC) that was deficient
in hSAV-, RASSF1A-, and homodimer-complex formation
(Figure S9). Surprisingly, overexpressed MST1(DC) phosphor-
ylated NDR1/2 on Thr444 similarly to MST1(wt) kinase
(Figure S9).
Given this observation, we introduced MST1(wt), (kd), and
(DC) cDNAs refractory to shRNA into U2-OS-expressing induc-
ible vector-based RNAi against MST1 (Figure 5A). Although
expression of shRNA-resistant MST1(wt) restored centrosome
overduplication and Thr444 phosphorylation of NDR1/2 in
MST1-depleted cells, shRNA-resistant MST1(kd) did not
compensate for MST1 depletion, despite similar localization
and expression levels (Figure 5; data not shown). Significantly,
expression of shRNA-resistant MST1(DC) supported centro-
some amplification upon depletion of endogenous MST1
(Figure 5B) and phosphorylation of Thr444 (Figure 5A). These
data show that binding of MST1 to RASSF1A, hSAV, or homo-
dimer formation through the SARAH domain is dispensable for
centrosome overduplication, whereas MST1 kinase activity is
crucial.
The MST1/hMOB1/NDR Cascade Is Required for Human
Centriole Duplication, but Dispensable for Centriolar
‘‘Seed’’ Formation
To understand in more detail the role of MST1/hMOB1/NDR
signaling in human centriole duplication, we investigated
whether the MST1/hMOB1/NDR machinery is required for
PLK4-driven centriole biogenesis (Figure 6). As already
reported [21], overexpression of PLK4 is sufficient to trigger
centriole amplification, where two types of procentriole
arrangements have been observed: centrioles arranged either
in (1) flower-like structures around parental centrioles, or (2)
clusters of centrioles after disengagement [36]. Significantly,
PLK4-driven centriole amplification was impaired in
hMOB1A/B-, MST1-, or NDR1-depleted cells, although PLK4
expression and centriole localization were not obviouslyaffected (Figure 6; Figure S10; data not shown). Moreover, no
significant differences in cell cycle profiles were observed
upon depletion of MST1/hMOB1/NDR signaling components
and/or PLK4 overexpression (Figure 6D; Figures S10 and
S11), suggesting that the observed defect in centriole amplifi-
cation is not simply a consequence of a general cell cycle
arrest. Overall, reduction of MST1/hMOB1/NDR signaling
appears to negatively affect PLK4-driven centriole biogenesis
without any direct effect on PLK4 expression, subcellular local-
ization, and cell cycle profiles.
Next, we addressed whether MST1/hMOB1/NDR signaling
might play a role in other steps of the centriole assembly
pathway conserved from lower to higher eukaryotes [37–52].
In human cells, after the activation of PLK4 on the parental
centriole, g-tubulin, CPAP, Cep135, and HsSAS-6 are rapidly
recruited to the centriole [36]. Then, CP110 forms a cap on
the newly forming procentriole, and finally, the centriole grows
by addition of tubulin. To determine any involvement of MST1/
hMOB1/NDR signaling in this pathway, we focused our anal-
ysis on centrosomes and centrioles at the end of the centriole
duplication cycle (as already defined in Figure 2F). Cell lines
expressing inducible shRNA directed against hMOB1A/B,
MST1, or NDR1 were cultured in the absence or presence of
tetracycline without apparent changes in cell cycle profiles
and protein expression, except for the targeted proteins of
interest (Figures 7A and 7B; Figures S11 and S12). As expected
[53, 54], normal prophase cells (with condensed DNA and
Figure 5. MST1 Kinase Activity, Not the SARAH Domain, Is Required for
Centrosome Overduplication in Human Cells
(A) U2-OS stably expressing shRNA against MST1 were infected with empty
vector (lanes 1–3), HA-MST1 wild-type (lanes 4–6), kinase-dead (lanes 7–9),
or a C-terminally truncated mutant cDNA (DC; lanes 10–12) that is refractory
to shRNA [wt_7N, kd_7N, or DC_7N]. After incubation for 72 hr with (+) or
without (2) tetracycline and for an additional 72 hr with aphidicolin, cells
were processed for immunoblotting with indicated antibodies.
(B) In parallel, the number of centrosomes per cell was determined. Histo-
grams show the percentage of cells with excess centrosomes. Cumulative
data from three independent experiments with at least two replicates of
100 cells counted per experiment. Error bars indicate standard deviations.
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two CP110 signals at each spindle pole (Figures 7C and 7E).
Interestingly, the association of HsSAS-6 with prophase
centrosomes was not altered upon hMOB1A/B, MST1, or
NDR1 depletion (Figure 7C; data not shown). Irrespective of
the decreased centriole number per spindle pole, HsSAS-6
associated with centriole pairs or single centrioles (Figure 7D;
data not shown).
Next, to address in more detail whether the cell cycle-
dependent centriole localization of HsSAS-6 [54] relies on
MST1/hMOB1/NDR signaling components, we determined
the cell cycle stages of individual cells by PCNA staining (Fig-
ures S13 and S14). In full agreement with existing literature
[54], HsSAS-6 was not detected on centrioles in most U2-OS
cells during G1 phase, but was present on the majority of
centrioles in S and G2 phase (Figure S14). It is noteworthy
that depletion of hMOB1A/B, MST1, or NDR1 did not affect
this cell cycle-regulated HsSAS-6 localization pattern (Fig-
ure S14; data not shown). Taken together, these findings
suggest that the initiation of procentriole formation (also
termed centriolar ‘‘seed’’ formation; see [36, 54]) is indepen-
dent of MST1/hMOB1/NDR signaling.
In contrast, despite unaffected DNA condensation and
centrosome separation, a significant portion of hMOB1A/B-,
MST1-, or NDR1-depleted cells lacked at least one CP110
centriole signal in prophase (Figure 7E; control [without
Figure 6. PLK4-driven centriole biogenesis is
impaired upon hMOB1A/B or MST1 depletion
(A and B) U2-OS stably expressing shRNA
against hMOB1A/B (lanes 1–3), or MST1 (lanes
4–6) were incubated without (2) or with (+) tetra-
cycline for 72 hr before being transfected with
GFP-PLK4(wt) overnight. Subsequently, cells
were processed for immunoblotting (A) or immu-
nofluorescence (B) with the indicated antibodies.
(B) Insets show enlargements of centrioles. GFP-
PLK4 is in green and centrioles are shown in red.
DNA is stained blue.
(C) Histograms showing percentages of cells with
excess centrioles (R5). Cumulative data from
two independent experiments, with at least two
replicates of 100 cells counted per experiment.
Error bars indicate standard deviations.
(D) In parallel, cells from the same samples were
analyzed for DNA content by FACS.
tetracycline induction], 8% [n = 130];
hMOB1A/B knockdown, 44% [n = 142];
control, 7% [n = 121]; MST1 knockdown,
30% [n = 127]; control, 9% [n = 131];
NDR1 knockdown, 41% [n = 116]). As
already described for centrin-2 (see
Figures 2F, 2G, and 4E), CP110 signals
displayed reduced numbers of centri-
oles in depleted cells (Figure 7F; data
not shown). Two additional centriole
markers (glutamylated-tubulin and
acetylated-a-tubulin) further confirmed
that centriole numbers are decreased
upon hMOB1A/B, MST1, or NDR1
depletion (Figure S15; data not shown).
Overall, the analysis of depleted
cells with five independent centriole
markers—HsSAS-6, CP110, centrin-2,
glutamylated-tubulin, and acetylated-a-tubulin—revealed
that MST1/hMOB1/NDR signaling is required for normal
centriole duplication in human cells, although the association
of HsSAS-6 with centrioles does not appear to be affected.
Discussion
Taken together, our findings indicate that MST1/hMOB1/NDR
signaling contributes to centriole duplication in human cells.
Endogenous hMOB1A/B and MST1 are required for normal
centriole duplication (Figures 2, 4, and 5). The association of
hMOB1A/B with NDR1/2 kinases is essential for centrosome
duplication (Figure 3; Figure S5). Moreover, centrosome over-
duplication requires MST1 kinase activity but is independent
of the SARAH domain of MST1 (Figure 5). Because MST1
binding to hSAV, RASSF1A, NORE1, and CNK1 depends on
the SARAH domain of MST1 [30], this suggests that all
currently known activators/inhibitors of MST1 are unlikely to
contribute to MST1 signaling in centrosome duplication.
Our data would indicate that MST1 kinase activity plays
a role in human centrosome duplication, although MST1 is
best known as a proapoptotic kinase [30] whose activity is
enhanced by RASSF1A/MST1 complex formation [34].
RASSF1A binding to MST1 through the SARAH domain also
increased NDR1/2 kinase activity in apoptotic cells [27]. In
contrast, MST1 signaling in centrosome duplication is SARAH
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domain of MST1 might exemplify the means by which human
cells utilize similar signaling systems for the regulation of
very different biological processes (e.g., programmed cell
death versus centrosome duplication in the case of MST1/
hMOB1/NDR signaling). Considering further that centrosome
duplication occurs in S phase, it is tempting to speculate
that MST1 kinase regulates NDR1/2 kinases in a cell cycle-
dependent manner. Intriguingly, we could confirm the reported
[55] S-phase-induced phosphorylation of MST1 (Figure S16),
suggesting that MST1 kinase activity could oscillate during
the cell cycle. As a result, a new line of research will be required
to elucidate how MST1 activity is regulated (in)dependently of
its SARAH domain during the cell cycle. Hence, future research
addressing the role of MST1/hMOB1/NDR signaling in cell
cycle progression is warranted.
Our data suggest that MST1 regulates human centrosome
duplication through the phosphorylation of endogenous
NDR1/2 in S phase (Figures 4 and 5). However, human
LATS1/2, histone 2B (H2B), and FoxO have also been identified
as MST1 substrates [56–58]. In this context, it is noteworthy
that LATS1/2 are not involved in centrosome duplication [9].
Of further importance, caspase-cleaved MST1 phosphorylates
H2B in the nucleus, whereas full-length MST1 targets cytosolic
Figure 7. Centriole Localization of CP110, but
Not of HsSAS-6, Depends on MST1/hMOB1
Signaling
(A and B) U2-OS cells expressing shRNA directed
against hMOB1A/B (lanes 1 and 2) or MST1 (lanes
3 and 4) were incubated without (2) or with (+)
tetracycline for 96 hr before processing for
immunoblotting (A) or DNA content analysis by
FACS (B).
(C–F) In parallel, U2-OS cells expressing shRNA
directed against hMOB1A/B were processed for
immunofluorescence with indicated antibodies.
g-tubulin (centrosome) and acetylated-a-tubulin
(centriole) stainings are in red. DNA is shown
blue. Insets show enlargements of centro-
somes/centrioles. Schemes on the right indicate
HsSAS-6 and CP110 localization on centrioles
in green.
FoxO1 in a SARAH domain-dependent
manner [59]. Therefore, considering
that cytoplasmic MST1 lacking the
SARAH domain is capable of driving
centrosome overduplication (Figure 5;
data not shown), it is rather unlikely
that the phosphorylation of H2B or
FoxO by MST1 plays a role in the centro-
some cycle. Taking into further account
that shRNA-resistant NDR1(T444A)
cannot restore centrosome overduplica-
tion in NDR1-depleted cells (Figure S17),
our data indicate that the phosphoryla-
tion of NDR1/2 on Thr444 by MST1 is
a key event in the regulation of centro-
some duplication in this setting.
We also found that hydrophobic motif
phosphorylation of NDR1/2 requires
endogenous hMOB1A/B in addition to
MST1 (Figures 2 and 4). The analysis of
NDR1 and hMOB1A mutants (Figure 3;
Figure S5) showed that a functional NDR/hMOB1 complex is
critical for the phosphorylation of NDR on the hydrophobic
motif by MST1, which in turn is required for human centrosome
duplication (Figure S18).
Significantly, we also addressed at which step MST1/
hMOB1/NDR signaling controls centriole duplication in human
cells. Although PLK4-driven centriole amplification is impaired
upon depletion of MST1/hMOB1/NDR components, the asso-
ciation of PLK4 with centrioles is not affected (Figure 6). The
recruitment of HsSAS-6 to centrioles is also independent of
the MST1/hMOB1/NDR cascade (Figure 7). Therefore, the
two first steps of the human centriole assembly pathway [36,
54], namely PLK4 and HsSAS-6 localization to centrioles,
appear to be normal upon knockdown of MST1/hMOB1/NDR
signaling components. However, recruitment of centrin-2
and CP110 to procentrioles appears to depend on an intact
MST1/hMOB1/NDR cascade (Figures 2, 4, and 7). Although
the incorporation of CP110 and centrin-2 into nascent procen-
trioles occurs rapidly [36], we observed that a significant
fraction of MST1/hMOB1/NDR knockdown cells displayed
reduced centriole staining (Figures 2, 4, and 7). Collectively,
these observations suggest that MST1/hMOB1/NDR signaling
is important for efficient centriole duplication (daughter
centriole formation), even though the initiation of procentriole
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centrioles) appears to be normal (Figure S18).
The stabilization of a first centriolar seed is very likely to be
a rate-limiting step in human centriole duplication [36, 54].
However, our data would suggest that human centriole dupli-
cation can also be regulated after the initiation step involving
PLK4/HsSAS-6. Currently, we do not know precisely at which
step centriole duplication is blocked in MST1-, hMOB1-, or
NDR1-depleted cells (Figure S18). Most likely, a combination
of live cell imaging and electron microscopy will be required
to decipher exactly at which stage daughter centriole forma-
tion depends on MST1/hMOB1/NDR signaling. Given that the
MST1/hMOB1/NDR cascade also plays a role in the regulation
of apoptosis [27], future research will also be needed to
address how MST1/hMOB1/NDR signaling can be fine-tuned
to allow the regulation of different biological aspects by the
same signaling modules. In this context, another future chal-
lenge will be the identification of NDR substrates that play
a direct role in centriole duplication and/or apoptosis. A further
challenge will be to test how far the role of MST1/hMOB1/NDR
signaling in centrosome duplication is conserved from yeast to
man. Taken together, the elucidation of a role for the MST1/
hMOB1/NDR pathway in centrosome duplication reported
here might open novel avenues in the pursuit of centriole dupli-
cation signaling as well as molecular function(s) that might
contribute to tumor-suppressing activities of MST1 and
hMOB1.
Experimental Procedures
Cell Culture, Transfections, and Chemicals
U2-OS, HeLa, PT67, COS-7, and RPE1-hTert cells were maintained in
DMEM supplemented with 10% fetal calf serum. U2-OS, HeLa, COS-7,
and RPE1-hTert cells were plated at a consistent confluence and trans-
fected with Fugene 6 (Roche), jetPEI (PolyPlus Transfection), or Lipofect-
amine 2000 (Invitrogen) as described by the manufacturer. Aphidicolin
was from Calbiochem.
Generation of Stable Cell Lines
To generate tetracycline-inducible cell lines, U2-OS T-Rex cells were trans-
fected with pTER constructs [60] expressing shRNA against hMOB1A/B or
MST1. Cell clones were selected and maintained as described previously
[9]. Retroviral pools of rescue cell lines were generated as described else-
where [9]. U2-OS Tet-On cells expressing tetracycline-regulated shRNA
against NDR1 have been described already [9].
Immunoblotting, Immunoprecipitation, Cell Fractionation,
Immunofluorescence Microscopy, and FACS
Immunoblotting, coimmunoprecipitation, and cell fractionation experi-
ments were performed as described [25]. Cells were processed for FACS
and immunofluorescence as defined elsewhere [9].
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
(construction of plasmids; antibody sources) and 21 figures and can be
found with this article online at http://www.cell.com/current-biology/
supplemental/S0960-9822(09)01698-4.
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Ischaemia and reperfusion injuryotein kinases 1 and 2 (NDR1/2) are closely-related AGC family kinases that are
strongly conserved through evolution. In mammals, they are activated inter alia by phosphorylation of an
hydrophobic domain threonine-residue [NDR1(Thr-444)/NDR2(Thr-442)] by an extrinsic protein kinase
followed by autophosphorylation of a catalytic domain serine-residue [NDR1(Ser-281)/NDR2(Ser-282)]. We
examined NDR1/2 expression and regulation in primary cultures of neonatal rat cardiac myocytes and in
perfused adult rat hearts. In myocytes, transcripts for NDR2, but not NDR1, were induced by the hypertrophic
agonist, endothelin-1. NDR1(Thr-444) and NDR2(Thr-442)were rapidly phosphorylated (maximal in 15–30min)
inmyocytes exposed to somephosphoprotein Ser-/Thr-phosphatase1/2 inhibitors (calyculinA, okadaic acid) and,
to a lesser extent, by hyperosmotic shock, lowconcentrations of H2O2, or chelerythrine. Inmyocytes adenovirally-
transduced to express FLAG-NDR2 (which exhibited a mainly-cytoplasmic localisation), the same agents
increased FLAG-NDR2 activity as assessed by in vitro protein kinase assays, indicative of FLAG-NDR2(Ser-
282/Thr-442) phosphorylation. Calyculin A-induced phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
and activation of FLAG-NDR2 were inhibited by staurosporine, but not by other protein kinase inhibitors
tested. In ex vivo rat hearts, NDR1(Thr-444)/NDR2(Thr-442) were phosphorylated in response to ischaemia-
reperfusion or calyculin A. From a pathological viewpoint, we conclude that activities of NDR1 and NDR2 are
responsive to cytotoxic stresses in heart preparations and this may represent a previously-unidentified
response to myocardial ischaemia in vivo.
© 2008 Elsevier Inc. All rights reserved.1. IntroductionThe nuclear Dbf2-related protein kinases (NDRs) are members of
the AGC protein serine-/threonine-kinase family and are strongly
conserved between species as diverse as yeasts and Homo sapiens
[1,2]. Human (and mouse) cells express two isoforms encoded by
separate genes, namely NDR1 (or serine-/threonine kinase 38, STK38)
and NDR2 (or serine-/threonine kinase 38-like, STK38L) [1,2]. These
cells also express two NDR1-/NDR2-related protein kinases, large
tumour suppressor-1 (LATS1) and LATS2 [1,2]. The NDRs are widely-
expressed in mouse [3] and human [4,5] tissues. In mouse, NDR1
transcripts are most-highly expressed in spleen and are also
moderately expressed in brain, lung, thymus, testis and adipose tissueicine, Imperial College London,
7 2AZ, UK. Tel.: +44 20 7594
n).
l rights reserved.whereas NDR2 transcripts are most-highly expressed in the gastro-
intestinal tract (large and small intestine, stomach) and moderately
expressed in testis [3]. The heart also expresses NDR1 and NDR2
transcripts, albeit at lower levels [3]. In human tissues, NDR1 and
NDR2 are most highly expressed in thymus [4]. NDR1 is also highly
expressed in human skeletal muscles whereas NDR2 is highly
expressed in heart and brain [4]. It is not known whether these
apparent differences in expression profiles between mouse and Homo
sapiens are real or reflect inter-laboratory variations. The consensus
sequence phosphorylated by this group of kinases has been variously
reported to be (K/R)XX(S/T) (human NDR1 [6]), RXXS (preferred to
RXXT) (yeast Dbf2 [7]) or HX(R/H/K)XX(S/T) (human LATS1 [8]). The
physiological functions of the NDRs in mammals are obscure. NDR2
may be involved in the organisation of the actin cytoskeleton in
pheochromocytoma 12 (PC12) cells and its transcript is also rapidly
but transiently induced in mouse amygdalae following Pavlovian fear
conditioning training [9]. Recently, NDR1/NDR2 have been implicated
in centrosome duplication with overexpression inducing centrosome
overduplication [10].
1565S.J. Fuller et al. / Cellular Signalling 20 (2008) 1564–1577In their inactive state, NDRs are autoinhibited by an insert between
the catalytic domain subdomains VII and VIII (the autoinhibitory
sequence) that is rich in basic residues [11] and was originally thought
to represent a nuclear localisation signal [5]. Activation of NDRs
involves regulatory phosphorylations and/or interactions with other
proteins. As with many AGC kinases, NDRs are phosphorylated on two
conserved residues, one in the C-terminal hydrophobic domain (Thr-
444 in human, mouse or rat NDR1, Thr-442 in human or mouse NDR2)
and one in the activation loop (or T loop) of the catalytic domain (Ser-
281 in human, mouse or rat NDR1, Ser-282 in human or mouse NDR2)
[3,12]. One protein kinase which phosphorylates NDR1(Thr-444)/
NDR2(Thr-442) is the mammalian serine-/threonine-STE20-like
kinase 3 (MST3) [13] with dephosphorylation catalysed by phospho-
protein serine-/threonine-phosphatase (PPP) PP2A [3,12], now known
as PPP2. In contrast (and unusually for AGC kinases), phosphorylation
of NDR1(Ser-281)/NDR2(Ser-282) is thought to represent an autopho-
sphorylation [3,13,14]. In addition, activation may involve interactions
with other proteins. Initially, the S100 Ca2+ binding protein was
thought to be of major importance and to account for the Ca2+-
sensitivity of NDR activation [3,6,14]. One suggestion is that
phosphorylation of NDR2(Thr-75) in a S100/Ca2+-dependent manner
leads to phosphorylation of NDR2(Thr-442) in the phospho-NDR2
(Thr-75) [NDR2(PThr-75)] species by an unknown kinase [14,15]. The
NDR2(Ser-281) residue in the NDR2(PThr-75/PThr-442) species is
then autophosphorylated leading to activation [14,15]. However, the
emphasis has now switched to the Mps-one binder (MOB) proteins
which interact with basic residues in the N-terminal regulatory
domains of the NDRs [4,11]. It is not entirely clear how MOB proteins
activate NDRs. One view is that they bring NDRs to the plasma
membrane for interaction with the upstream kinases for the
hydrophobic domain phosphorylation, thus allowing enhanced
autophosphorylation of the activation loop [16]. However, other
mechanisms proposed are the release of the inhibition imposed by the
autoinhibitory sequence [11] or, in yeast, perturbation and disruption
of inhibitory self-associations [17].
Our interests in NDRs were stimulated by the observation that a
microarray screen of the changes in transcript abundances following
exposure of neonatal rat cardiac (ventricular) myocytes to the Gq
protein-coupled receptor agonist, endothelin-1 (ET-1), revealed that
NDR2 transcript abundances were increased N2-fold after 4 h [18]. In
these cells, which become terminally differentiated during the
perinatal period and are thus unable to undergo complete cycles of
cell division, ET-1 is a powerful stimulator of hypertrophic growth,
and this response has pathophysiological relevance [19–21]. These
effects of ET-1 are brought about by rapid (within minutes) but
transient activation of intracellular signalling pathways, particularly
the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade [22,23],
and rapid but phasic activation of successive waves of gene
expression, the earliest of which involve expression of immediate
early genes [18]. Many of the early changes in gene expression are
sensitive to inhibition of the ERK1/2 cascade [18,24]. Ultimately, these
early changes lead to expression of genes associated with the
established hypertrophic response [25]. Here, we have characterised
the acute activation of NDRs in cardiac myocytes and have found that,
whilst the expression of NDR2 was stimulated by ET-1, their activities
were stimulated by cytotoxic interventions and particularly by PPP
inhibitors.
2. Materials and methods
2.1. Materials
With the exception of ET-1 (which was from Bachem), biochemical reagents were
from Sigma-Aldrich, Calbiochem or Alexis/Axxora, and laboratory chemicals were from
VWR. Anti-NDR antibodies were raised to residues 59–86 of Homo sapiens NDR1 (for
the measurement of the total pool) [16], and to a phosphopeptide (residues 436–450)
encompassing NDR1(PThr-444) for measurement of the species phosphorylated in the
hydrophobic domain [14]. These antibodies also recognise human NDR2 and NDR2(PThr-442), respectively [13]. Since rat NDR1 is identical to human NDR1 and rat NDR2
is identical to human NDR2 in these immunogen regions, (see Supplementary Material,
Fig. 1), these antibodies should and do recognise rat NDR1 and rat NDR2. Rabbit
polyclonal anti-OctA (FLAG®) Probe (D-8) (sc-807) and mouse monoclonal anti-OctA
(FLAG®) Probe (H-6) (sc-7787) were from Santa Cruz Biotechnology. Secondary
antibodies and fluorescent mounting medium were from Dako. [γ-32P]ATP, rainbow
molecular weight markers, streptavidin-Texas red and Hyperfilm MP were from GE
Healthcare.
2.2. Primary culture of neonatal rat cardiac myocytes
Myocytes were dissociated from the ventricles of 1- to 3-day-old Sprague-Dawley
rat hearts by an adaptation of the method of Iwaki et al. [26] as previously described
[27]. Unless stated otherwise, cells were plated in gelatin-coated Primaria culture
dishes (BD Biosciences) at a density of 2×106 cells/35mmdish or 4×106 cells/60mm for
18 h in 15% (v/v) foetal calf serum. Unless experiments involved adenoviral infection,
serum was withdrawn for the 24 h before experimentation.
2.3. Infections with adenoviral vectors
Details of the construction of the adenoviral vectors (Adv) encoding rat N-
terminally FLAG-tagged wild-type NDR2 (FLAG-NDR2) and N-terminally FLAG-tagged
NDR2-PIFtide {rat NDR2(1-432), i.e. lacking the hydrophobic domain residues 433-464,
with the human PIFtide [3-phosphoinositide-dependent kinase 1 (PDK1) interacting
fragment] from protein kinase N2 (PKN2, residues 969–983) spliced to the C-terminus,
FLAG-NDR2-PIFtide} are provided in the ‘Supplementary Material’ section. For Adv
infections other than those for immunofluorescence staining, serum was withdrawn
from myocytes (2×106 cells/35 mm dish) for approximately 6 h before infection with
Adv encoding FLAG-NDR2 or FLAG-NDR2-PIFtide. In initial experiments, the multi-
plicities of infectionwere titrated so that the relative levels of expression of FLAG-NDR2
and endogenous NDR1/NDR2 were similar, as assessed by immunoblotting using the
rabbit polyclonal anti-NDR1/NDR2 antibody. Likewise, the multiplicity of infection of
Adv.FLAG-NDR2-PIFtide was adjusted so that expression of FLAG-NDR2-PIFtide and
FLAG-NDR2 was approximately equal as shown using the rabbit polyclonal anti-FLAG
antibody. Myocytes were used for experimentation (no change of medium) at 20 h after
they had been infected.
2.4. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting
Following exposure to agonists, myocytes were washed twice with ice-cold
phosphate-buffered saline (PBS). For whole cell extracts, myocytes were scraped into
150 μl/dish of Buffer A [20 mM β-glycerophosphate pH 7.5, 2 mM EDTA, 5 mM
dithiothreitol (DTT), 50 mM NaF, 0.2 mM Na3VO4, 2 μM microcystin LR, 10 mM
benzamidine, 300 μMphenylmethylsulphonylfluoride (PMSF), 200 μM leupeptin,10 μM
trans-epoxy-succinyl-l-leucylamido-(4-guanidino)-butane (E64), containing 1% (v/v)
Triton X-100]. Samples were incubated on ice for 10 min and then centrifuged
(10,000 ×g, 5 min, 4 °C). The supernatants were retained and protein contentsmeasured
by the Bradford assay (BioRad) [28]. Samples were boiled with 0.33 vol of SDS-PAGE
sample buffer [10% SDS (w/v), 13% glycerol (v/v), 300 mM Tris–HCl pH 6.8, 130 mMDTT,
0.2% bromophenol blue (w/v)]. Proteins (20–50 μg/lane, but equal for each blot) were
separated by SDS-PAGE using 10% (w/v) resolving gels and 4% (w/v) stacking gels, and
transferred to nitrocellulose as described previously [29]. Non-specific binding sites
were blocked with 5% (w/v) non-fat milk powder in TBST [20 mM Tris–HCl pH 7.5,
137 mM NaCl, 0.1% (v/v) Tween 20]. Membranes were incubated (overnight, 4 °C) with
primary antibodies [1:300 for total NDR1/NDR2 and for NDR1(PThr-444)NDR2(PThr-
442)] diluted in TBST containing 5% (w/v) bovine serum albumin. The NDR1(PThr-444)
NDR2(PThr-442) antibody in TBST/albumin could be used repeatedly providing it was
stored at 4 °C in the interim.Membranes werewashed in TBST, incubated (60min, room
temperature) with horseradish peroxidase-conjugated secondary antibodies (1/5000)
in TBST containing 1% (w/v) nonfat milk powder, and were then washed in TBST. Bands
were detected by enhanced chemiluminescence (Santa Cruz Biotechnology) using
Hyperfilm MP and were quantified by scanning densitometry.
2.5. Assay of FLAG-NDR2 activity (immunoprecipitation kinase assays)
Myocytes werewashed twice with ice-cold PBS and extracted into 100 μl of Buffer B
[20mMTris–HCl pH 7.5,10% (v/v) glycerol,100mMKCl, 5mMMgCl2,1 mMEDTA, 0.05%
(v/v) 2-mercaptoethanol, 5 mM DTT, 5 mM NaF, 0.2 mM Na3VO4, 2 μM microcystin LR,
300 μM PMSF, 200 μM leupeptin, 10 μM E64, containing 1% (v/v) Triton X-100]. Samples
were incubated on ice for 10 min and then centrifuged (10,000 ×g, 5 min, 4 °C). The
supernatants were retained and samples were taken for immunoprecipitation (75 or
90% of the supernatant used), protein determination by Bradford assay [28] and
occasionally for immunoblotting. For immunoprecipitation, samples were added to
Eppendorf tubes containing 20 μl of protein A-Sepharose (1:1 slurry in Buffer B) and 5 μl
of rabbit anti-FLAG antibody that had been pre-incubated together overnight at 4 °C
with rotation. Samples were rotated overnight at 4 °C and the pellets collected by
centrifugation (10,000 ×g, 1 min, 4 °C). The pellets were washed three times in Buffer B
(0.7 ml), once with kinase assay buffer (150 μl, 20 mM Tris–HCl pH 7.5, 1 mM DTT, 1 μM
microcystin LR, 4 μM leupeptin, 1 mM benzamidine) and finally resuspended in 45 μl of
Table 1
Quantitative PCR primers
Gene Accession no./probe set Size (bp) Forward primer Reverse primer
NDR1 NM_001015025 176 TTCGAGGGCCTGACAGCCAG (807–826) TCAGAGACTTGACTAGGACGCAGT (960–983)
NDR2 EF444939.1 238 AGGTCATCCGTTCTTTGAGGGTGTG (1284–1308) ACGTGGGGATGGAGCCTCGCTG (1501–1522)
Gapdh NM_017008 83 GCTGGCATTGCTCTCAATGACA (1738–1759) TCCACCACCCTGTTGCTGTA (1801–1820)
Nucleotide positions in transcripts are shown in parentheses for each primer. mRNA sequences for established genes were obtained from the Rat Genome Database (http://rgb.mcw.
edu, viewed at http://www.ncbi.nlm.nih.gov/entrez).
1566 S.J. Fuller et al. / Cellular Signalling 20 (2008) 1564–1577kinase assay buffer containing 1 mM KKRNRRLSVA peptide substrate [6]. The recovery
of FLAG-NDR2 or FLAG-NDR2-PIFtide (estimated by immunoblotting using the
monoclonal anti-FLAG antibody following immunoprecipitation with the rabbit
polyclonal anti-FLAG antibody) was about 75% of the input.
FLAG-NDR2 or FLAG-NDR2-PIFtide assays were initiated by the addition of 5 μl of
1mM [γ-32P]ATP(1 μCi/assay)/100mMMgCl2 followed by incubation at 30 °C for 30min.
Reactionswere terminated by the addition of 5 μl 0.5MEDTA, pH7.5, followed bycooling
on ice. Sampleswere centrifuged (10,000 ×g,1min, 4 °C) and duplicate samples (20 μl) of
the supernatants were spotted onto P81 paper squares which were then washed in
75 mM H3PO4 (4×15 min) on a rocking platform. Radioactivity was measured by
Čerenkov radiation counting. Blanks (one with kinase assay buffer+[γ-32P]ATP/MgCl2
and one involving assay of KKRNRRLSVA kinase activity with immunopreciptates from
cells infected with ‘empty’ FLAG-tag Adv) were routinely included.
2.6. Ex vivo heart preparations
Hearts of female rats (279±6 g body wt.) that had littered 7–10 days previously
were perfused retrogradely at 10 kPawith Krebs–Henseleit bicarbonate-buffered saline
as described previously [30]. In each set of experiments, following a 15 min retrograde
stabilisation perfusion, hearts were either (i) perfused retrogradely for a further 20min,
(ii) rendered globally-ischemic for 10 min by occlusion of the aortic inflow, (iii)
reperfused retrogradely for 10 min following 10 min of global ischaemia, or (iv)
perfused retrogradely with 40 nM calyculin A for 5 min. The hearts were then frozenFig. 1. Quantitative PCR of (A) NDR2 and (B) NDR1 mRNA abundances in cardiac
myocytes exposed to endothelin-1 (ET-1). Myocytes (4 independent preparations for
NDR2, 5 independent preparations for NDR1) were exposed to 100 nM ET-1 for the
times indicated and RNA extracted. Transcript levels were normalised to those of
Gapdh, then expressed relative to the zero-time controls. Results are expressed as
means±SEM. Statistical significance versus the zero-time control: ⁎Pb0.05; ⁎⁎Pb0.01
by a paired two-tailed Student's t test.between tongs cooled in liquid N2 and powdered by grinding in a pestle and mortar
cooled in liquid N2.
2.7. Immunofluorescence staining
Myocytes were cultured on glass coverslips [precoated with laminin (20 μg/ml in
PBS) and 1% (w/v) gelatin] placed in 35 mm Primaria culture dishes at a density of
1.5×106 cells/dish for 18 h in the presence of 15% (v/v) foetal calf serum. Myocytes
were infected with Adv.FLAG-NDR2 (as described under ‘Infection with adenoviral
vectors’ above) for 16 h in serum-free medium. The medium was discarded and the
cells were washed with ice-cold PBS (3×0.5 ml). Cells were fixed in 4% (w/v)
formaldehyde (10 min), permeabilised with 0.3% (v/v) Triton X-100 in PBS, and non-
specific antibody binding was blocked with 10% (w/v) horse serum in PBS containing
0.3% (v/v) Triton X-100. FLAG-NDR2 was detected by incubation of cells with mouse
anti-FLAG antibody (1:25 dilution, 2 h, 37 °C), a biotinylated goat anti-mouse IgG
secondary antibody (1:200 dilution, 30 min, room temperature) and streptavidin-
Texas Red (1:200 dilution, 30 min, room temperature). Sarcomeric structures were
identified by FITC-phalloidin (1:100, 1 h, room temperature). Nuclei were stained
with Hoechst 33258 (50 μg/ml, 10 min, room temperature). Cells were washed with
PBS (3×0.5 ml) between each incubation. Slides were mounted and examined using a
Zeiss Axioskop microscope with a 100× oil immersion objective and photographed
using a digital camera.
2.8. Quantitative PCR (qPCR)
RNAwas extracted and cDNA synthesised using reverse transcription as previously
described [31]. qPCR was performed using a Real-Time PCR System model 7500
(Applied Biosystems). Amplifications were carried out in optical 96-well reaction-plates
(Applied Biosystems) with each well containing 12.5 μl of SYBR Green Jump Start Taq
Readymix (Sigma Aldrich Chemical Co.), 5 μl of oligonucleotide primers (5 pmol each of
forward and reverse primers) and 7.5 μl of cDNA template (diluted 15-fold in water).
Details of the primers used are given in Table 1. qPCR analysis of Gapdh was performed
as a control and the relative quantification protocol was used. PCR conditions for all
primer pairs were 50 °C for 2 min, 95 °C for 10 min (Jump-Start Taq polymerase
activation step), followed by 40 cycles of 95 °C for 15 s and 59 °C for 60 s. Following
qPCR, dissociation curve analysis was routinely performed to check for aberrant
amplification products (e.g. primer-dimers).
2.9. Calculation of results and statistical methods
Within a single experiment (i.e. a single preparation of cardiac myocytes), results
are expressed relative to the maximum signal for the quantified immunoblots or FLAG-
NDR2 activities. Statistical significance was tested using two-tailed Student's t test for
paired samples or one-way ANOVA with Tukey's multiple comparison test as
appropriate. A statistically significant difference required that Pb0.05.
3. Results
3.1. Molecular cloning of rat NDR2 cDNA
In an Affymetrix rat 230 2.0 array screen of primary cultures of
neonatal rat cardiac myocytes exposed to ET-1 for 4 h, two probe-setsTable 2
Potencies of PPP1/PPP2 inhibitors
Inhibitor IC50 against Reference
PPP1 PPP2
Calyculin A 0.3 nM 0.13 nM [65]
Okadaic acid 3.4 nM 0.07 nM [65]
Microcystin LR 0.1 nM 0.1 nM [65]
Fostriecin 4 μM 40 nM [66]
Tautomycetin 1.6 nM 62 nM [67]
1567S.J. Fuller et al. / Cellular Signalling 20 (2008) 1564–1577(1372955_at and 1383299_at) identified an expressed sequence tag
(EST) that was significantly upregulated to 2.28-fold (average of both
probe-sets) of the zero-time control [18]. A BLAST search revealed that
this rat EST corresponded to the mouse NDR2 nucleotide sequence.
Rat NDR2 cDNA was cloned as described in ‘Supplementary Material’
and the sequence obtained (bases 1-2406) deposited in Genbank
(accession no. EF444939.1). The translational open reading frame
(bases 151-1542, 464 amino acids) was aligned against human, mouse
and rat NDR1, and human and mouse NDR2 using the ClustalW
program (www.ebi.ac.uk/clustalw) (Supplementary Material, Fig. 1).
The primary structure of rat NDR2 (calculated molecular mass:
53.6 kDa) is identical to mouse NDR2 except for replacement of
mouse Asn-15 and Val-216 with Ser-15 and Ile-216, respectively, in rat
NDR2.
Using qPCR, we verified that NDR2 mRNA was significantly
upregulated (3- to 4-fold of zero-time control) by ET-1 at 1.5 h and
remained upregulated at this level until at least 8 h (Fig.1A). In contrast,
NDR1 mRNA was not significantly altered over the same time periodFig. 2. Phosphorylation of NDR1(Thr-444) and NDR2(Thr-442), and activation of FLAG-NDR
(A) Myocytes (3 independent preparations) were exposed to 200 nM calyculin A for the
immunoblotting with an anti-NDR phosphopeptide antibody. Therewere no changes in the a
signals were assessed by scanning densitometry and expressed relative to the maximum va
depending on the time point at which the greater extent of phosphorylation was observed.
concentration was assessed in myocytes (4 independent preparations) exposed to calyculi
assessed as described under (A) and expressed relative to the maximum values which occu
greater extent of phosphorylation was observed. (C) Myocytes were infected with Adv.FLAG
NDR1/NDR2 and FLAG-NDR2 were expressed in approximately equal amounts. (D) The dep
myocytes (4 independent preparations) exposed to calyculin A for 20min. Activities were exp
A, depending on the concentration at which the greater activity was observed.(Fig. 1B). However, using the antibody which recognises both
NDR1 and NDR2, we were unable to detect any change in the
abundances of NDR proteins by ET-1 over the same time period
(results not shown). The primary structures of NDR1 and NDR2
show a high degree of identity (Supplementary Material, Fig. 1)
and the proteins are very similar in molecular mass (NDR1 is
54.0 kDa), so that it is possible that any newly-synthesised NDR2
would not necessarily be readily detectable against the pre-existing
NDR1/NDR2 background.
3.2. Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of
FLAG-NDR2 by calyculin A
Calyculin A is an inhibitor of PPP1 and PPP2 (formerly known as
PP2A), inhibiting each approximately equipotently (Table 2). Calyculin
A (200 nM) induced a rapid phosphorylation (detectable by 1 min) of
NDR1(Thr-444)/NDR2(Thr-442) in cardiac myocytes, reaching a
maximum at 10–20 min and remaining stable for at least 90 min2 in cardiac myocytes exposed to calyculin A. All results are expressed as means±SEM.
times indicated and phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) assessed by
bundances of total NDR1/NDR2. The intensities of the NDR1(PThr-444)/NDR2(PThr-442)
lues which occurred after either 45 or 90 min of exposure of myocytes to calyculin A,
(B) The dependence of NDR1(Thr-444)/NDR2(Thr-442) phosphorylation on calyculin A
n A for 20 min. The intensities of the NDR1(PThr-444)/NDR2(PThr-442) signals were
rred at either 100 or 300 nM calyculin A, depending on the concentration at which the
-NDR2. Immunoblotting with an anti-NDR1/NDR2 antibody showed that endogenous
endence of FLAG-NDR2 activity on calyculin A concentrations was assessed in infected
ressed relative to themaximumvalues which occurred at either 100 or 300 nM calyculin
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(Fig. 2A). Because of their similarities in molecular mass, NDR1 and
NDR2 usually co-migrate though, if samples are electrophoresed for
longer, occasionally two closely-migrating bands are detectable with
the antibody to NDR1(PThr-444)/NDR2(PThr-442). Using this anti-
phospho-NDR antibody, the EC50 for the calyculin A-mediated
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) was computed
to be approximately 10 nM (Fig. 2B). The activation of NDR1 or NDR2
requires dual phosphorylation of NDR1(Ser-281/Thr-444) or NDR2
(Ser-282/Thr-442), the phosphorylation of NDR1(Ser-281)/NDR2(Ser-
282) representing autophosphorylations following the NDR1(Thr-
444)/NDR2(Thr-442) phosphorylations [3,13,14]. However, the avail-
able antibody [14] raised against NDR1(PSer-281)/NDR2(PSer-282) is
of relatively low affinity/efficacy and we could not examine the
phosphorylation of these sites. We did investigate whether, following
adenovirally-mediated transfer of FLAG-NDR2, the activity of FLAG-
NDR2 as measured by immunoprecipitation kinase assays was
commensurate with phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442). We adjusted the adenoviral infections so that we achieved
essentially equal expression of FLAG-NDR2 and endogenous NDR1/
NDR2 (Fig. 2C). Immunprecipitation kinase assays using the anti-FLAG
antibody showed that, as for the phosphorylation of NDR1(Thr-444)/
NDR2(Thr-442) (Fig. 2B), the activity of FLAG-NDR2 was also
stimulated by calyculin A with an EC50 of approximately 10 nM (Fig.
2D). We noticed that calyculin A also appeared to be positively
chronotropic in these myocyte cultures and thus considered the
possibility that contractile activity might be responsible for NDR
phosphorylation. However, contractile arrest by blockade of the L-
type- and T-type Ca2+ channels with 10 μM nifedipine and 1.8 μM
mibefradil did not reduce the effects of calyculin A (results not
shown).
3.3. Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) by hyperosmotic
shock and oxidative stress
Exposure of myocytes to hyperosmotic shock (0.5 M sorbitol)
resulted in a rapid (maximal in 10 min or less) phosphorylation of
NDR1(Thr-444)/NDR2(Thr-442) (Fig. 3A) though, unlike phosphor-
ylation elicited by 200 nM calyculin A (Fig. 2A), phosphorylation had
declined by 90 min. Oxidative stress (0.5 mM H2O2) caused a
somewhat slower phosphorylation (maximal at about 20 min) and
this again declined by 90min (Fig. 3B). In neither conditionwas there
any change in the abundance of total NDR1/NDR2 (Fig. 3A–B). The
phosphorylation elicited by oxidative stress was detectable at
0.1 mM H2O2 and showed a distinct peak occurring at about
0.5 mM (Fig. 3C). At higher concentrations (1–10 mM H2O2),
phosphorylation declined. There were no losses of myocytes from
the dishes at up to 3 mMH2O2, as shown by the immunoblots against
total NDR1/NDR2 (Fig. 3C), though it is possible that some losses
occurred at 10 mM H2O2.
3.4. Relative potencies of phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) and activation of FLAG-NDR2 by calyculin A, hyperosmotic shock
and H2O2, and identification of additional modulators
We examined the ability of a wide range of known modulators of
myocardial processes to mediate phosphorylation of NDR1(Thr-444)/Fig. 3. Phosphorylation of NDR1(Thr-444) and NDR2(Thr-442) in cardiac myocytes exposed to
Myocytes (3 independent preparations) were exposed to hyperosmotic shock (HOS; 0.5 M s
assessed by immunoblotting with an anti-NDR phosphopeptide antibody. There were no chan
(PThr-442) signals were assessed by scanning densitometry and were expressed relative to th
hyperosmotic shock (A) or 20 or 45min of exposure to 0.5mMH2O2 (B), depending on the time
NDR1(Thr-444)/NDR2(Thr-442) phosphorylation on H2O2 concentrationwas assessed inmyocy
(PThr-444)/NDR2(PThr-442) signals were assessed as described under (A and B) and were expNDR2(Thr-442) and/or activation of FLAG-NDR2 (see Supplementary
Material, Table 2 for details of agonists/interventions without effect).
We also set any modulators identified as being effective in a hierarchy
in comparison with calyculin A. Chelerythrine is allegedly a protein
kinase C (PKC) inhibitor [32], though this has been questioned at least
in the case of the PKCα isoform [33]. In cardiac myocytes,
chelerythrine causes conventional and novel PKC-independent
pyknosis, shrinkage and death that may result from the induction of
oxidative stress [34]. In comparison with 200 nM calyculin A (NDR1/
NDR2 control not subtracted), chelerythrine is about 45 to 50% as
effective in inducing phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) (Fig. 4A), but is only about 20% (control FLAG-NDR2 activity not
subtracted) as effective in inducing activation of FLAG-NDR2 (Fig. 4B).
Likewise, 0.5 mM H2O2 is about 40 to 45% as effective as 200 nM
calyculin A in inducing phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) but is only about 5 to 10% as effective in inducing activation of
FLAG-NDR2 (Fig. 4A–B). The PPP2 inhibitor okadaic acid (OKA), which
also inhibits PPP1 though less effectively (Table 2), is known to induce
phosphorylation and activation of NDR1/NDR2 [3,12]. In our hands,
after a 60 min incubation, 1 μM OKA is almost as effective as
incubation with 200 nM calyculin A for 20 or 60 min in inducing
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) (Fig. 4A). How-
ever, following a 20 min incubation, 1 μM OKA does not elicit any
statistically significant phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) compared with a control incubation (Fig. 4A), though there is a
statistically-insignificant increase to about 30% of the level observed
with 200 nM calyculin A for 20 or 60 min. For activation of FLAG-
NDR2, OKA (1 μM, 20 min) was b10% as effective as calyculin A
(200 nM, 20 min) (Fig. 4C). However, after a 60 min incubation with
OKA, this had increased to 45 to 50% (Fig. 4C). The general conclusions
are (i) calyculin A is the most powerful stimulator of NDR1(Thr-444)/
NDR2(Thr-442) and activation of FLAG-NDR2 that we have identified,
(ii) generally, activation of FLAG-NDR2 lags behind phosphorylation of
NDR1(Thr-444)/NDR2(Thr-442). Because it could be argued that this
difference was related to the different species of NDRs examined
(endogenous NDR1/NDR2 or FLAG-NDR2), we examined the phos-
phorylation of endogenous NDR1/NDR2 and FLAG-NDR2 in FLAG-
NDR2-transduced cardiac myocytes (Fig. 4D). This was feasible
because of the lower mobility of FLAG-NDR2. No differences between
the phosphorylation of endogenous NDR1(Thr-444)/NDR2(Thr-442)
and FLAG-NDR2(Thr-442) could be identified for any agonist. We also
calculated the approximate ratio of expression of FLAG-NDR2(PThr-
442) to endogenous NDR1(PThr-444)/NDR2(PThr-442) using the anti-
NDR1(PThr-444)/NDR2(PThr-442) antibody. If it can be assumed that
the most significant factor influencing this ratio is the levels of
expression, the value should approximate to the FLAG-NDR2/
endogenous NDR1/NDR2 ratio (Fig. 2C). The FLAG-NDR2(PThr-442)/
endogenous NDR1(PThr-444)/NDR2(PThr-442) ratio is approximately
1.5, i.e. similar to that observed in Fig. 2C.
Given that calyculin A is an equipotent PPP1/PPP2 inhibitor
whereas OKA inhibits PPP2 more potently (Table 2), the spectrum of
NDR1/NDR2 phosphorylation (Fig. 4A,D) and FLAG-NDR2 activation
(Fig. 4C) suggests that the effects of calyculin A could be exerted
primarily through PPP1. We therefore investigated the effects of
tautomycetin (200 nM for up to 4 h) which is primarily a PPP1
inhibitor (Table 2) and fostriecin (200 nM for up to 4 h) which is
primarily a PPP2 inhibitor (Table 2) on activity of FLAG-NDR2. Neitherhyperosmotic shock or oxidative stress. All results are expressed asmeans±SEM. (A and B)
orbitol) (A) or 0.5 mM H2O2 (B) and phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
ges in the abundances of total NDR1/NDR2. The intensities of the NDR1(PThr-444)/NDR2
e maximum values which occurred after either 10 or 20 min of exposure of myocytes to
point at which the greater extent of phosphorylationwas observed. (C) The dependence of
tes (5 independent preparations) exposed to H2O2 for 20min. The intensities of the NDR1
ressed relative to the maximum values which occurred at 0.5 mM H2O2.
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the potent PPP1/PPP2 inhibitor (Table 2), microcystin LR (2 μM), did
not activate FLAG-NDR2, nor did it induce phosphorylation ofendogenous NDR1(Thr-444)/NDR2(Thr-442) or FLAG-NDR2(Thr-
442). The effects of PPP inhibitors on the NDRs are therefore limited
largely to calyculin A, with lesser effects of OKA.
Fig. 4. Direct comparison of induction of phosphorylation of NDR1(Thr-444) and NDR2(Thr-442), and activation of FLAG-NDR2 in cardiac myocytes exposed to a range of
interventions. HOS, hyperosmotic shock; OKA, okadaic acid. (A) Myocytes (3 to 8 independent preparations) were exposed to NDRmodulators at the concentrations and for the times
indicated and phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) assessed by immunoblotting with an anti-NDR phosphopeptide antibody. The intensities of the NDR1(PThr-444)/
NDR2(PThr-442) signals were assessed by scanning densitometry. Results are expressed relative to maximum phosphorylationwhich was observedwith 200 nM calyculin A at either
20 min or 60 min, depending on the time point at which the greater extent of phosphorylation was observed, and are means±SEM. Statistical significance: ⁎Pb0.05; ⁎⁎Pb0.01,
⁎⁎⁎Pb0.001 versus control or †Pb0.01 versus OKA (1 μM, 60 min) by a 1-tailed ANOVA with Tukey's multiple comparison test. (B and C) FLAG-NDR2 activity following exposure of
myocytes [8 independent preparations in (B), 3 independent preparations in (C)] to the interventions indicated and expressed relative to the maximum activity which was observed
with 200 nM calyculin A at either 20 min or 60 min, depending on the time point at which the greater activity was observed. Results are means±SEM. (D) Myocytes expressing the
FLAG-NDR2 transgene (2 independent preparations of myocytes) were exposed to NDR modulators at the concentrations and for the times indicated and phosphorylation of NDR1
(Thr-444)/NDR2(Thr-442) assessed by immunoblottingwith an anti-NDR phosphopeptide antibody. The intensities of the NDR1(PThr-444)/NDR2(PThr-442) signals were assessed as
under (A). The upper band represents FLAG-NDR2(PThr-442) and the two lower bands represent NDR1(PThr-444)/NDR2(PThr-442). The unfilled bars in the histogram represent
FLAG-NDR2(PThr-442) whereas the filled bars represent endogenous NDR1(PThr-444)/NDR2(PThr-442). Results are expressed relative to maximum phosphorylation which was
observed with 200 nM calyculin A at 60 min and are means±SD.
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1571S.J. Fuller et al. / Cellular Signalling 20 (2008) 1564–15773.5. Inhibitors of calyculin A-mediated activation of FLAG-NDR2
We investigated the ability of a number of known protein kinase
inhibitors to reduce the activation of FLAG-NDR2 resulting from
exposure of cardiac myocytes to 50 nM calyculin A. Of the inhibitors
examined, the only inhibitor with any effect was staurosporine.
Staurosporine was originally identified as a PKC inhibitor [35] but is
now recognised to be a non-selective protein kinase inhibitor [36] (see
also Reference [33] for 7-hydroxystaurosporine). Staurosporine
exhibited an IC50 of approximately 40 nM for the inhibition of the
activation of FLAG-NDR2 by 50 nM calyculin A (Fig. 5A). This inhibition
was not attributable to ‘carry-over’ of staurosporine from the cell
incubations into the assay because addition of staurosporine up to
1 μM for the last 5 min of a 20 min exposure of myocytes to 50 nM
calyculin A [i.e. after FLAG-NDR2 would have been essentially
completely activated by calyculin A (Fig. 2A) but prior to extraction
and immunoprecipitation] did not result in any significant reduction
in FLAG-NDR2 activity. It is possible that staurosporinemay not inhibit
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) but could selec-
tively inhibit the autophosphorylation of NDR1(Ser-281)/NDR2(Ser-
282). We therefore also examined its effects on the calyculin A-
stimulated phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and
FLAG-NDR2(Thr-442) (Fig. 5B). Staurosporine also inhibited the
calyculin A-stimulated phosphorylation of endogenous NDR1(Thr-
444)/NDR2(Thr-442) and of exogenous FLAG-NDR2(Thr-442) (Fig. 5B),
and this in itself should prevent phosphorylation of FLAG-NDR2(Ser-
282) and its activation (Fig. 5A). We do not know whether
staurosporine also inhibits the autophosphorylation of NDR1(PThr-
444)/NDR2(PThr-442) at the T loop residues.The following were ineffective in inhibiting activation of FLAG-
NDR2 by calyculin A: 100 μM genistein (a generalised Tyr-protein
kinase inhibitor [37]), 10 μM GF109203X (generalised PKC inhibitor
[38] which also inhibits a number of other protein kinases [33]), 20 μM
HA1077 (a PKN inhibitor [39] which inhibits a number of protein
kinases including protein kinase A and Rho kinase [33]), 10 μM
SB203580 [inhibitor of theα and β isoforms of p38-mitogen-activated
protein kinase (p38-MAPK) [40]] or 10 μM Y27632 (Rho kinase
inhibitor [41] which also inhibits PKN [33]). Equally, no inhibitor
activated FLAG-NDR2 in the absence of calyculin A (results not
shown). The phosphoinositide 3-kinase (PI3K) inhibitor, LY294002
[42] (50 μM), did not inhibit NDR1(Thr-444)/NDR2(Thr-442) phos-
phorylation or activation of FLAG-NDR2 (results not shown). [We
ensured that the LY294002 preparation used was active by demon-
strating that it prevented stimulation of protein kinase B/Akt (PKB/
Akt) phosphorylation by 300 nM insulin.]
3.6. Activity of FLAG-NDR2-PIFtide
Mutation of the two phosphorylation sites in the catalytic and
hydrophobic domains of NDR1 (i.e. Ser-281 and Thr-444) to acidic
residues is relatively-ineffective in producing a kinase with increased
constitutive activity [3]. A constitutively-activated species can be
produced by splicing NDR2(1-432) to PKN2(969-983) to produce
NDR2-PIFtide, as has been previously described for human NDR2 [3].
We examined the activities of FLAG-NDR2 (rat) and FLAG-NDR2-
PIFtide (rat-human chimera) in the absence or presence of calyculin A
and approximately matching the abundances of FLAG-NDR2 and
FLAG-NDR2-PIFtide (Fig. 6). After subtracting the activity seen
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accurately matched for multiplicity of infection with Adv.FLAG-
NDR2 and Adv.FLAG-NDR2-PIFtide) and correcting for differences in
relative abundance, the constitutive activity of FLAG-NDR2-PIFtide
was found to be approximately 10-fold greater than that of FLAG-
NDR2 (Fig. 6). Not unexpectedly, FLAG-NDR2-PIFtide (which lacks the
Thr-442 phosphorylation site) could not be activated by calyculin A
(Fig. 6).
3.7. Intracellular localisation of NDR2 in cardiac myocytes
Using the antibodies available, we were unsuccessful in staining
for endogenous dephospho-NDR (as were Hergovich et al. [16] in U2-
OS cells), nor were we successful in staining for phospho-NDRs. We
therefore examined the intracellular localisation of NDR2 by infecting
myocytes with Adv.FLAG-NDR2 and staining for the FLAG epitope.
FLAG-NDR2 localised to the cytoplasm in cardiac myocytes and was
clearly excluded from the nucleus (Fig. 7). The pattern of staining was
somewhat uneven in the cytoplasm and there was a suggestion of
some partition of NDR2 to the plasma membrane. There was noFig. 5. Inhibition of calyculin A-induced activation of FLAG-NDR2 and phosphorylation of en
Adv, adenoviral vector. (A and B) Myocytes were preincubated for 20 min with staurosporin
20 min. (A) Inhibition of calyculin A-induced stimulation of FLAG-NDR2 activity by staurospo
absence of staurosporine and results were expressed relative to this. FLAG-NDR2 activity
(B) Inhibition of calyculin A-induced phosphorylation of endogenous NDR1(Thr-444)/NDR2(
444)/NDR2(Thr-442) and FLAG-NDR2(Thr-442) (right hand immunoblot panel and filled
Intensities of the endogenous NDR1(PThr-444)/NDR2(PThr-442) signals (left hand immuno
(right hand immunoblot panel) were quantified by scanning densitometry and expressed rela
grouping. Results are means±SEM for 3 (A) or 4 (B) independent preparations of myocytesevidence of any change in localisation following exposure to 30 nM
calyculin A for 20 min (results not shown).
3.8. Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) in intact heart
by calyculin A or by ischaemia and reperfusion
Calyculin A proved to be the most powerful stimulator of NDR1
(Thr-444)/NDR2(Thr-442) phosphorylation and activator of FLAG-
NDR2 in neonatal rat cardiacmyocytes that we identified here (see Fig.
4A–D). Some of the interventions resulting in phosphorylation of
NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2 in
myocytes are established cytotoxic stresses in neonatal cardiac
myocytes (chelerythrine [34], H2O2 [43] and hyperosmotic shock
[44]). However, it is important to show that these findings are not
confined to neonatal cells. We therefore investigated the effects of
calyculin A and of pathologically-relevant cardiac stresses, namely
ischaemia and ischaemia-reperfusion in intact adult rat hearts. As
expected, calyculin A (40 nM, 5 min) induced a highly-significant
(Pb0.0001) increase in the phosphorylation of NDR1(Thr-444)/NDR2
(Thr-442) in perfused hearts (Fig. 8). Although there was somedogenous NDR1(Thr-444)/NDR2(Thr-442) and FLAG-NDR2(Thr-442) by staurosporine.
e at the concentrations indicated, then were exposed to 50 nM calyculin A for a further
rine. FLAG-NDR2 activity in control 1 was assessed at 50 nM calyculin A (20 min) in the
in control 2 was assessed in the absence of 50 nM calyculin A and staurosporine.
Thr-442) (left hand immunoblot panel and unfilled bars), and of endogenous NDR1(Thr-
bars) was assessed by immunoblotting with an anti-NDR phosphopeptide antibody.
blot panel) or endogenous NDR1(PThr-444)/NDR2(PThr-442) + FLAG-NDR2(PThr-442)
tive to the values obtainedwith calyculin A (50 nM, 20min) for each single experimental
.
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of NDR1(Thr-444)/NDR2(Thr-442), this was not significantly different
from control normoxic perfusions. In contrast, global ischaemia
(10 min) followed by reperfusion (10 min) resulted in significant
(Pb0.0001) phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
which, after subtraction of the control, was equivalent to about 30%
of the level induced by 40 nM calyculin A for 5 min (Fig. 8).
4. Discussion
4.1. General comments
The NDRs are highly-conserved protein Ser-/Thr-kinases that are
members of the AGC kinase superfamily [1,2]. In terms of their
activation, the current scheme is that NDR1(Thr-444) and NDR2(Thr-
442) (the hydrophobic domain residues) are first phosphorylated by
an upstream kinase and then NDR1(PThr-444) and NDR2(PThr-442)
each autophosphorylate their own T loop residues in their catalytic
domains to produce the active species NDR1(PSer-281/PThr-444)
and NDR2(PSer-282/PThr-442) [1,2]. The fact that activation of FLAG-
NDR2 tends to lag behind phosphorylation of NDR1(Thr-444)/NDR2
(Thr-442) (for example, seen clearly for OKA in Fig. 4A, C) suggests
that this ordered phosphorylation occurs in cardiac myocytes. The
agonists that lead to activation of NDRs are poorly-characterised and
their biological functions in higher organisms are poorly-under-
stood. Given that NDR1/NDR2 are highly-conserved through evolu-
tion, it seems likely that they possess important functions. NDR2
may be involved in organisation of the actin cytoskeleton [9] and,
recently, a role for NDR1/NDR2 in centrosome duplication has been
identified [2,10]. Although populations of myocytes range from the
mononucleate to the multinucleate and thus must possess some
capacity for karyokinesis, they are generally considered to be
terminally-differentiated and incapable of cytokinesis. It therefore
seems unlikely that centrosome duplication is of major importance
in their case.Fig. 6. Stimulation of NDR2 activity in the FLAG-NDR2-PIFtide chimera. Myocytes were infecte
FLAG-NDR2-PIFtide. The relative levels of expression of FLAG-NDR2(wild-type) and FLAG-ND
expressing the transgenes were exposed to 200 nM calyculin A for 20min and the activities of
expressed relative to the FLAG-NDR2(wild-type) infected myocytes exposed to 200 nM calyc
results shown were not corrected for expression levels and the Adv blank was not subtract4.2. Expression of the NDR1 and NDR2 genes
At the level of mRNA, NDR2 transcripts are rapidly but transiently
induced in amygdalae of mice following emotional stress [9] and, here,
we show that NDR2 mRNA is also rapidly induced by ET-1 in neonatal
rat cardiac myocytes (Fig. 1A). In contrast, NDR1 mRNA is not induced
by ET-1 (Fig. 1B). Presumably, their promoter regions are sufficiently
different to allow differential transcription or else transcript stability
may be involved. Using microarrays (Affymetrix rat 230 2.0 array at
30 min or the more-restricted Affymetrix rat U34Amicroarrays at 2 or
4 h) in conjunction with semi-quantitative PCR and/or qPCR, we have
shown that, for ET-1, the activation of the ERK1/2 cascade is required
for the increased expression of the majority of transcripts upregulated
at 30min, 2 h or 4 h [18,24]. We have not yet studied in detail whether
this is the case for NDR2 mRNA [the U34A microarrays did not have a
probe set for rat NDR2 [24] and we only studied the 30 min time point
in our more recent study [18] when NDR2 transcripts are not
upregulated (Fig. 1A)].
4.3. Involvement of PPPs in NDR phosphorylation and activation
The PPP superfamily, of which there are seven sub-families, is
encoded by 20 genes in Homo sapiens and these encode about 28
catalytic subunits [45]. There is also amultiplicity of regulatory subunits
(particularly for PPP1) which are involved in targeting (to control
subcellular localisation and substrate specificity) and regulation (e.g.
inhibitory subunits). Previously, OKA has been identified as an agent
that stimulates phosphorylation and activation of NDR1/NDR2 [3,12].
This is presumably achieved by inhibiting a PPP, allowing unknown
NDR1/NDR2 kinases to phosphorylate NDRs. Here, we show that, at
maximally-effective concentrations, calyculin A is more effective than
OKA in inducing NDR1(Thr-444)/NDR2(Thr-442) phosphorylation and
activation of FLAG-NDR2 in neonatal rat cardiac myocytes after 20 min
(Fig. 4A, C). Although calyculin A or OKA treatment result in equivalent
NDR1(Thr-444)/NDR2(Thr-442) phosphorylation after 60 min,dwith an adenovirus (Adv) empty vector, with Adv.FLAG-NDR2(wild-type) or with Adv.
R2-PIFtide were assessed with an antibody to the FLAG epitope (upper panel). Myocytes
FLAG-NDR2(wild type) or FLAG-NDR2-PIFtideweremeasured (lower panel). Results are
ulin A for 20 min and are means±SEM for 6 independent preparations of myocytes. The
ed (but see the Results section for these calculations).
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(Fig. 4A, C). A similar hysteresis between phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442) and activation of FLAG-NDR2 is seen in the
individual comparisons of all interventions (Fig. 4). It probably reflects
the ordered nature of the phosphorylation of first NDR1(Thr-444)/
NDR2(Thr-442) followed by NDR1(Ser281)/NDR2(Ser-282). In previous
work inwhich COS cells were transfectedwith tagged NDRs, OKA (1 μM,
60min) stimulated NDR activity by 12- to 25-fold [3,12]. This compares
with 21-fold in our analogous experiments (Fig. 4C), but we find that
calyculin A (200 nM, 60 min) stimulates activity by about 45-fold
(Fig. 4C). We do not know whether these differences result from
trivial causes (e.g. differences in permeability) or whether there are
mechanistic differences. Importantly, calyculin A stimulates phosphor-
ylation of NDR1(Thr-444)/NDR2(Thr-442) in adult perfused heart
(Fig. 8), confirming that the findings in neonatal myocyte are not
confined to this particular stage of maturation.
Though calyculin A and OKA may show differing selectivities for
PPP1 and PPP2 [OKA has a 50-fold greater IC50 for PPP1 than PPP2
(Table 2)], they are both relatively potent inhibitors of both PPPs at least
in vitro (Table 2). We had hoped possibly to discriminate between PPP1
andPPP2using themore selective inhibitors fostriecin and tautomycetin
(Table 2), andwe also studied the effects ofmicrocystin LR. However, we
were never able to activate FLAG-NDR2 with these, nor did microcystin
LR cause phosphorylation of endogenous NDR1(Thr-444)/NDR2(Thr-
442) or FLAG-NDR2(Thr-442). We do not understand the reasons for
this. They could be trivial (e.g. permeability), but all ineffective inhibitors
have been used in intact cell preparations previously. Equally, theremayFig. 7. Subcellular localisation of FLAG-NDR2. Myocytes were infected with Adv.FLAG-
NDR2 and were stained with (A) monoclonal anti-FLAG, (B) phalloidin, or (C) Hoechst
33258 and a representative image of a single field is shown.be PPP1/PPP2 holoenzyme species which are insensitive to fostriecin,
tautomycetin or microcystin LR, or there may be PPP species other than
PPP1 and PPP2which are sensitive to calyculin A and OKAbutwhich are
not sensitive to fostriecin, tautomycetin ormicrocystin LR. Furthermore,
it may be incorrect to assume that the actions of calyculin A or OKA are
exerted at the level of the PPP(s) directly responsible for depho-
sphorylatingNDRs. The point(s) of action could lie further upstream. The
current predominating view that PPP2 is responsible for the depho-
sphorylation of NDR1(PSer-281/PThr-444) and NDR2(PSer-282/PThr-
442) is based on experiments in intact cells with OKA [3,12], and on in
vitro experiments involving dephosphorylation ofNDR1(PSer-281/PThr-
444) with recombinant PPP2 [12]. However, the concentration of OKA
used in these experiments was 1 μM or 300-times greater than the IC50
even for PPP1. Whilst there may be unassessed permeability problems
related to the access of OKA to the intracellular compartment, these
experiments are not unequivocal. Equally, in vitro experiments with
recombinant PPP2 are not unequivocal because of the possibility that
any PPP might dephosphorylate the phospho-NDRs if present in high
enough excess. The PPP(s) responsible for dephosphorylating NDR1
(PSer-281/PThr-444) and NDR2(PSer-282/PThr-442) remain somewhat
obscure.
4.4. Phosphorylation and activation of NDR1/NDR2
Here, we have shown that NDR1/NDR2 are phosphorylated and
activated by a variety of stimuli in cardiac myocytes and intact heart.
Though we have not identified the kinases responsible, these experi-
ments show that the endogenous upstream signalling is intact. With
respect to the established kinases, PDK1 is often involved in
phosphorylation of a T loop Ser-/Thr-residue in AGC kinases, i.e. a
Ser-/Thr-residue in the catalytic domain [46,47]. Activation of PDK1,
which is probably potentially active in the basal state by virtue of its
high affinity interactions with 3-phosphoinositides [48], is mediated by
PI3K-dependent phosphorylation of phosphatidylinositol 4,5-bispho-
sphate [PtdIns(4,5)P2] to PtdIns(3,4,5)P3 and lies downstream from the
insulin or insulin-like growth factor 1 (IGF1) receptor protein tyrosine
kinases (RPTKs) as well as other RPTKs [47,49]. These T loop
phosphorylations are either regulatory (i.e. respond to external stimuli
to change phosphorylation state and activity of the kinase involved) or
are essentially facilitative (i.e. are constitutive rather than regulatory,
but are necessary for activity). Evidence has beenpresented that neither
PDK1 nor insulin or IGF1 is involved in the regulation of NDR1 [12]
though, equally, contradictory evidence has been presented that IGF1-
activated PDK1 is an NDR2(Thr-442) kinase and this phosphorylation
precedes the autophosphorylation of the T loop residue [15].We did not
find any evidence that insulin (which does cause PI3K/PDK1-dependent
phosphorylation of PKB/Akt in cardiac myocytes [50]) stimulated
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) (Supplementary
Material, Table 2A) nor did LY294002 inhibit the phosphorylation of
NDR1(Thr-444)/NDR2(Thr-442) or activation of FLAG-NDR2 by calycu-
lin A. Our data thus do not support a role for PDK1. A second mode of
activation proposed by Suzuki et al. [15] involves a S100/Ca2+-
dependent phosphorylation of NDR2(Thr-75), then phosphorylation of
NDR2(Thr-442) in the NDR2(PThr-75) species by an unknown kinase,
and finally autophosphorylation of NDR2(Ser-281) in the NDR2(PThr-
75/PThr-442) species leading to activation [14,15]. The necessary
increase in Ca2+ concentrations is mediated through phospholipase
Cγ (PLCγ) and hydrolysis of PtdIns(4,5)P2 to the Ca2+-mobilising ‘second
messenger’, inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] [15]. However, in
cardiac myocytes, platelet-derived growth factor stimulates PtdIns(4,5)
P2 hydrolysis and Tyr-phosphorylation of PLCγ1 [50], but does not
stimulate NDR1(Thr-444)/NDR2(Thr-442) phosphorylation (Supple-
mentary Material, Table 2A). Furthermore, ET-1 stimulates PLCβ-
mediated hydrolysis of PtdIns(4,5)P2 in cardiac myocytes [51] but
does not stimulate phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
or activation of FLAG-NDR2 (Supplementary Material, Table 2A and B).
Fig. 8. Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) in intact hearts. In each separate set of experiments, following a 15 min retrograde stabilisation perfusion, ex vivo rat heart
preparations were either (i) perfused retrogradely for a further 20 min, (ii) rendered globally-ischemic for 10 min by occlusion of the aortic inflow, (iii) reperfused retrogradely for
10 min following global ischaemia (10 min), or (iv) perfused retrogradely with 40 nM calyculin A for 5 min. Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) was assessed by
immunoblotting with an anti-NDR phosphopeptide antibody, and intensities of the NDR1(PThr-444)/NDR2(PThr-442) signals were quantified by scanning densitometry and
expressed relative to the values obtained with perfusions with calyculin A (40 nM, 5 min) for each single experimental grouping. Results are means±SEM for 8 complete sets of
experiments. Statistical significance versus the control perfusions: ⁎Pb0.0001 versus control by an unpaired two-tailed Student's t test.
1575S.J. Fuller et al. / Cellular Signalling 20 (2008) 1564–1577One upstream kinase that may be involved in the phosphorylation
of NDR1(Thr-444)/NDR2(Thr-442) is mammalian STE20-like kinase 3
(MST3) [13], also known as STK24, a member of the germinal centre
kinase family GCK-III subclass [52,53]. The regulation of these kinases
in terms of the agonists that lead to their activation is not well-
understood and indeed Pombo et al. [53] state that ‘To date, no stimuli
have been shown to activate MST3’. In fact, like the NDRs, MST3 is
activated by OKA [13] and calyculin A [54]. Overexpression of MST3 in
HEK293 cell causes fragmentation of DNA indicative of apoptosis/cell
death [55]. If the NDRs are involved, this would suggest that their
activation by MST3 should be pro-apoptotic. It will be of interest to
examine whether, in addition to calyculin A and OKA, pro-apoptotic
stimuli such as chelerythrine, hyperosmotic shock and H2O2 activate
MST3. One characteristic of the upstream NDR1(Thr-444)/NDR2(Thr-
442) kinase that we did identify is that it is inhibited by staurosporine
(Fig. 5A–B). Staurosporine and its derivatives inhibit a broad spectrum
of Ser-/Thr-protein kinases (including PDK1), though a number of
kinases are relatively insensitive [33,36]. A prerequisite of the NDR1
(Thr-444)/NDR2(Thr-442) kinase is that its activity or activation should
be inhibited by staurosporine.
4.5. Pathophysiological relevance of interventions which stimulate
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of
FLAG-NDR2
The interventions which stimulate phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442) and activation of FLAG-NDR2 most clearly are
calyculin A (Figs. 2A–B, D, 4A, C, 8) and OKA (Fig. 4A, C). Other than
possibly contributing to the understanding of diarrhetic shellfishpoisoning for which OKA is responsible, these findings have very little
pathophysiological significance. The phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442) and activation of FLAG-NDR2 are also stimulated
by a relatively-limited subset of cell stress stimuli, notably hyper-
osmotic shock (Figs. 3A, 4A–B) and oxidative stress (Figs. 3B–C, 4A–B)
in neonatal cardiac myocytes. Perhaps most notably, global ischaemia/
reperfusion, a pathologically-important pro-apoptotic stress in the
heart [56], stimulates phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) in isolated adult rat hearts (Fig. 8). Although there is a suggestion
that ischaemia alone also resulted in phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442), this result did not achieve statistical significance
(Fig. 8). In isolated hearts, the stress-activated protein kinases of the
MAPK family are activated (by phosphorylation) by ischaemia and
ischaemia/reperfusion [57]. Thus, ischaemia activates p38-MAPKs and
this is increased on reperfusion [56,57]. Ischaemia alone does not
activate the c-Jun N-terminal kinases (JNKs), but they are activated on
reperfusion [57]. However, p38-MAPKs and JNKs are activated by a
wider range of cellular stresses (e.g. anisomycin) in cardiac myocytes
than those that lead to phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) (Supplementary Material, Table 2A) or activation of FLAG-NDR2
(Supplementary Material, Table 2B), and they are also activated by
some G protein receptor agonists, e.g. ET-1 and phenylephrine [58–
60]. As with phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and
activation of FLAG-NDR2 (Figs. 3 B–C, 4A–B), JNKs and p38-MAPKs are
activated by oxidative stress in cardiac myocytes and the perfused
heart [30,61], and our findings indicate that the increases in oxidative
stress that the heart experiences during ischaemia and, more
particularly, on reperfusion [62] contribute to their activation [30]. A
similar mechanism could apply to the NDRs.
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The subcellular localisation of the NDRs as assessed by either
immunofluorescence or subcellular fractionation is controversial. NDR1
was first thought to be localised to the nucleus [5]. Tagged NDR1
overexpressed in HeLa cells also appears to localise primarily to the
nucleuswith evidenceof anadditional cytoplasmic localisation at higher
levels of expression [4]. Somewhat surprisingly in view of the similarity
in their primary sequences (see SupplementaryMaterial, Fig.1), endoge-
nous or overexpressed tagged NDR2 appears to localise primarily to the
cytoplasm (sometimes in a punctate manner) with evidence of nuclear
localisation or perinuclear concentration when expression at higher
levels [3,4]. However, Hergovich et al. [16] (see also Reference [10]) have
now demonstrated that both endogenous NDR1 and overexpressed
NDR1 are primarily cytoplasmic and suggest that some previous studies
demonstrating a nuclear localisation resulted from misinterpretation of
immunofluorescence data. In our hands, FLAG-NDR2 expressed ectopi-
cally to about the same level as total endogenous NDRs localises to the
cytoplasm of cardiac myocytes, though there is some evidence of
increased concentration at the plasma membrane (Fig. 7). This might
perhaps be in keepingwith the need for NDR2, on associationwithMOB
proteins, to translocate to the plasma membrane for activation by
phosphorylation [11,16]. We did not assess the localisation of NDR1.
4.7. NDR2-PIFtide
When protein kinases are activated by Ser-/Thr-phosphorylation,
the normal tactic to increase the level of constitutive activity is to
mutate the Ser-/Thr- residues to Asp- or Glu-. However, mutation of
NDR1(Ser-281) does not affect activity and mutation of NDR1(Thr-
444) caused only a 1.5- to 2-fold increase in activity [12]. In PKB/
Akt, phosphorylation of the homologous hydrophobic domain Ser-
(Ser-473, Ser-474 or Ser-472) depending on the isoform (α, β or γ,
respectively)] results in full activation of PKB/Akt phosphorylated on
the PDK1 site in the T loop (Thr-308 in PKBα, or Thr-309 in PKBβ and
PKBγ) [49]. Crystallographic studies show that phosphorylation of
PKBβ/Akt2(Ser-474) results in a disorder-to-order transition of the αC
helix and interaction with PKB/Akt(PThr-309) [63]. This ordered
structure can be mimicked by the hydrophobic motif C-terminal
region of PKN2 which contains the so-called PIFtide sequence which
is highly ordered [64]. In NDR2, replacement of residues 433-464
with the PKN2 PIF domain (human PKN2 residues 969-983) produces
an NDR2 species which was estimated as possessing a 20-fold
increase in activity over the wild type NDR2 and in which the T loop
phosphorylation site is phosphorylated [3]. The specific activity of
tagged NDR2-PIFtide is about 2-fold greater than that of the tagged
NDR2(wild type) from COS cells treated with 1 μM OKA for 60 min,
and its activity might be slightly further increased by exposure of the
cells to OKA [3]. We estimate here that the activity of FLAG-NDR2-PIF-
tide was about 10-fold greater than FLAG-NDR2(wild-type) (Fig. 6),
and this was still much less (about 15–20%) than that of FLAG-NDR2
(wild-type) that had been activated by 200 nM calyculin A for 20 min.
Calyculin A did not further activate FLAG-NDR2-PIFtide (Fig. 6),
presumably because Thr-442 is absent. We were hoping that ectopic
expression of the activated FLAG-NDR2-PIFtide might cause some
obvious changes in its subcellular localisation and/or myocyte
morphology. However, we were not able to detect any such changes
and a more-detailed examination of any prospective phenotypes is
currently being undertaken.
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